id	sid	tid	token	lemma	pos
admet-322	1	1	manuscript	manuscript	PROPN
admet-322	1	2	doi	doi	PROPN
admet-322	1	3	:	:	PUNCT
admet-322	1	4	10.5599	10.5599	NUM
admet-322	1	5	/	/	SYM
admet-322	1	6	admet.4.4.352	admet.4.4.352	SYM
admet-322	1	7	302	302	NUM
admet-322	1	8	admet	admet	NOUN
admet-322	1	9	&	&	CCONJ
admet-322	1	10	dmpk	dmpk	PROPN
admet-322	1	11	4(4	4(4	NUM
admet-322	1	12	)	)	PUNCT
admet-322	1	13	(	(	PUNCT
admet-322	1	14	2016	2016	NUM
admet-322	1	15	)	)	PUNCT
admet-322	1	16	302	302	NUM
admet-322	1	17	-	-	SYM
admet-322	1	18	313	313	NUM
admet-322	1	19	;	;	PUNCT
admet-322	1	20	doi	doi	NOUN
admet-322	1	21	:	:	PUNCT
admet-322	1	22	10.5599	10.5599	NUM
admet-322	1	23	/	/	SYM
admet-322	1	24	admet.4.4.322	admet.4.4.322	NOUN
admet-322	1	25	open	open	ADJ
admet-322	1	26	access	access	NOUN
admet-322	1	27	:	:	PUNCT
admet-322	1	28	issn	issn	PROPN
admet-322	1	29	:	:	PUNCT
admet-322	1	30	1848	1848	NUM
admet-322	1	31	-	-	SYM
admet-322	1	32	7718	7718	NUM
admet-322	1	33	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-322	1	34	original	original	ADJ
admet-322	1	35	scientific	scientific	ADJ
admet-322	1	36	paper	paper	NOUN
admet-322	1	37	tyrosine	tyrosine	NOUN
admet-322	1	38	and	and	CCONJ
admet-322	1	39	aurora	aurora	PROPN
admet-322	1	40	kinase	kinase	PROPN
admet-322	1	41	inhibitors	inhibitor	NOUN
admet-322	1	42	diminish	diminish	VERB
admet-322	1	43	transport	transport	NOUN
admet-322	1	44	function	function	NOUN
admet-322	1	45	of	of	ADP
admet-322	1	46	multidrug	multidrug	NOUN
admet-322	1	47	resistance	resistance	NOUN
admet-322	1	48	-	-	PUNCT
admet-322	1	49	associated	associate	VERB
admet-322	1	50	protein	protein	NOUN
admet-322	1	51	(	(	PUNCT
admet-322	1	52	mrp	mrp	NOUN
admet-322	1	53	)	)	PUNCT
admet-322	1	54	4	4	NUM
admet-322	1	55	and	and	CCONJ
admet-322	1	56	breast	breast	NOUN
admet-322	1	57	cancer	cancer	NOUN
admet-322	1	58	resistance	resistance	NOUN
admet-322	1	59	protein	protein	NOUN
admet-322	1	60	(	(	PUNCT
admet-322	1	61	bcrp	bcrp	PROPN
admet-322	1	62	)	)	PUNCT
admet-322	1	63	rhiannon	rhiannon	PROPN
admet-322	1	64	n.	n.	PROPN
admet-322	1	65	hardwick1	hardwick1	PROPN
admet-322	1	66	,	,	PUNCT
admet-322	1	67	marina	marina	PROPN
admet-322	1	68	snellings2	snellings2	PROPN
admet-322	1	69	,	,	PUNCT
admet-322	1	70	brian	brian	PROPN
admet-322	1	71	c.	c.	PROPN
admet-322	1	72	ferslew2	ferslew2	PROPN
admet-322	1	73	,	,	PUNCT
admet-322	1	74	yang	yang	PROPN
admet-322	1	75	lu2	lu2	PROPN
admet-322	1	76	,	,	PUNCT
admet-322	1	77	kim	kim	PROPN
admet-322	1	78	l.r	l.r	PROPN
admet-322	1	79	.	.	PUNCT
admet-322	2	1	brouwer1,2	brouwer1,2	PROPN
admet-322	2	2	*	*	SYM
admet-322	2	3	1	1	NUM
admet-322	2	4	curriculum	curriculum	NOUN
admet-322	2	5	in	in	ADP
admet-322	2	6	toxicology	toxicology	NOUN
admet-322	2	7	,	,	PUNCT
admet-322	2	8	unc	unc	PROPN
admet-322	2	9	school	school	NOUN
admet-322	2	10	of	of	ADP
admet-322	2	11	medicine	medicine	NOUN
admet-322	2	12	,	,	PUNCT
admet-322	2	13	north	north	PROPN
admet-322	2	14	carolina	carolina	PROPN
admet-322	2	15	,	,	PUNCT
admet-322	2	16	us	us	PROPN
admet-322	2	17	2	2	NUM
admet-322	2	18	division	division	NOUN
admet-322	2	19	of	of	ADP
admet-322	2	20	pharmacotherapy	pharmacotherapy	NOUN
admet-322	2	21	and	and	CCONJ
admet-322	2	22	experimental	experimental	ADJ
admet-322	2	23	therapeutics	therapeutic	NOUN
admet-322	2	24	,	,	PUNCT
admet-322	2	25	unc	unc	PROPN
admet-322	2	26	eshelman	eshelman	PROPN
admet-322	2	27	school	school	NOUN
admet-322	2	28	of	of	ADP
admet-322	2	29	pharmacy	pharmacy	NOUN
admet-322	2	30	,	,	PUNCT
admet-322	2	31	the	the	DET
admet-322	2	32	university	university	NOUN
admet-322	2	33	of	of	ADP
admet-322	2	34	north	north	PROPN
admet-322	2	35	carolina	carolina	PROPN
admet-322	2	36	at	at	ADP
admet-322	2	37	chapel	chapel	PROPN
admet-322	2	38	hill	hill	PROPN
admet-322	2	39	,	,	PUNCT
admet-322	2	40	us	we	PRON
admet-322	2	41	*	*	PUNCT
admet-322	2	42	corresponding	correspond	VERB
admet-322	2	43	author	author	NOUN
admet-322	2	44	:	:	PUNCT
admet-322	2	45	e	e	NOUN
admet-322	2	46	-	-	NOUN
admet-322	2	47	mail	mail	NOUN
admet-322	2	48	:	:	PUNCT
admet-322	2	49	kbrouwer@unc.edu	kbrouwer@unc.edu	NOUN
admet-322	2	50	;	;	PUNCT
admet-322	2	51	tel	tel	PROPN
admet-322	2	52	.	.	PUNCT
admet-322	2	53	:	:	PUNCT
admet-322	3	1	+1	+1	PROPN
admet-322	3	2	-	-	PUNCT
admet-322	3	3	919	919	NUM
admet-322	3	4	-	-	PUNCT
admet-322	3	5	962	962	NUM
admet-322	3	6	-	-	SYM
admet-322	3	7	7030	7030	NUM
admet-322	3	8	;	;	PUNCT
admet-322	3	9	fax	fax	NOUN
admet-322	3	10	:	:	PUNCT
admet-322	3	11	+1	+1	PROPN
admet-322	3	12	-	-	PUNCT
admet-322	3	13	919	919	NUM
admet-322	3	14	-	-	PUNCT
admet-322	3	15	962	962	NUM
admet-322	3	16	-	-	PUNCT
admet-322	3	17	0644	0644	NUM
admet-322	3	18	received	receive	VERB
admet-322	3	19	:	:	PUNCT
admet-322	3	20	june	june	PROPN
admet-322	3	21	27	27	NUM
admet-322	3	22	,	,	PUNCT
admet-322	3	23	2016	2016	NUM
admet-322	3	24	;	;	PUNCT
admet-322	3	25	revised	revise	VERB
admet-322	3	26	:	:	PUNCT
admet-322	3	27	december	december	PROPN
admet-322	3	28	07	07	NUM
admet-322	3	29	,	,	PUNCT
admet-322	3	30	2016	2016	NUM
admet-322	3	31	;	;	PUNCT
admet-322	3	32	published	publish	VERB
admet-322	3	33	:	:	PUNCT
admet-322	3	34	december	december	PROPN
admet-322	3	35	26	26	NUM
admet-322	3	36	,	,	PUNCT
admet-322	3	37	2016	2016	NUM
admet-322	3	38	abstract	abstract	ADJ
admet-322	3	39	tyrosine	tyrosine	NOUN
admet-322	3	40	and	and	CCONJ
admet-322	3	41	aurora	aurora	PROPN
admet-322	3	42	kinases	kinase	NOUN
admet-322	3	43	are	be	AUX
admet-322	3	44	important	important	ADJ
admet-322	3	45	effectors	effector	NOUN
admet-322	3	46	in	in	ADP
admet-322	3	47	signal	signal	ADJ
admet-322	3	48	transduction	transduction	NOUN
admet-322	3	49	pathways	pathway	NOUN
admet-322	3	50	that	that	PRON
admet-322	3	51	are	be	AUX
admet-322	3	52	often	often	ADV
admet-322	3	53	involved	involve	VERB
admet-322	3	54	in	in	ADP
admet-322	3	55	aberrant	aberrant	ADJ
admet-322	3	56	cancer	cancer	NOUN
admet-322	3	57	cell	cell	NOUN
admet-322	3	58	growth	growth	NOUN
admet-322	3	59	.	.	PUNCT
admet-322	4	1	tyrosine	tyrosine	NOUN
admet-322	4	2	(	(	PUNCT
admet-322	4	3	tki	tki	PROPN
admet-322	4	4	)	)	PUNCT
admet-322	4	5	and	and	CCONJ
admet-322	4	6	aurora	aurora	PROPN
admet-322	4	7	(	(	PUNCT
admet-322	4	8	aki	aki	PROPN
admet-322	4	9	)	)	PUNCT
admet-322	4	10	kinase	kinase	PROPN
admet-322	4	11	inhibitors	inhibitor	NOUN
admet-322	4	12	are	be	AUX
admet-322	4	13	anti	anti	ADJ
admet-322	4	14	-	-	ADJ
admet-322	4	15	cancer	cancer	ADJ
admet-322	4	16	agents	agent	NOUN
admet-322	4	17	specifically	specifically	ADV
admet-322	4	18	designed	design	VERB
admet-322	4	19	to	to	PART
admet-322	4	20	target	target	VERB
admet-322	4	21	such	such	ADJ
admet-322	4	22	signaling	signal	VERB
admet-322	4	23	pathways	pathway	NOUN
admet-322	4	24	through	through	ADP
admet-322	4	25	tki	tki	PROPN
admet-322	4	26	/	/	SYM
admet-322	4	27	aki	aki	NOUN
admet-322	4	28	binding	bind	VERB
admet-322	4	29	to	to	ADP
admet-322	4	30	the	the	DET
admet-322	4	31	atp	atp	NOUN
admet-322	4	32	-	-	PUNCT
admet-322	4	33	binding	bind	VERB
admet-322	4	34	pocket	pocket	NOUN
admet-322	4	35	of	of	ADP
admet-322	4	36	kinases	kinase	NOUN
admet-322	4	37	thereby	thereby	ADV
admet-322	4	38	leading	lead	VERB
admet-322	4	39	to	to	ADP
admet-322	4	40	diminished	diminished	ADJ
admet-322	4	41	kinase	kinase	PROPN
admet-322	4	42	activity	activity	NOUN
admet-322	4	43	.	.	PUNCT
admet-322	5	1	some	some	DET
admet-322	5	2	tkis	tkis	NOUN
admet-322	5	3	have	have	AUX
admet-322	5	4	been	be	AUX
admet-322	5	5	identified	identify	VERB
admet-322	5	6	as	as	ADP
admet-322	5	7	inhibitors	inhibitor	NOUN
admet-322	5	8	of	of	ADP
admet-322	5	9	atp	atp	NOUN
admet-322	5	10	-	-	PUNCT
admet-322	5	11	binding	bind	VERB
admet-322	5	12	cassette	cassette	NOUN
admet-322	5	13	(	(	PUNCT
admet-322	5	14	abc	abc	PROPN
admet-322	5	15	)	)	PUNCT
admet-322	5	16	transporters	transporter	NOUN
admet-322	5	17	such	such	ADJ
admet-322	5	18	as	as	ADP
admet-322	5	19	p	p	NOUN
admet-322	5	20	-	-	PUNCT
admet-322	5	21	glycoprotein	glycoprotein	NOUN
admet-322	5	22	and	and	CCONJ
admet-322	5	23	breast	breast	NOUN
admet-322	5	24	cancer	cancer	NOUN
admet-322	5	25	resistance	resistance	NOUN
admet-322	5	26	protein	protein	NOUN
admet-322	5	27	(	(	PUNCT
admet-322	5	28	bcrp	bcrp	ADJ
admet-322	5	29	)	)	PUNCT
admet-322	5	30	,	,	PUNCT
admet-322	5	31	which	which	PRON
admet-322	5	32	are	be	AUX
admet-322	5	33	commonly	commonly	ADV
admet-322	5	34	upregulated	upregulate	VERB
admet-322	5	35	in	in	ADP
admet-322	5	36	malignant	malignant	ADJ
admet-322	5	37	cells	cell	NOUN
admet-322	5	38	.	.	PUNCT
admet-322	6	1	tki	tki	PROPN
admet-322	6	2	/	/	SYM
admet-322	6	3	akis	akis	PROPN
admet-322	6	4	have	have	AUX
admet-322	6	5	been	be	AUX
admet-322	6	6	investigated	investigate	VERB
admet-322	6	7	as	as	SCONJ
admet-322	6	8	abc	abc	PROPN
admet-322	6	9	transporter	transporter	VERB
admet-322	6	10	inhibitors	inhibitor	NOUN
admet-322	6	11	in	in	ADP
admet-322	6	12	order	order	NOUN
admet-322	6	13	to	to	PART
admet-322	6	14	facilitate	facilitate	VERB
admet-322	6	15	the	the	DET
admet-322	6	16	accumulation	accumulation	NOUN
admet-322	6	17	of	of	ADP
admet-322	6	18	concomitantly	concomitantly	ADV
admet-322	6	19	administered	administer	VERB
admet-322	6	20	chemotherapeutics	chemotherapeutic	NOUN
admet-322	6	21	within	within	ADP
admet-322	6	22	cancer	cancer	NOUN
admet-322	6	23	cells	cell	NOUN
admet-322	6	24	.	.	PUNCT
admet-322	7	1	however	however	ADV
admet-322	7	2	,	,	PUNCT
admet-322	7	3	abc	abc	PROPN
admet-322	7	4	transporters	transporter	NOUN
admet-322	7	5	are	be	AUX
admet-322	7	6	prominently	prominently	ADV
admet-322	7	7	expressed	express	VERB
admet-322	7	8	in	in	ADP
admet-322	7	9	the	the	DET
admet-322	7	10	liver	liver	NOUN
admet-322	7	11	and	and	CCONJ
admet-322	7	12	other	other	ADJ
admet-322	7	13	eliminating	eliminate	VERB
admet-322	7	14	organs	organ	NOUN
admet-322	7	15	,	,	PUNCT
admet-322	7	16	and	and	CCONJ
admet-322	7	17	their	their	PRON
admet-322	7	18	inhibition	inhibition	NOUN
admet-322	7	19	has	have	AUX
admet-322	7	20	been	be	AUX
admet-322	7	21	linked	link	VERB
admet-322	7	22	to	to	ADP
admet-322	7	23	intracellular	intracellular	ADJ
admet-322	7	24	accumulation	accumulation	NOUN
admet-322	7	25	of	of	ADP
admet-322	7	26	drugs	drug	NOUN
admet-322	7	27	,	,	PUNCT
admet-322	7	28	altered	alter	VERB
admet-322	7	29	disposition	disposition	NOUN
admet-322	7	30	,	,	PUNCT
admet-322	7	31	and	and	CCONJ
admet-322	7	32	toxicity	toxicity	NOUN
admet-322	7	33	.	.	PUNCT
admet-322	8	1	the	the	DET
admet-322	8	2	potential	potential	NOUN
admet-322	8	3	for	for	ADP
admet-322	8	4	tkis	tkis	PROPN
admet-322	8	5	/	/	SYM
admet-322	8	6	akis	akis	PROPN
admet-322	8	7	to	to	PART
admet-322	8	8	inhibit	inhibit	VERB
admet-322	8	9	other	other	ADJ
admet-322	8	10	important	important	ADJ
admet-322	8	11	hepatic	hepatic	ADJ
admet-322	8	12	efflux	efflux	NOUN
admet-322	8	13	transporters	transporter	NOUN
admet-322	8	14	,	,	PUNCT
admet-322	8	15	particularly	particularly	ADV
admet-322	8	16	multidrug	multidrug	VERB
admet-322	8	17	resistance	resistance	NOUN
admet-322	8	18	-	-	PUNCT
admet-322	8	19	associated	associate	VERB
admet-322	8	20	proteins	protein	NOUN
admet-322	8	21	(	(	PUNCT
admet-322	8	22	mrps	mrps	PROPN
admet-322	8	23	)	)	PUNCT
admet-322	8	24	,	,	PUNCT
admet-322	8	25	remains	remain	VERB
admet-322	8	26	unknown	unknown	ADJ
admet-322	8	27	.	.	PUNCT
admet-322	9	1	the	the	DET
admet-322	9	2	aim	aim	NOUN
admet-322	9	3	of	of	ADP
admet-322	9	4	the	the	DET
admet-322	9	5	current	current	ADJ
admet-322	9	6	study	study	NOUN
admet-322	9	7	was	be	AUX
admet-322	9	8	to	to	PART
admet-322	9	9	compare	compare	VERB
admet-322	9	10	the	the	DET
admet-322	9	11	inhibitory	inhibitory	ADJ
admet-322	9	12	potency	potency	NOUN
admet-322	9	13	of	of	ADP
admet-322	9	14	20	20	NUM
admet-322	9	15	selected	select	VERB
admet-322	9	16	tki	tki	PROPN
admet-322	9	17	/	/	SYM
admet-322	9	18	akis	akis	PROPN
admet-322	9	19	against	against	ADP
admet-322	9	20	mrp4	mrp4	PROPN
admet-322	9	21	and	and	CCONJ
admet-322	9	22	bcrp	bcrp	VERB
admet-322	9	23	through	through	ADP
admet-322	9	24	the	the	DET
admet-322	9	25	use	use	NOUN
admet-322	9	26	of	of	ADP
admet-322	9	27	inverted	inverted	ADJ
admet-322	9	28	membrane	membrane	NOUN
admet-322	9	29	vesicle	vesicle	NOUN
admet-322	9	30	assays	assay	NOUN
admet-322	9	31	.	.	PUNCT
admet-322	10	1	relative	relative	ADJ
admet-322	10	2	ic50	ic50	PROPN
admet-322	10	3	values	value	NOUN
admet-322	10	4	were	be	AUX
admet-322	10	5	estimated	estimate	VERB
admet-322	10	6	by	by	ADP
admet-322	10	7	determining	determine	VERB
admet-322	10	8	tki	tki	PROPN
admet-322	10	9	/	/	SYM
admet-322	10	10	aki	aki	NOUN
admet-322	10	11	inhibition	inhibition	NOUN
admet-322	10	12	of	of	ADP
admet-322	10	13	mrp4	mrp4	NOUN
admet-322	10	14	-	-	PUNCT
admet-322	10	15	mediated	mediate	VERB
admet-322	10	16	[	[	PUNCT
admet-322	10	17	3	3	NUM
admet-322	10	18	h]-dehydroepiandrosterone	h]-dehydroepiandrosterone	NOUN
admet-322	10	19	sulfate	sulfate	NOUN
admet-322	10	20	uptake	uptake	NOUN
admet-322	10	21	and	and	CCONJ
admet-322	10	22	bcrp	bcrp	ADV
admet-322	10	23	-	-	PUNCT
admet-322	10	24	mediated	mediate	VERB
admet-322	10	25	[	[	PUNCT
admet-322	10	26	3	3	NUM
admet-322	10	27	h]estrone	h]estrone	NOUN
admet-322	10	28	sulfate	sulfate	NOUN
admet-322	10	29	uptake	uptake	NOUN
admet-322	10	30	.	.	PUNCT
admet-322	11	1	to	to	PART
admet-322	11	2	provide	provide	VERB
admet-322	11	3	insight	insight	NOUN
admet-322	11	4	to	to	ADP
admet-322	11	5	the	the	DET
admet-322	11	6	clinical	clinical	ADJ
admet-322	11	7	relevance	relevance	NOUN
admet-322	11	8	of	of	ADP
admet-322	11	9	tki	tki	PROPN
admet-322	11	10	/	/	SYM
admet-322	11	11	aki	aki	NOUN
admet-322	11	12	inhibition	inhibition	NOUN
admet-322	11	13	of	of	ADP
admet-322	11	14	abc	abc	PROPN
admet-322	11	15	efflux	efflux	VERB
admet-322	11	16	transporters	transporter	NOUN
admet-322	11	17	,	,	PUNCT
admet-322	11	18	the	the	DET
admet-322	11	19	ratio	ratio	NOUN
admet-322	11	20	of	of	ADP
admet-322	11	21	the	the	DET
admet-322	11	22	steady	steady	ADJ
admet-322	11	23	-	-	PUNCT
admet-322	11	24	state	state	NOUN
admet-322	11	25	maximum	maximum	ADJ
admet-322	11	26	total	total	ADJ
admet-322	11	27	plasma	plasma	NOUN
admet-322	11	28	concentration	concentration	NOUN
admet-322	11	29	(	(	PUNCT
admet-322	11	30	css	css	PROPN
admet-322	11	31	)	)	PUNCT
admet-322	11	32	to	to	ADP
admet-322	11	33	the	the	DET
admet-322	11	34	ic50	ic50	PROPN
admet-322	11	35	for	for	ADP
admet-322	11	36	each	each	DET
admet-322	11	37	compound	compound	NOUN
admet-322	11	38	was	be	AUX
admet-322	11	39	calculated	calculate	VERB
admet-322	11	40	with	with	ADP
admet-322	11	41	css	css	PROPN
admet-322	11	42	/	/	SYM
admet-322	11	43	ic50	ic50	PROPN
admet-322	11	44	ratio	ratio	NOUN
admet-322	11	45	>	>	NOUN
admet-322	11	46	0.1	0.1	NUM
admet-322	11	47	deemed	deem	VERB
admet-322	11	48	potentially	potentially	ADV
admet-322	11	49	clinically	clinically	ADV
admet-322	11	50	relevant	relevant	ADJ
admet-322	11	51	.	.	PUNCT
admet-322	12	1	such	such	ADJ
admet-322	12	2	analysis	analysis	NOUN
admet-322	12	3	identified	identify	VERB
admet-322	12	4	several	several	ADJ
admet-322	12	5	potentially	potentially	ADV
admet-322	12	6	clinically	clinically	ADV
admet-322	12	7	relevant	relevant	ADJ
admet-322	12	8	inhibitors	inhibitor	NOUN
admet-322	12	9	of	of	ADP
admet-322	12	10	mrp4	mrp4	NOUN
admet-322	12	11	:	:	PUNCT
admet-322	12	12	alisertib	alisertib	ADJ
admet-322	12	13	,	,	PUNCT
admet-322	12	14	danusertib	danusertib	NOUN
admet-322	12	15	,	,	PUNCT
admet-322	12	16	erlotinib	erlotinib	PROPN
admet-322	12	17	,	,	PUNCT
admet-322	12	18	lapatinib	lapatinib	PROPN
admet-322	12	19	,	,	PUNCT
admet-322	12	20	neratinib	neratinib	NOUN
admet-322	12	21	,	,	PUNCT
admet-322	12	22	nilotinib	nilotinib	NOUN
admet-322	12	23	,	,	PUNCT
admet-322	12	24	pazopanib	pazopanib	NOUN
admet-322	12	25	,	,	PUNCT
admet-322	12	26	sorafenib	sorafenib	NOUN
admet-322	12	27	,	,	PUNCT
admet-322	12	28	and	and	CCONJ
admet-322	12	29	tozasertib	tozasertib	VERB
admet-322	12	30	.	.	PUNCT
admet-322	13	1	the	the	DET
admet-322	13	2	potentially	potentially	ADV
admet-322	13	3	clinically	clinically	ADV
admet-322	13	4	relevant	relevant	ADJ
admet-322	13	5	inhibition	inhibition	NOUN
admet-322	13	6	of	of	ADP
admet-322	13	7	bcrp	bcrp	ADV
admet-322	13	8	was	be	AUX
admet-322	13	9	much	much	ADV
admet-322	13	10	more	more	ADV
admet-322	13	11	extensive	extensive	ADJ
admet-322	13	12	and	and	CCONJ
admet-322	13	13	included	include	VERB
admet-322	13	14	alisertib	alisertib	NOUN
admet-322	13	15	,	,	PUNCT
admet-322	13	16	barasertib	barasertib	ADJ
admet-322	13	17	,	,	PUNCT
admet-322	13	18	danusertib	danusertib	NOUN
admet-322	13	19	,	,	PUNCT
admet-322	13	20	enzastaurin	enzastaurin	NOUN
admet-322	13	21	,	,	PUNCT
admet-322	13	22	erlotinib	erlotinib	NOUN
admet-322	13	23	,	,	PUNCT
admet-322	13	24	gefitinib	gefitinib	NOUN
admet-322	13	25	,	,	PUNCT
admet-322	13	26	imatinib	imatinib	NOUN
admet-322	13	27	,	,	PUNCT
admet-322	13	28	neratinib	neratinib	NOUN
admet-322	13	29	,	,	PUNCT
admet-322	13	30	nilotinib	nilotinib	NOUN
admet-322	13	31	,	,	PUNCT
admet-322	13	32	pazopanib	pazopanib	NOUN
admet-322	13	33	,	,	PUNCT
admet-322	13	34	selumetinib	selumetinib	NOUN
admet-322	13	35	,	,	PUNCT
admet-322	13	36	sorafenib	sorafenib	NOUN
admet-322	13	37	,	,	PUNCT
admet-322	13	38	sunitinib	sunitinib	NOUN
admet-322	13	39	,	,	PUNCT
admet-322	13	40	tozasertib	tozasertib	NOUN
admet-322	13	41	,	,	PUNCT
admet-322	13	42	and	and	CCONJ
admet-322	13	43	vandetanib	vandetanib	PROPN
admet-322	13	44	.	.	PUNCT
admet-322	14	1	these	these	DET
admet-322	14	2	findings	finding	NOUN
admet-322	14	3	indicate	indicate	VERB
admet-322	14	4	the	the	DET
admet-322	14	5	significant	significant	ADJ
admet-322	14	6	potential	potential	NOUN
admet-322	14	7	for	for	SCONJ
admet-322	14	8	tki	tki	NOUN
admet-322	14	9	/	/	SYM
admet-322	14	10	akis	akis	PROPN
admet-322	14	11	to	to	PART
admet-322	14	12	inhibit	inhibit	VERB
admet-322	14	13	multiple	multiple	ADJ
admet-322	14	14	abc	abc	PROPN
admet-322	14	15	efflux	efflux	VERB
admet-322	14	16	transporters	transporter	NOUN
admet-322	14	17	.	.	PUNCT
admet-322	15	1	the	the	DET
admet-322	15	2	resulting	result	VERB
admet-322	15	3	inhibition	inhibition	NOUN
admet-322	15	4	data	datum	NOUN
admet-322	15	5	could	could	AUX
admet-322	15	6	provide	provide	VERB
admet-322	15	7	insight	insight	NOUN
admet-322	15	8	regarding	regard	VERB
admet-322	15	9	the	the	DET
admet-322	15	10	clinical	clinical	ADJ
admet-322	15	11	interpretation	interpretation	NOUN
admet-322	15	12	of	of	ADP
admet-322	15	13	pharmacokinetic	pharmacokinetic	ADJ
admet-322	15	14	/	/	SYM
admet-322	15	15	pharmacodynamic	pharmacodynamic	ADJ
admet-322	15	16	outcomes	outcome	NOUN
admet-322	15	17	when	when	SCONJ
admet-322	15	18	tki	tki	PROPN
admet-322	15	19	/	/	SYM
admet-322	15	20	akis	akis	PROPN
admet-322	15	21	are	be	AUX
admet-322	15	22	administered	administer	VERB
admet-322	15	23	concomitantly	concomitantly	ADV
admet-322	15	24	with	with	ADP
admet-322	15	25	additional	additional	ADJ
admet-322	15	26	chemotherapeutic	chemotherapeutic	ADJ
admet-322	15	27	agents	agent	NOUN
admet-322	15	28	.	.	PUNCT
admet-322	16	1	keywords	keyword	VERB
admet-322	16	2	abc	abc	PROPN
admet-322	16	3	transporters	transporter	NOUN
admet-322	16	4	;	;	PUNCT
admet-322	16	5	transport	transport	NOUN
admet-322	16	6	inhibition	inhibition	NOUN
admet-322	16	7	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-322	16	8	mailto:kbrouwer@unc.edu	mailto:kbrouwer@unc.edu	PROPN
admet-322	16	9	admet	admet	NOUN
admet-322	16	10	&	&	CCONJ
admet-322	16	11	dmpk	dmpk	PROPN
admet-322	16	12	4(4	4(4	NUM
admet-322	16	13	)	)	PUNCT
admet-322	16	14	(	(	PUNCT
admet-322	16	15	2016	2016	NUM
admet-322	16	16	)	)	PUNCT
admet-322	16	17	302	302	NUM
admet-322	16	18	-	-	SYM
admet-322	16	19	313	313	NUM
admet-322	16	20	tkis	tki	NOUN
admet-322	16	21	and	and	CCONJ
admet-322	16	22	akis	akis	PROPN
admet-322	16	23	diminish	diminish	VERB
admet-322	16	24	transport	transport	NOUN
admet-322	16	25	of	of	ADP
admet-322	16	26	function	function	NOUN
admet-322	16	27	of	of	ADP
admet-322	16	28	mrp4	mrp4	NOUN
admet-322	16	29	and	and	CCONJ
admet-322	16	30	bcrp	bcrp	PROPN
admet-322	16	31	doi	doi	PROPN
admet-322	16	32	:	:	PUNCT
admet-322	16	33	10.5599	10.5599	NUM
admet-322	16	34	/	/	SYM
admet-322	16	35	admet.4.4.322	admet.4.4.322	ADP
admet-322	16	36	303	303	NUM
admet-322	16	37	introduction	introduction	NOUN
admet-322	16	38	small	small	ADJ
admet-322	16	39	molecule	molecule	NOUN
admet-322	16	40	kinase	kinase	NOUN
admet-322	16	41	inhibitors	inhibitor	NOUN
admet-322	16	42	have	have	AUX
admet-322	16	43	revolutionized	revolutionize	VERB
admet-322	16	44	the	the	DET
admet-322	16	45	field	field	NOUN
admet-322	16	46	of	of	ADP
admet-322	16	47	oncology	oncology	NOUN
admet-322	16	48	by	by	ADP
admet-322	16	49	facilitating	facilitate	VERB
admet-322	16	50	the	the	DET
admet-322	16	51	targeting	targeting	NOUN
admet-322	16	52	of	of	ADP
admet-322	16	53	specific	specific	ADJ
admet-322	16	54	kinases	kinase	NOUN
admet-322	16	55	,	,	PUNCT
admet-322	16	56	which	which	PRON
admet-322	16	57	have	have	AUX
admet-322	16	58	been	be	AUX
admet-322	16	59	found	find	VERB
admet-322	16	60	to	to	PART
admet-322	16	61	be	be	AUX
admet-322	16	62	over	over	ADV
admet-322	16	63	-	-	PUNCT
admet-322	16	64	expressed	express	VERB
admet-322	16	65	and/or	and/or	CCONJ
admet-322	16	66	mutated	mutate	VERB
admet-322	16	67	in	in	ADP
admet-322	16	68	specific	specific	ADJ
admet-322	16	69	tumor	tumor	NOUN
admet-322	16	70	types	type	NOUN
admet-322	16	71	.	.	PUNCT
admet-322	17	1	such	such	ADJ
admet-322	17	2	targeting	targeting	NOUN
admet-322	17	3	has	have	AUX
admet-322	17	4	enabled	enable	VERB
admet-322	17	5	a	a	DET
admet-322	17	6	more	more	ADV
admet-322	17	7	directed	directed	ADJ
admet-322	17	8	,	,	PUNCT
admet-322	17	9	individualistic	individualistic	ADJ
admet-322	17	10	treatment	treatment	NOUN
admet-322	17	11	regimen	regiman	NOUN
admet-322	17	12	for	for	ADP
admet-322	17	13	many	many	ADJ
admet-322	17	14	patients	patient	NOUN
admet-322	17	15	[	[	X
admet-322	17	16	1	1	NUM
admet-322	17	17	-	-	SYM
admet-322	17	18	4	4	NUM
admet-322	17	19	]	]	PUNCT
admet-322	17	20	.	.	PUNCT
admet-322	18	1	these	these	DET
admet-322	18	2	small	small	ADJ
admet-322	18	3	molecule	molecule	NOUN
admet-322	18	4	kinase	kinase	NOUN
admet-322	18	5	inhibitors	inhibitor	NOUN
admet-322	18	6	have	have	AUX
admet-322	18	7	been	be	AUX
admet-322	18	8	designed	design	VERB
admet-322	18	9	primarily	primarily	ADV
admet-322	18	10	to	to	PART
admet-322	18	11	target	target	VERB
admet-322	18	12	specific	specific	ADJ
admet-322	18	13	receptor	receptor	NOUN
admet-322	18	14	tyrosine	tyrosine	NOUN
admet-322	18	15	kinases	kinase	NOUN
admet-322	18	16	,	,	PUNCT
admet-322	18	17	namely	namely	ADV
admet-322	18	18	the	the	DET
admet-322	18	19	epidermal	epidermal	ADJ
admet-322	18	20	growth	growth	NOUN
admet-322	18	21	factor	factor	NOUN
admet-322	18	22	receptor	receptor	NOUN
admet-322	18	23	(	(	PUNCT
admet-322	18	24	egfr	egfr	NOUN
admet-322	18	25	and	and	CCONJ
admet-322	18	26	her2	her2	PROPN
admet-322	18	27	)	)	PUNCT
admet-322	18	28	,	,	PUNCT
admet-322	18	29	vascular	vascular	ADJ
admet-322	18	30	endothelial	endothelial	ADJ
admet-322	18	31	growth	growth	NOUN
admet-322	18	32	factor	factor	NOUN
admet-322	18	33	receptor	receptor	NOUN
admet-322	18	34	(	(	PUNCT
admet-322	18	35	vegfr	vegfr	NOUN
admet-322	18	36	)	)	PUNCT
admet-322	18	37	,	,	PUNCT
admet-322	18	38	platelet	platelet	NOUN
admet-322	18	39	-	-	PUNCT
admet-322	18	40	derived	derive	VERB
admet-322	18	41	growth	growth	NOUN
admet-322	18	42	factor	factor	NOUN
admet-322	18	43	receptor	receptor	NOUN
admet-322	18	44	(	(	PUNCT
admet-322	18	45	pdgfr	pdgfr	ADJ
admet-322	18	46	)	)	PUNCT
admet-322	18	47	,	,	PUNCT
admet-322	18	48	and	and	CCONJ
admet-322	18	49	the	the	DET
admet-322	18	50	bcr	bcr	PROPN
admet-322	18	51	/	/	SYM
admet-322	18	52	abl	abl	PROPN
admet-322	18	53	(	(	PUNCT
admet-322	18	54	breakpoint	breakpoint	NOUN
admet-322	18	55	cluster	cluster	NOUN
admet-322	18	56	region	region	NOUN
admet-322	18	57	/	/	SYM
admet-322	18	58	abelson	abelson	NOUN
admet-322	18	59	)	)	PUNCT
admet-322	18	60	fusion	fusion	NOUN
admet-322	18	61	protein	protein	NOUN
admet-322	18	62	;	;	PUNCT
admet-322	18	63	however	however	ADV
admet-322	18	64	,	,	PUNCT
admet-322	18	65	some	some	DET
admet-322	18	66	off	off	ADP
admet-322	18	67	-	-	PUNCT
admet-322	18	68	target	target	NOUN
admet-322	18	69	inhibition	inhibition	NOUN
admet-322	18	70	of	of	ADP
admet-322	18	71	intracellular	intracellular	ADJ
admet-322	18	72	kinases	kinase	NOUN
admet-322	18	73	can	can	AUX
admet-322	18	74	occur	occur	VERB
admet-322	18	75	.	.	PUNCT
admet-322	19	1	receptor	receptor	NOUN
admet-322	19	2	tyrosine	tyrosine	NOUN
admet-322	19	3	kinases	kinase	NOUN
admet-322	19	4	are	be	AUX
admet-322	19	5	important	important	ADJ
admet-322	19	6	mediators	mediator	NOUN
admet-322	19	7	of	of	ADP
admet-322	19	8	intracellular	intracellular	ADJ
admet-322	19	9	signaling	signal	VERB
admet-322	19	10	cascades	cascade	NOUN
admet-322	19	11	[	[	X
admet-322	19	12	4	4	NUM
admet-322	19	13	-	-	SYM
admet-322	19	14	6	6	NUM
admet-322	19	15	]	]	PUNCT
admet-322	19	16	.	.	PUNCT
admet-322	20	1	specifically	specifically	ADV
admet-322	20	2	,	,	PUNCT
admet-322	20	3	upon	upon	SCONJ
admet-322	20	4	binding	bind	VERB
admet-322	20	5	of	of	ADP
admet-322	20	6	ligand	ligand	NOUN
admet-322	20	7	to	to	ADP
admet-322	20	8	the	the	DET
admet-322	20	9	receptor	receptor	NOUN
admet-322	20	10	tyrosine	tyrosine	PROPN
admet-322	20	11	kinase	kinase	PROPN
admet-322	20	12	,	,	PUNCT
admet-322	20	13	autocatalytic	autocatalytic	ADJ
admet-322	20	14	phosphorylation	phosphorylation	NOUN
admet-322	20	15	events	event	NOUN
admet-322	20	16	spark	spark	VERB
admet-322	20	17	the	the	DET
admet-322	20	18	propagation	propagation	NOUN
admet-322	20	19	of	of	ADP
admet-322	20	20	one	one	NUM
admet-322	20	21	or	or	CCONJ
admet-322	20	22	more	more	ADJ
admet-322	20	23	signaling	signaling	ADJ
admet-322	20	24	cascades	cascade	NOUN
admet-322	20	25	ultimately	ultimately	ADV
admet-322	20	26	leading	lead	VERB
admet-322	20	27	to	to	ADP
admet-322	20	28	transcription	transcription	NOUN
admet-322	20	29	of	of	ADP
admet-322	20	30	genes	gene	NOUN
admet-322	20	31	.	.	PUNCT
admet-322	21	1	aberrant	aberrant	ADJ
admet-322	21	2	regulation	regulation	NOUN
admet-322	21	3	of	of	ADP
admet-322	21	4	receptor	receptor	NOUN
admet-322	21	5	tyrosine	tyrosine	NOUN
admet-322	21	6	kinases	kinase	NOUN
admet-322	21	7	can	can	AUX
admet-322	21	8	result	result	VERB
admet-322	21	9	in	in	ADP
admet-322	21	10	amplification	amplification	NOUN
admet-322	21	11	of	of	ADP
admet-322	21	12	genes	gene	NOUN
admet-322	21	13	related	relate	VERB
admet-322	21	14	to	to	ADP
admet-322	21	15	proliferation	proliferation	NOUN
admet-322	21	16	,	,	PUNCT
admet-322	21	17	apoptosis	apoptosis	NOUN
admet-322	21	18	,	,	PUNCT
admet-322	21	19	and	and	CCONJ
admet-322	21	20	differentiation	differentiation	NOUN
admet-322	21	21	,	,	PUNCT
admet-322	21	22	and	and	CCONJ
admet-322	21	23	thus	thus	ADV
admet-322	21	24	enable	enable	VERB
admet-322	21	25	cancer	cancer	NOUN
admet-322	21	26	cell	cell	NOUN
admet-322	21	27	growth	growth	NOUN
admet-322	21	28	and	and	CCONJ
admet-322	21	29	metastasis	metastasis	PRON
admet-322	21	30	[	[	X
admet-322	21	31	3	3	NUM
admet-322	21	32	,	,	PUNCT
admet-322	21	33	6	6	NUM
admet-322	21	34	]	]	PUNCT
admet-322	21	35	.	.	PUNCT
admet-322	22	1	aurora	aurora	PROPN
admet-322	22	2	kinases	kinase	NOUN
admet-322	22	3	are	be	AUX
admet-322	22	4	different	different	ADJ
admet-322	22	5	from	from	ADP
admet-322	22	6	receptor	receptor	NOUN
admet-322	22	7	tyrosine	tyrosine	NOUN
admet-322	22	8	kinases	kinase	NOUN
admet-322	22	9	in	in	SCONJ
admet-322	22	10	that	that	SCONJ
admet-322	22	11	they	they	PRON
admet-322	22	12	are	be	AUX
admet-322	22	13	primarily	primarily	ADV
admet-322	22	14	active	active	ADJ
admet-322	22	15	during	during	ADP
admet-322	22	16	mitosis	mitosis	NOUN
admet-322	22	17	,	,	PUNCT
admet-322	22	18	but	but	CCONJ
admet-322	22	19	also	also	ADV
admet-322	22	20	have	have	AUX
admet-322	22	21	been	be	AUX
admet-322	22	22	found	find	VERB
admet-322	22	23	to	to	PART
admet-322	22	24	be	be	AUX
admet-322	22	25	upregulated	upregulate	VERB
admet-322	22	26	in	in	ADP
admet-322	22	27	many	many	ADJ
admet-322	22	28	tumor	tumor	NOUN
admet-322	22	29	types	type	NOUN
admet-322	22	30	[	[	X
admet-322	22	31	7	7	NUM
admet-322	22	32	,	,	PUNCT
admet-322	22	33	8	8	NUM
admet-322	22	34	]	]	PUNCT
admet-322	22	35	.	.	PUNCT
admet-322	23	1	as	as	ADP
admet-322	23	2	such	such	ADJ
admet-322	23	3	,	,	PUNCT
admet-322	23	4	several	several	ADJ
admet-322	23	5	small	small	ADJ
admet-322	23	6	molecule	molecule	NOUN
admet-322	23	7	inhibitors	inhibitor	NOUN
admet-322	23	8	have	have	AUX
admet-322	23	9	been	be	AUX
admet-322	23	10	designed	design	VERB
admet-322	23	11	in	in	ADP
admet-322	23	12	an	an	DET
admet-322	23	13	effort	effort	NOUN
admet-322	23	14	to	to	PART
admet-322	23	15	mitigate	mitigate	VERB
admet-322	23	16	the	the	DET
admet-322	23	17	activity	activity	NOUN
admet-322	23	18	of	of	ADP
admet-322	23	19	aurora	aurora	PROPN
admet-322	23	20	kinases	kinase	NOUN
admet-322	23	21	during	during	ADP
admet-322	23	22	cancer	cancer	NOUN
admet-322	23	23	cell	cell	NOUN
admet-322	23	24	growth	growth	NOUN
admet-322	23	25	.	.	PUNCT
admet-322	24	1	though	though	SCONJ
admet-322	24	2	kinase	kinase	PROPN
admet-322	24	3	inhibitors	inhibitor	NOUN
admet-322	24	4	are	be	AUX
admet-322	24	5	designed	design	VERB
admet-322	24	6	with	with	ADP
admet-322	24	7	a	a	DET
admet-322	24	8	particular	particular	ADJ
admet-322	24	9	target	target	NOUN
admet-322	24	10	in	in	ADP
admet-322	24	11	mind	mind	NOUN
admet-322	24	12	,	,	PUNCT
admet-322	24	13	cross	cross	NOUN
admet-322	24	14	-	-	NOUN
admet-322	24	15	reactivity	reactivity	NOUN
admet-322	24	16	with	with	ADP
admet-322	24	17	off	off	ADP
admet-322	24	18	-	-	PUNCT
admet-322	24	19	target	target	NOUN
admet-322	24	20	kinases	kinase	NOUN
admet-322	24	21	can	can	AUX
admet-322	24	22	occur	occur	VERB
admet-322	24	23	in	in	ADP
admet-322	24	24	nonmalignant	nonmalignant	ADJ
admet-322	24	25	cells	cell	NOUN
admet-322	24	26	,	,	PUNCT
admet-322	24	27	which	which	PRON
admet-322	24	28	may	may	AUX
admet-322	24	29	increase	increase	VERB
admet-322	24	30	the	the	DET
admet-322	24	31	potential	potential	NOUN
admet-322	24	32	for	for	ADP
admet-322	24	33	off	off	ADP
admet-322	24	34	-	-	PUNCT
admet-322	24	35	target	target	NOUN
admet-322	24	36	,	,	PUNCT
admet-322	24	37	potentially	potentially	ADV
admet-322	24	38	toxic	toxic	ADJ
admet-322	24	39	effects	effect	NOUN
admet-322	24	40	[	[	X
admet-322	24	41	4	4	NUM
admet-322	24	42	,	,	PUNCT
admet-322	24	43	9	9	NUM
admet-322	24	44	]	]	PUNCT
admet-322	24	45	.	.	PUNCT
admet-322	25	1	tkis	tkis	PROPN
admet-322	25	2	and	and	CCONJ
admet-322	25	3	akis	akis	PROPN
admet-322	25	4	exert	exert	VERB
admet-322	25	5	their	their	PRON
admet-322	25	6	effects	effect	NOUN
admet-322	25	7	by	by	ADP
admet-322	25	8	acting	act	VERB
admet-322	25	9	as	as	ADP
admet-322	25	10	atp	atp	NOUN
admet-322	25	11	-	-	PUNCT
admet-322	25	12	mimics	mimic	NOUN
admet-322	25	13	and	and	CCONJ
admet-322	25	14	binding	bind	VERB
admet-322	25	15	to	to	ADP
admet-322	25	16	the	the	DET
admet-322	25	17	atp	atp	NOUN
admet-322	25	18	-	-	PUNCT
admet-322	25	19	binding	bind	VERB
admet-322	25	20	pocket	pocket	NOUN
admet-322	25	21	of	of	ADP
admet-322	25	22	kinases	kinase	NOUN
admet-322	25	23	to	to	PART
admet-322	25	24	decrease	decrease	VERB
admet-322	25	25	the	the	DET
admet-322	25	26	kinase	kinase	PROPN
admet-322	25	27	catalytic	catalytic	ADJ
admet-322	25	28	activity	activity	NOUN
admet-322	25	29	[	[	X
admet-322	25	30	2	2	NUM
admet-322	25	31	]	]	PUNCT
admet-322	25	32	.	.	PUNCT
admet-322	26	1	in	in	ADP
admet-322	26	2	recent	recent	ADJ
admet-322	26	3	years	year	NOUN
admet-322	26	4	,	,	PUNCT
admet-322	26	5	tkis	tkis	PROPN
admet-322	26	6	have	have	AUX
admet-322	26	7	been	be	AUX
admet-322	26	8	identified	identify	VERB
admet-322	26	9	as	as	ADP
admet-322	26	10	inhibitors	inhibitor	NOUN
admet-322	26	11	of	of	ADP
admet-322	26	12	several	several	ADJ
admet-322	26	13	atp	atp	NOUN
admet-322	26	14	-	-	PUNCT
admet-322	26	15	binding	bind	VERB
admet-322	26	16	cassette	cassette	NOUN
admet-322	26	17	(	(	PUNCT
admet-322	26	18	abc	abc	PROPN
admet-322	26	19	)	)	PUNCT
admet-322	26	20	efflux	efflux	VERB
admet-322	26	21	transporters	transporter	NOUN
admet-322	26	22	that	that	PRON
admet-322	26	23	are	be	AUX
admet-322	26	24	commonly	commonly	ADV
admet-322	26	25	upregulated	upregulate	VERB
admet-322	26	26	in	in	ADP
admet-322	26	27	cancer	cancer	NOUN
admet-322	26	28	cells	cell	NOUN
admet-322	26	29	including	include	VERB
admet-322	26	30	p	p	NOUN
admet-322	26	31	-	-	PUNCT
admet-322	26	32	glycoprotein	glycoprotein	NOUN
admet-322	26	33	(	(	PUNCT
admet-322	26	34	multidrug	multidrug	VERB
admet-322	26	35	resistance	resistance	NOUN
admet-322	26	36	protein	protein	NOUN
admet-322	26	37	1	1	NUM
admet-322	26	38	)	)	PUNCT
admet-322	26	39	,	,	PUNCT
admet-322	26	40	breast	breast	NOUN
admet-322	26	41	cancer	cancer	NOUN
admet-322	26	42	resistance	resistance	NOUN
admet-322	26	43	protein	protein	NOUN
admet-322	26	44	(	(	PUNCT
admet-322	26	45	bcrp	bcrp	ADJ
admet-322	26	46	)	)	PUNCT
admet-322	26	47	,	,	PUNCT
admet-322	26	48	and	and	CCONJ
admet-322	26	49	multidrug	multidrug	VERB
admet-322	26	50	resistance	resistance	NOUN
admet-322	26	51	-	-	PUNCT
admet-322	26	52	associated	associate	VERB
admet-322	26	53	protein	protein	NOUN
admet-322	26	54	(	(	PUNCT
admet-322	26	55	mrp	mrp	NOUN
admet-322	26	56	)	)	PUNCT
admet-322	26	57	1	1	NUM
admet-322	27	1	[	[	SYM
admet-322	27	2	10	10	NUM
admet-322	27	3	-	-	SYM
admet-322	27	4	18	18	NUM
admet-322	27	5	]	]	PUNCT
admet-322	27	6	.	.	PUNCT
admet-322	28	1	abc	abc	PROPN
admet-322	28	2	efflux	efflux	VERB
admet-322	28	3	transporters	transporter	NOUN
admet-322	28	4	consist	consist	VERB
admet-322	28	5	of	of	ADP
admet-322	28	6	a	a	DET
admet-322	28	7	large	large	ADJ
admet-322	28	8	family	family	NOUN
admet-322	28	9	of	of	ADP
admet-322	28	10	membrane	membrane	NOUN
admet-322	28	11	-	-	PUNCT
admet-322	28	12	spanning	span	VERB
admet-322	28	13	proteins	protein	NOUN
admet-322	28	14	involved	involve	VERB
admet-322	28	15	in	in	ADP
admet-322	28	16	the	the	DET
admet-322	28	17	active	active	ADJ
admet-322	28	18	extrusion	extrusion	NOUN
admet-322	28	19	of	of	ADP
admet-322	28	20	substrates	substrate	NOUN
admet-322	28	21	such	such	ADJ
admet-322	28	22	as	as	ADP
admet-322	28	23	endogenous	endogenous	ADJ
admet-322	28	24	molecules	molecule	NOUN
admet-322	28	25	,	,	PUNCT
admet-322	28	26	drugs	drug	NOUN
admet-322	28	27	,	,	PUNCT
admet-322	28	28	and	and	CCONJ
admet-322	28	29	drug	drug	NOUN
admet-322	28	30	metabolites	metabolite	NOUN
admet-322	28	31	from	from	ADP
admet-322	28	32	the	the	DET
admet-322	28	33	cell	cell	NOUN
admet-322	28	34	through	through	ADP
admet-322	28	35	hydrolysis	hydrolysis	NOUN
admet-322	28	36	of	of	ADP
admet-322	28	37	atp	atp	NOUN
admet-322	28	38	[	[	X
admet-322	28	39	19	19	NUM
admet-322	28	40	-	-	SYM
admet-322	28	41	21	21	NUM
admet-322	28	42	]	]	PUNCT
admet-322	28	43	.	.	PUNCT
admet-322	29	1	abc	abc	PROPN
admet-322	29	2	efflux	efflux	VERB
admet-322	29	3	transporters	transporter	NOUN
admet-322	29	4	are	be	AUX
admet-322	29	5	expressed	express	VERB
admet-322	29	6	prominently	prominently	ADV
admet-322	29	7	in	in	ADP
admet-322	29	8	eliminating	eliminate	VERB
admet-322	29	9	organs	organ	NOUN
admet-322	29	10	such	such	ADJ
admet-322	29	11	as	as	ADP
admet-322	29	12	the	the	DET
admet-322	29	13	liver	liver	NOUN
admet-322	29	14	and	and	CCONJ
admet-322	29	15	kidney	kidney	NOUN
admet-322	29	16	,	,	PUNCT
admet-322	29	17	and	and	CCONJ
admet-322	29	18	thus	thus	ADV
admet-322	29	19	can	can	AUX
admet-322	29	20	play	play	VERB
admet-322	29	21	a	a	DET
admet-322	29	22	significant	significant	ADJ
admet-322	29	23	role	role	NOUN
admet-322	29	24	in	in	ADP
admet-322	29	25	the	the	DET
admet-322	29	26	overall	overall	ADJ
admet-322	29	27	disposition	disposition	NOUN
admet-322	29	28	of	of	ADP
admet-322	29	29	a	a	DET
admet-322	29	30	drug	drug	NOUN
admet-322	29	31	within	within	ADP
admet-322	29	32	the	the	DET
admet-322	29	33	body	body	NOUN
admet-322	29	34	[	[	X
admet-322	29	35	19	19	NUM
admet-322	29	36	]	]	PUNCT
admet-322	29	37	.	.	PUNCT
admet-322	30	1	upregulation	upregulation	NOUN
admet-322	30	2	of	of	ADP
admet-322	30	3	abc	abc	PROPN
admet-322	30	4	efflux	efflux	VERB
admet-322	30	5	transporters	transporter	NOUN
admet-322	30	6	in	in	ADP
admet-322	30	7	cancer	cancer	NOUN
admet-322	30	8	cells	cell	NOUN
admet-322	30	9	confers	confer	NOUN
admet-322	30	10	chemoresistance	chemoresistance	NOUN
admet-322	30	11	,	,	PUNCT
admet-322	30	12	and	and	CCONJ
admet-322	30	13	imparts	impart	VERB
admet-322	30	14	a	a	DET
admet-322	30	15	greater	great	ADJ
admet-322	30	16	ability	ability	NOUN
admet-322	30	17	of	of	ADP
admet-322	30	18	the	the	DET
admet-322	30	19	cell	cell	NOUN
admet-322	30	20	to	to	PART
admet-322	30	21	limit	limit	VERB
admet-322	30	22	exposure	exposure	NOUN
admet-322	30	23	to	to	ADP
admet-322	30	24	,	,	PUNCT
admet-322	30	25	and	and	CCONJ
admet-322	30	26	diminish	diminish	VERB
admet-322	30	27	the	the	DET
admet-322	30	28	effects	effect	NOUN
admet-322	30	29	of	of	ADP
admet-322	30	30	,	,	PUNCT
admet-322	30	31	chemotherapeutic	chemotherapeutic	ADJ
admet-322	30	32	agents	agent	NOUN
admet-322	30	33	[	[	X
admet-322	30	34	12	12	NUM
admet-322	30	35	,	,	PUNCT
admet-322	30	36	22	22	NUM
admet-322	30	37	,	,	PUNCT
admet-322	30	38	23	23	NUM
admet-322	30	39	]	]	PUNCT
admet-322	30	40	.	.	PUNCT
admet-322	31	1	the	the	DET
admet-322	31	2	upregulation	upregulation	NOUN
admet-322	31	3	of	of	ADP
admet-322	31	4	abc	abc	PROPN
admet-322	31	5	transporters	transporter	NOUN
admet-322	31	6	during	during	ADP
admet-322	31	7	chemoresistance	chemoresistance	NOUN
admet-322	31	8	has	have	AUX
admet-322	31	9	made	make	VERB
admet-322	31	10	them	they	PRON
admet-322	31	11	an	an	DET
admet-322	31	12	attractive	attractive	ADJ
admet-322	31	13	target	target	NOUN
admet-322	31	14	in	in	ADP
admet-322	31	15	overcoming	overcome	VERB
admet-322	31	16	the	the	DET
admet-322	31	17	clinical	clinical	ADJ
admet-322	31	18	difficulty	difficulty	NOUN
admet-322	31	19	of	of	ADP
admet-322	31	20	maintaining	maintain	VERB
admet-322	31	21	intracellular	intracellular	ADJ
admet-322	31	22	exposure	exposure	NOUN
admet-322	31	23	to	to	ADP
admet-322	31	24	chemotherapeutics	chemotherapeutic	NOUN
admet-322	31	25	.	.	PUNCT
admet-322	32	1	due	due	ADP
admet-322	32	2	to	to	ADP
admet-322	32	3	their	their	PRON
admet-322	32	4	ability	ability	NOUN
admet-322	32	5	to	to	PART
admet-322	32	6	inhibit	inhibit	VERB
admet-322	32	7	abc	abc	PROPN
admet-322	32	8	transporters	transporter	NOUN
admet-322	32	9	commonly	commonly	ADV
admet-322	32	10	upregulated	upregulate	VERB
admet-322	32	11	in	in	ADP
admet-322	32	12	cancer	cancer	NOUN
admet-322	32	13	cells	cell	NOUN
admet-322	32	14	,	,	PUNCT
admet-322	32	15	kinase	kinase	PROPN
admet-322	32	16	inhibitors	inhibitor	NOUN
admet-322	32	17	recently	recently	ADV
admet-322	32	18	have	have	AUX
admet-322	32	19	been	be	AUX
admet-322	32	20	investigated	investigate	VERB
admet-322	32	21	for	for	ADP
admet-322	32	22	their	their	PRON
admet-322	32	23	capability	capability	NOUN
admet-322	32	24	to	to	PART
admet-322	32	25	reverse	reverse	VERB
admet-322	32	26	chemoresistance	chemoresistance	NOUN
admet-322	32	27	.	.	PUNCT
admet-322	33	1	in	in	ADP
admet-322	33	2	particular	particular	ADJ
admet-322	33	3	,	,	PUNCT
admet-322	33	4	bcrp	bcrp	PROPN
admet-322	33	5	can	can	AUX
admet-322	33	6	confer	confer	VERB
admet-322	33	7	resistance	resistance	NOUN
admet-322	33	8	to	to	ADP
admet-322	33	9	gefitinib	gefitinib	NOUN
admet-322	33	10	,	,	PUNCT
admet-322	33	11	but	but	CCONJ
admet-322	33	12	in	in	ADP
admet-322	33	13	contrast	contrast	NOUN
admet-322	33	14	also	also	ADV
admet-322	33	15	is	be	AUX
admet-322	33	16	inhibited	inhibit	VERB
admet-322	33	17	by	by	ADP
admet-322	33	18	gefitinib	gefitinib	NOUN
admet-322	33	19	,	,	PUNCT
admet-322	33	20	vandetanib	vandetanib	NOUN
admet-322	33	21	,	,	PUNCT
admet-322	33	22	and	and	CCONJ
admet-322	33	23	neratinib	neratinib	NOUN
admet-322	33	24	[	[	X
admet-322	33	25	18	18	NUM
admet-322	33	26	]	]	PUNCT
admet-322	33	27	.	.	PUNCT
admet-322	34	1	similarly	similarly	ADV
admet-322	34	2	,	,	PUNCT
admet-322	34	3	it	it	PRON
admet-322	34	4	has	have	AUX
admet-322	34	5	been	be	AUX
admet-322	34	6	shown	show	VERB
admet-322	34	7	that	that	SCONJ
admet-322	34	8	sunitinib	sunitinib	NOUN
admet-322	34	9	is	be	AUX
admet-322	34	10	an	an	DET
admet-322	34	11	inhibitor	inhibitor	NOUN
admet-322	34	12	of	of	ADP
admet-322	34	13	bcrp	bcrp	PROPN
admet-322	34	14	and	and	CCONJ
admet-322	34	15	can	can	AUX
admet-322	34	16	reverse	reverse	VERB
admet-322	34	17	chemoresistance	chemoresistance	NOUN
admet-322	34	18	to	to	AUX
admet-322	34	19	co	co	VERB
admet-322	34	20	-	-	VERB
admet-322	34	21	administered	administer	VERB
admet-322	34	22	chemotherapeutics	chemotherapeutic	NOUN
admet-322	34	23	in	in	ADP
admet-322	34	24	bcrp	bcrp	ADV
admet-322	34	25	over	over	ADP
admet-322	34	26	-	-	PUNCT
admet-322	34	27	expressing	express	VERB
admet-322	34	28	cells	cell	NOUN
admet-322	34	29	[	[	X
admet-322	34	30	16	16	NUM
admet-322	34	31	]	]	PUNCT
admet-322	34	32	.	.	PUNCT
admet-322	35	1	others	other	NOUN
admet-322	35	2	have	have	AUX
admet-322	35	3	shown	show	VERB
admet-322	35	4	that	that	SCONJ
admet-322	35	5	dasatinib	dasatinib	NOUN
admet-322	35	6	,	,	PUNCT
admet-322	35	7	nilotinib	nilotinib	NOUN
admet-322	35	8	,	,	PUNCT
admet-322	35	9	and	and	CCONJ
admet-322	35	10	imatinib	imatinib	NOUN
admet-322	35	11	are	be	AUX
admet-322	35	12	competitive	competitive	ADJ
admet-322	35	13	inhibitors	inhibitor	NOUN
admet-322	35	14	of	of	ADP
admet-322	35	15	p	p	NOUN
admet-322	35	16	-	-	PUNCT
admet-322	35	17	glycoprotein	glycoprotein	NOUN
admet-322	35	18	and	and	CCONJ
admet-322	35	19	bcrp	bcrp	ADV
admet-322	35	20	,	,	PUNCT
admet-322	35	21	meaning	mean	VERB
admet-322	35	22	that	that	SCONJ
admet-322	35	23	they	they	PRON
admet-322	35	24	are	be	AUX
admet-322	35	25	substrates	substrate	NOUN
admet-322	35	26	at	at	ADP
admet-322	35	27	low	low	ADJ
admet-322	35	28	concentrations	concentration	NOUN
admet-322	35	29	,	,	PUNCT
admet-322	35	30	while	while	SCONJ
admet-322	35	31	they	they	PRON
admet-322	35	32	inhibit	inhibit	VERB
admet-322	35	33	transport	transport	NOUN
admet-322	35	34	function	function	NOUN
admet-322	35	35	at	at	ADP
admet-322	35	36	high	high	ADJ
admet-322	35	37	concentrations	concentration	NOUN
admet-322	35	38	[	[	X
admet-322	35	39	24	24	NUM
admet-322	35	40	]	]	PUNCT
admet-322	35	41	.	.	PUNCT
admet-322	36	1	although	although	SCONJ
admet-322	36	2	these	these	DET
admet-322	36	3	data	datum	NOUN
admet-322	36	4	indicate	indicate	VERB
admet-322	36	5	the	the	DET
admet-322	36	6	potential	potential	NOUN
admet-322	36	7	for	for	SCONJ
admet-322	36	8	kinase	kinase	PROPN
admet-322	36	9	inhibitors	inhibitor	NOUN
admet-322	36	10	to	to	PART
admet-322	36	11	be	be	AUX
admet-322	36	12	used	use	VERB
admet-322	36	13	as	as	ADP
admet-322	36	14	tools	tool	NOUN
admet-322	36	15	to	to	PART
admet-322	36	16	overcome	overcome	VERB
admet-322	36	17	chemoresistance	chemoresistance	NOUN
admet-322	36	18	through	through	ADP
admet-322	36	19	abc	abc	PROPN
admet-322	36	20	efflux	efflux	VERB
admet-322	36	21	transporter	transporter	NOUN
admet-322	36	22	inhibition	inhibition	NOUN
admet-322	36	23	in	in	ADP
admet-322	36	24	vitro	vitro	NOUN
admet-322	36	25	,	,	PUNCT
admet-322	36	26	several	several	ADJ
admet-322	36	27	clinical	clinical	ADJ
admet-322	36	28	trials	trial	NOUN
admet-322	36	29	employing	employ	VERB
admet-322	36	30	kinase	kinase	NOUN
admet-322	36	31	inhibitors	inhibitor	NOUN
admet-322	36	32	for	for	ADP
admet-322	36	33	mitigation	mitigation	NOUN
admet-322	36	34	of	of	ADP
admet-322	36	35	chemoresistance	chemoresistance	NOUN
admet-322	36	36	have	have	AUX
admet-322	36	37	been	be	AUX
admet-322	36	38	unable	unable	ADJ
admet-322	36	39	to	to	PART
admet-322	36	40	definitively	definitively	ADV
admet-322	36	41	demonstrate	demonstrate	VERB
admet-322	36	42	improvements	improvement	NOUN
admet-322	36	43	in	in	ADP
admet-322	36	44	progression	progression	NOUN
admet-322	36	45	free	free	ADJ
admet-322	36	46	survival	survival	NOUN
admet-322	36	47	and/or	and/or	CCONJ
admet-322	36	48	overall	overall	ADJ
admet-322	36	49	survival	survival	NOUN
admet-322	36	50	of	of	ADP
admet-322	36	51	patients	patient	NOUN
admet-322	36	52	[	[	X
admet-322	36	53	25	25	NUM
admet-322	36	54	-	-	SYM
admet-322	36	55	28	28	NUM
admet-322	36	56	]	]	PUNCT
admet-322	36	57	.	.	PUNCT
admet-322	37	1	studies	study	NOUN
admet-322	37	2	seeking	seek	VERB
admet-322	37	3	to	to	PART
admet-322	37	4	utilize	utilize	VERB
admet-322	37	5	kinase	kinase	NOUN
admet-322	37	6	inhibitors	inhibitor	NOUN
admet-322	37	7	for	for	ADP
admet-322	37	8	mitigation	mitigation	NOUN
admet-322	37	9	of	of	ADP
admet-322	37	10	chemoresistance	chemoresistance	NOUN
admet-322	37	11	though	though	SCONJ
admet-322	37	12	inhibition	inhibition	NOUN
admet-322	37	13	of	of	ADP
admet-322	37	14	specific	specific	ADJ
admet-322	37	15	abc	abc	PROPN
admet-322	37	16	efflux	efflux	NOUN
admet-322	37	17	transporters	transporter	NOUN
admet-322	37	18	that	that	PRON
admet-322	37	19	are	be	AUX
admet-322	37	20	upregulated	upregulate	VERB
admet-322	37	21	in	in	ADP
admet-322	37	22	cancer	cancer	NOUN
admet-322	37	23	cells	cell	NOUN
admet-322	37	24	often	often	ADV
admet-322	37	25	fail	fail	VERB
admet-322	37	26	to	to	PART
admet-322	37	27	address	address	VERB
admet-322	37	28	a	a	DET
admet-322	37	29	key	key	ADJ
admet-322	37	30	r.n	r.n	PROPN
admet-322	37	31	.	.	PROPN
admet-322	37	32	hardwick	hardwick	PROPN
admet-322	37	33	et	et	PROPN
admet-322	37	34	al	al	PROPN
admet-322	37	35	.	.	PROPN
admet-322	37	36	admet	admet	PROPN
admet-322	37	37	&	&	CCONJ
admet-322	37	38	dmpk	dmpk	PROPN
admet-322	37	39	4(4	4(4	NUM
admet-322	37	40	)	)	PUNCT
admet-322	37	41	(	(	PUNCT
admet-322	37	42	2016	2016	NUM
admet-322	37	43	)	)	PUNCT
admet-322	37	44	302	302	NUM
admet-322	37	45	-	-	SYM
admet-322	37	46	313	313	NUM
admet-322	37	47	304	304	NUM
admet-322	37	48	complication	complication	NOUN
admet-322	37	49	:	:	PUNCT
admet-322	37	50	off	off	ADP
admet-322	37	51	-	-	PUNCT
admet-322	37	52	target	target	NOUN
admet-322	37	53	inhibition	inhibition	NOUN
admet-322	37	54	of	of	ADP
admet-322	37	55	abc	abc	PROPN
admet-322	37	56	efflux	efflux	VERB
admet-322	37	57	transporters	transporter	NOUN
admet-322	37	58	in	in	ADP
admet-322	37	59	eliminating	eliminate	VERB
admet-322	37	60	organs	organ	NOUN
admet-322	37	61	such	such	ADJ
admet-322	37	62	as	as	ADP
admet-322	37	63	liver	liver	NOUN
admet-322	37	64	,	,	PUNCT
admet-322	37	65	kidney	kidney	NOUN
admet-322	37	66	,	,	PUNCT
admet-322	37	67	and	and	CCONJ
admet-322	37	68	intestine	intestine	NOUN
admet-322	37	69	.	.	PUNCT
admet-322	38	1	several	several	ADJ
admet-322	38	2	mrps	mrps	NOUN
admet-322	38	3	including	include	VERB
admet-322	38	4	mrp2	mrp2	PROPN
admet-322	38	5	,	,	PUNCT
admet-322	38	6	mrp3	mrp3	PROPN
admet-322	38	7	,	,	PUNCT
admet-322	38	8	and	and	CCONJ
admet-322	38	9	mrp4	mrp4	PROPN
admet-322	38	10	are	be	AUX
admet-322	38	11	differentially	differentially	ADV
admet-322	38	12	localized	localize	VERB
admet-322	38	13	to	to	ADP
admet-322	38	14	the	the	DET
admet-322	38	15	apical	apical	ADJ
admet-322	38	16	and	and	CCONJ
admet-322	38	17	basolateral	basolateral	ADJ
admet-322	38	18	membranes	membrane	NOUN
admet-322	38	19	of	of	ADP
admet-322	38	20	hepatocytes	hepatocyte	NOUN
admet-322	38	21	,	,	PUNCT
admet-322	38	22	enterocytes	enterocyte	NOUN
admet-322	38	23	,	,	PUNCT
admet-322	38	24	and	and	CCONJ
admet-322	38	25	proximal	proximal	ADJ
admet-322	38	26	tubule	tubule	NOUN
admet-322	38	27	cells	cell	NOUN
admet-322	38	28	,	,	PUNCT
admet-322	38	29	which	which	PRON
admet-322	38	30	enables	enable	VERB
admet-322	38	31	them	they	PRON
admet-322	38	32	to	to	PART
admet-322	38	33	direct	direct	VERB
admet-322	38	34	the	the	DET
admet-322	38	35	disposition	disposition	NOUN
admet-322	38	36	of	of	ADP
admet-322	38	37	some	some	DET
admet-322	38	38	chemotherapeutics	chemotherapeutic	NOUN
admet-322	38	39	[	[	X
admet-322	38	40	19	19	NUM
admet-322	38	41	,	,	PUNCT
admet-322	38	42	20	20	NUM
admet-322	38	43	]	]	PUNCT
admet-322	38	44	.	.	PUNCT
admet-322	39	1	for	for	ADP
admet-322	39	2	example	example	NOUN
admet-322	39	3	,	,	PUNCT
admet-322	39	4	mrp2	mrp2	PROPN
admet-322	39	5	is	be	AUX
admet-322	39	6	localized	localize	VERB
admet-322	39	7	to	to	ADP
admet-322	39	8	the	the	DET
admet-322	39	9	apical	apical	ADJ
admet-322	39	10	membrane	membrane	NOUN
admet-322	39	11	of	of	ADP
admet-322	39	12	hepatocytes	hepatocyte	NOUN
admet-322	39	13	while	while	SCONJ
admet-322	39	14	mrp3	mrp3	PROPN
admet-322	39	15	is	be	AUX
admet-322	39	16	situated	situate	VERB
admet-322	39	17	at	at	ADP
admet-322	39	18	the	the	DET
admet-322	39	19	basolateral	basolateral	ADJ
admet-322	39	20	membrane	membrane	NOUN
admet-322	39	21	.	.	PUNCT
admet-322	40	1	mrp2	mrp2	PROPN
admet-322	40	2	and	and	CCONJ
admet-322	40	3	mrp3	mrp3	PROPN
admet-322	40	4	share	share	NOUN
admet-322	40	5	substrate	substrate	NOUN
admet-322	40	6	specificity	specificity	NOUN
admet-322	40	7	yet	yet	ADV
admet-322	40	8	extrude	extrude	VERB
admet-322	40	9	drugs	drug	NOUN
admet-322	40	10	and	and	CCONJ
admet-322	40	11	drug	drug	NOUN
admet-322	40	12	metabolites	metabolite	NOUN
admet-322	40	13	into	into	ADP
admet-322	40	14	the	the	DET
admet-322	40	15	bile	bile	NOUN
admet-322	40	16	and	and	CCONJ
admet-322	40	17	systemic	systemic	ADJ
admet-322	40	18	circulation	circulation	NOUN
admet-322	40	19	,	,	PUNCT
admet-322	40	20	respectively	respectively	ADV
admet-322	40	21	[	[	X
admet-322	40	22	19	19	NUM
admet-322	40	23	]	]	PUNCT
admet-322	40	24	.	.	PUNCT
admet-322	41	1	inhibition	inhibition	NOUN
admet-322	41	2	of	of	ADP
admet-322	41	3	mrp2	mrp2	PROPN
admet-322	41	4	can	can	AUX
admet-322	41	5	shift	shift	VERB
admet-322	41	6	the	the	DET
admet-322	41	7	hepatobiliary	hepatobiliary	ADJ
admet-322	41	8	disposition	disposition	NOUN
admet-322	41	9	of	of	ADP
admet-322	41	10	a	a	DET
admet-322	41	11	drug	drug	NOUN
admet-322	41	12	from	from	ADP
admet-322	41	13	bile	bile	NOUN
admet-322	41	14	,	,	PUNCT
admet-322	41	15	and	and	CCONJ
admet-322	41	16	subsequent	subsequent	ADJ
admet-322	41	17	elimination	elimination	NOUN
admet-322	41	18	in	in	ADP
admet-322	41	19	feces	fece	NOUN
admet-322	41	20	,	,	PUNCT
admet-322	41	21	to	to	ADP
admet-322	41	22	the	the	DET
admet-322	41	23	sinusoidal	sinusoidal	ADJ
admet-322	41	24	blood	blood	NOUN
admet-322	41	25	resulting	result	VERB
admet-322	41	26	in	in	ADP
admet-322	41	27	greater	great	ADJ
admet-322	41	28	systemic	systemic	ADJ
admet-322	41	29	exposure	exposure	NOUN
admet-322	41	30	.	.	PUNCT
admet-322	42	1	similar	similar	ADJ
admet-322	42	2	to	to	ADP
admet-322	42	3	mrp3	mrp3	PROPN
admet-322	42	4	,	,	PUNCT
admet-322	42	5	mrp4	mrp4	PROPN
admet-322	42	6	resides	reside	VERB
admet-322	42	7	on	on	ADP
admet-322	42	8	the	the	DET
admet-322	42	9	basolateral	basolateral	ADJ
admet-322	42	10	membrane	membrane	NOUN
admet-322	42	11	of	of	ADP
admet-322	42	12	hepatocytes	hepatocyte	NOUN
admet-322	42	13	,	,	PUNCT
admet-322	42	14	while	while	SCONJ
admet-322	42	15	bcrp	bcrp	ADV
admet-322	42	16	,	,	PUNCT
admet-322	42	17	like	like	ADP
admet-322	42	18	mrp2	mrp2	PROPN
admet-322	42	19	,	,	PUNCT
admet-322	42	20	is	be	AUX
admet-322	42	21	localized	localize	VERB
admet-322	42	22	to	to	ADP
admet-322	42	23	the	the	DET
admet-322	42	24	apical	apical	ADJ
admet-322	42	25	membrane	membrane	NOUN
admet-322	42	26	with	with	ADP
admet-322	42	27	each	each	DET
admet-322	42	28	differentially	differentially	ADV
admet-322	42	29	extruding	extrude	VERB
admet-322	42	30	drugs	drug	NOUN
admet-322	42	31	and	and	CCONJ
admet-322	42	32	metabolites	metabolite	NOUN
admet-322	42	33	into	into	ADP
admet-322	42	34	the	the	DET
admet-322	42	35	systemic	systemic	ADJ
admet-322	42	36	circulation	circulation	NOUN
admet-322	42	37	and	and	CCONJ
admet-322	42	38	bile	bile	NOUN
admet-322	42	39	,	,	PUNCT
admet-322	42	40	respectively	respectively	ADV
admet-322	42	41	.	.	PUNCT
admet-322	43	1	mrp4	mrp4	PROPN
admet-322	43	2	transports	transport	NOUN
admet-322	43	3	nucleosides	nucleoside	VERB
admet-322	43	4	,	,	PUNCT
admet-322	43	5	phase	phase	NOUN
admet-322	43	6	ii	ii	NOUN
admet-322	43	7	conjugation	conjugation	NOUN
admet-322	43	8	products	product	NOUN
admet-322	43	9	,	,	PUNCT
admet-322	43	10	and	and	CCONJ
admet-322	43	11	conjugated	conjugate	VERB
admet-322	43	12	bile	bile	NOUN
admet-322	43	13	acids	acid	NOUN
admet-322	44	1	[	[	X
admet-322	44	2	20	20	NUM
admet-322	44	3	,	,	PUNCT
admet-322	44	4	29	29	NUM
admet-322	44	5	]	]	PUNCT
admet-322	44	6	.	.	PUNCT
admet-322	45	1	inhibition	inhibition	NOUN
admet-322	45	2	of	of	ADP
admet-322	45	3	mrp4	mrp4	NOUN
admet-322	45	4	-	-	PUNCT
admet-322	45	5	mediated	mediate	VERB
admet-322	45	6	transport	transport	NOUN
admet-322	45	7	has	have	AUX
admet-322	45	8	been	be	AUX
admet-322	45	9	associated	associate	VERB
admet-322	45	10	with	with	ADP
admet-322	45	11	an	an	DET
admet-322	45	12	increased	increase	VERB
admet-322	45	13	risk	risk	NOUN
admet-322	45	14	of	of	ADP
admet-322	45	15	cholestatic	cholestatic	ADJ
admet-322	45	16	potential	potential	NOUN
admet-322	45	17	,	,	PUNCT
admet-322	45	18	particularly	particularly	ADV
admet-322	45	19	among	among	ADP
admet-322	45	20	compounds	compound	NOUN
admet-322	45	21	that	that	PRON
admet-322	45	22	do	do	AUX
admet-322	45	23	not	not	PART
admet-322	45	24	inhibit	inhibit	VERB
admet-322	45	25	the	the	DET
admet-322	45	26	bile	bile	NOUN
admet-322	45	27	salt	salt	NOUN
admet-322	45	28	export	export	NOUN
admet-322	45	29	pump	pump	NOUN
admet-322	45	30	(	(	PUNCT
admet-322	45	31	bsep	bsep	NOUN
admet-322	45	32	)	)	PUNCT
admet-322	46	1	[	[	X
admet-322	46	2	29	29	NUM
admet-322	46	3	]	]	PUNCT
admet-322	46	4	.	.	PUNCT
admet-322	47	1	similarities	similarity	NOUN
admet-322	47	2	in	in	ADP
admet-322	47	3	the	the	DET
admet-322	47	4	chemical	chemical	NOUN
admet-322	47	5	properties	property	NOUN
admet-322	47	6	of	of	ADP
admet-322	47	7	mrp4	mrp4	NOUN
admet-322	47	8	inhibitors	inhibitor	NOUN
admet-322	47	9	and	and	CCONJ
admet-322	47	10	bsep	bsep	NOUN
admet-322	47	11	inhibitors	inhibitor	NOUN
admet-322	47	12	have	have	AUX
admet-322	47	13	been	be	AUX
admet-322	47	14	identified	identify	VERB
admet-322	47	15	[	[	PUNCT
admet-322	47	16	30	30	NUM
admet-322	47	17	]	]	PUNCT
admet-322	47	18	.	.	PUNCT
admet-322	48	1	collectively	collectively	ADV
admet-322	48	2	,	,	PUNCT
admet-322	48	3	data	datum	NOUN
admet-322	48	4	suggest	suggest	VERB
admet-322	48	5	that	that	SCONJ
admet-322	48	6	mrp4	mrp4	NOUN
admet-322	48	7	inhibition	inhibition	NOUN
admet-322	48	8	may	may	AUX
admet-322	48	9	serve	serve	VERB
admet-322	48	10	as	as	ADP
admet-322	48	11	a	a	DET
admet-322	48	12	confounding	confound	VERB
admet-322	48	13	factor	factor	NOUN
admet-322	48	14	in	in	ADP
admet-322	48	15	bsep	bsep	NOUN
admet-322	48	16	-	-	PUNCT
admet-322	48	17	mediated	mediate	VERB
admet-322	48	18	drug	drug	NOUN
admet-322	48	19	-	-	PUNCT
admet-322	48	20	induced	induce	VERB
admet-322	48	21	liver	liver	NOUN
admet-322	48	22	injury	injury	NOUN
admet-322	48	23	or	or	CCONJ
admet-322	48	24	,	,	PUNCT
admet-322	48	25	in	in	ADP
admet-322	48	26	some	some	DET
admet-322	48	27	cases	case	NOUN
admet-322	48	28	,	,	PUNCT
admet-322	48	29	lead	lead	VERB
admet-322	48	30	to	to	ADP
admet-322	48	31	drug	drug	NOUN
admet-322	48	32	-	-	PUNCT
admet-322	48	33	induced	induce	VERB
admet-322	48	34	liver	liver	NOUN
admet-322	48	35	injury	injury	NOUN
admet-322	48	36	in	in	ADP
admet-322	48	37	the	the	DET
admet-322	48	38	absence	absence	NOUN
admet-322	48	39	of	of	ADP
admet-322	48	40	bsep	bsep	NOUN
admet-322	48	41	inhibition	inhibition	NOUN
admet-322	48	42	.	.	PUNCT
admet-322	49	1	thus	thus	ADV
admet-322	49	2	,	,	PUNCT
admet-322	49	3	inhibition	inhibition	NOUN
admet-322	49	4	of	of	ADP
admet-322	49	5	one	one	NUM
admet-322	49	6	or	or	CCONJ
admet-322	49	7	more	more	ADJ
admet-322	49	8	abc	abc	PROPN
admet-322	49	9	efflux	efflux	NOUN
admet-322	49	10	transporters	transporter	NOUN
admet-322	49	11	can	can	AUX
admet-322	49	12	significantly	significantly	ADV
admet-322	49	13	affect	affect	VERB
admet-322	49	14	the	the	DET
admet-322	49	15	disposition	disposition	NOUN
admet-322	49	16	of	of	ADP
admet-322	49	17	a	a	DET
admet-322	49	18	co	co	ADJ
admet-322	49	19	-	-	ADJ
admet-322	49	20	administered	administered	ADJ
admet-322	49	21	drug	drug	NOUN
admet-322	49	22	,	,	PUNCT
admet-322	49	23	and	and	CCONJ
admet-322	49	24	in	in	ADP
admet-322	49	25	some	some	DET
admet-322	49	26	cases	case	NOUN
admet-322	49	27	,	,	PUNCT
admet-322	49	28	may	may	AUX
admet-322	49	29	impact	impact	VERB
admet-322	49	30	the	the	DET
admet-322	49	31	risk	risk	NOUN
admet-322	49	32	of	of	ADP
admet-322	49	33	hepatotoxicity	hepatotoxicity	NOUN
admet-322	49	34	.	.	PUNCT
admet-322	50	1	knowledge	knowledge	NOUN
admet-322	50	2	of	of	ADP
admet-322	50	3	the	the	DET
admet-322	50	4	inhibitory	inhibitory	ADJ
admet-322	50	5	potency	potency	NOUN
admet-322	50	6	of	of	ADP
admet-322	50	7	tkis	tkis	NOUN
admet-322	50	8	and	and	CCONJ
admet-322	50	9	akis	akis	PROPN
admet-322	50	10	for	for	ADP
admet-322	50	11	multiple	multiple	ADJ
admet-322	50	12	abc	abc	PROPN
admet-322	50	13	efflux	efflux	NOUN
admet-322	50	14	transporters	transporter	NOUN
admet-322	50	15	,	,	PUNCT
admet-322	50	16	not	not	PART
admet-322	50	17	limited	limit	VERB
admet-322	50	18	to	to	ADP
admet-322	50	19	those	those	PRON
admet-322	50	20	upregulated	upregulate	VERB
admet-322	50	21	in	in	ADP
admet-322	50	22	cancer	cancer	NOUN
admet-322	50	23	cells	cell	NOUN
admet-322	50	24	,	,	PUNCT
admet-322	50	25	is	be	AUX
admet-322	50	26	critically	critically	ADV
admet-322	50	27	important	important	ADJ
admet-322	50	28	to	to	PART
admet-322	50	29	predict	predict	VERB
admet-322	50	30	the	the	DET
admet-322	50	31	pharmacokinetic	pharmacokinetic	ADJ
admet-322	50	32	and	and	CCONJ
admet-322	50	33	pharmacodynamic	pharmacodynamic	ADJ
admet-322	50	34	outcomes	outcome	NOUN
admet-322	50	35	and	and	CCONJ
admet-322	50	36	potential	potential	NOUN
admet-322	50	37	for	for	ADP
admet-322	50	38	hepatotoxicity	hepatotoxicity	NOUN
admet-322	50	39	of	of	ADP
admet-322	50	40	tki	tki	PROPN
admet-322	50	41	/	/	SYM
admet-322	50	42	akis	akis	PROPN
admet-322	50	43	and	and	CCONJ
admet-322	50	44	co	co	VERB
admet-322	50	45	-	-	ADJ
admet-322	50	46	administered	administered	ADJ
admet-322	50	47	chemotherapeutics	chemotherapeutic	NOUN
admet-322	50	48	.	.	PUNCT
admet-322	51	1	the	the	DET
admet-322	51	2	purpose	purpose	NOUN
admet-322	51	3	of	of	ADP
admet-322	51	4	the	the	DET
admet-322	51	5	current	current	ADJ
admet-322	51	6	study	study	NOUN
admet-322	51	7	was	be	AUX
admet-322	51	8	to	to	PART
admet-322	51	9	compare	compare	VERB
admet-322	51	10	the	the	DET
admet-322	51	11	inhibitory	inhibitory	ADJ
admet-322	51	12	potency	potency	NOUN
admet-322	51	13	of	of	ADP
admet-322	51	14	20	20	NUM
admet-322	51	15	tkis	tkis	NOUN
admet-322	51	16	and	and	CCONJ
admet-322	51	17	akis	akis	PROPN
admet-322	51	18	(	(	PUNCT
admet-322	51	19	see	see	VERB
admet-322	51	20	table	table	NOUN
admet-322	51	21	1	1	NUM
admet-322	51	22	for	for	ADP
admet-322	51	23	selected	select	VERB
admet-322	51	24	compounds	compound	NOUN
admet-322	51	25	)	)	PUNCT
admet-322	51	26	against	against	ADP
admet-322	51	27	the	the	DET
admet-322	51	28	abc	abc	PROPN
admet-322	51	29	efflux	efflux	NOUN
admet-322	51	30	transporters	transporter	NOUN
admet-322	51	31	mrp4	mrp4	NOUN
admet-322	51	32	and	and	CCONJ
admet-322	51	33	bcrp	bcrp	ADV
admet-322	51	34	using	use	VERB
admet-322	51	35	inverted	inverted	ADJ
admet-322	51	36	membrane	membrane	NOUN
admet-322	51	37	vesicle	vesicle	NOUN
admet-322	51	38	assays	assay	NOUN
admet-322	51	39	.	.	PUNCT
admet-322	52	1	additionally	additionally	ADV
admet-322	52	2	,	,	PUNCT
admet-322	52	3	half	half	PRON
admet-322	52	4	maximal	maximal	ADJ
admet-322	52	5	inhibitory	inhibitory	ADJ
admet-322	52	6	concentration	concentration	NOUN
admet-322	52	7	(	(	PUNCT
admet-322	52	8	ic50	ic50	PROPN
admet-322	52	9	)	)	PUNCT
admet-322	52	10	data	datum	NOUN
admet-322	52	11	were	be	AUX
admet-322	52	12	leveraged	leverage	VERB
admet-322	52	13	against	against	ADP
admet-322	52	14	reported	report	VERB
admet-322	52	15	steady	steady	ADJ
admet-322	52	16	state	state	NOUN
admet-322	52	17	concentration	concentration	NOUN
admet-322	52	18	(	(	PUNCT
admet-322	52	19	css	css	ADJ
admet-322	52	20	)	)	PUNCT
admet-322	52	21	values	value	NOUN
admet-322	52	22	to	to	PART
admet-322	52	23	provide	provide	VERB
admet-322	52	24	insight	insight	NOUN
admet-322	52	25	to	to	ADP
admet-322	52	26	the	the	DET
admet-322	52	27	clinical	clinical	ADJ
admet-322	52	28	relevance	relevance	NOUN
admet-322	52	29	of	of	ADP
admet-322	52	30	tki	tki	PROPN
admet-322	52	31	/	/	SYM
admet-322	52	32	aki	aki	NOUN
admet-322	52	33	inhibition	inhibition	NOUN
admet-322	52	34	of	of	ADP
admet-322	52	35	mrp4and	mrp4and	NOUN
admet-322	52	36	bcrp	bcrp	ADV
admet-322	52	37	-	-	PUNCT
admet-322	52	38	mediated	mediate	VERB
admet-322	52	39	transport	transport	NOUN
admet-322	52	40	function	function	NOUN
admet-322	52	41	.	.	PUNCT
admet-322	53	1	table	table	NOUN
admet-322	53	2	1	1	NUM
admet-322	53	3	.	.	NUM
admet-322	53	4	selected	select	VERB
admet-322	53	5	tyrosine	tyrosine	NOUN
admet-322	53	6	(	(	PUNCT
admet-322	53	7	tki	tki	PROPN
admet-322	53	8	)	)	PUNCT
admet-322	53	9	and	and	CCONJ
admet-322	53	10	aurora	aurora	PROPN
admet-322	53	11	(	(	PUNCT
admet-322	53	12	aki	aki	PROPN
admet-322	53	13	)	)	PUNCT
admet-322	53	14	kinase	kinase	NOUN
admet-322	53	15	inhibitors	inhibitor	NOUN
admet-322	53	16	.	.	PUNCT
admet-322	54	1	twenty	twenty	NUM
admet-322	54	2	tki	tki	NOUN
admet-322	54	3	/	/	SYM
admet-322	54	4	akis	akis	PROPN
admet-322	54	5	were	be	AUX
admet-322	54	6	selected	select	VERB
admet-322	54	7	for	for	ADP
admet-322	54	8	analysis	analysis	NOUN
admet-322	54	9	of	of	ADP
admet-322	54	10	their	their	PRON
admet-322	54	11	potential	potential	NOUN
admet-322	54	12	to	to	PART
admet-322	54	13	inhibit	inhibit	VERB
admet-322	54	14	mrp4and	mrp4and	NOUN
admet-322	54	15	bcrp	bcrp	ADV
admet-322	54	16	-	-	PUNCT
admet-322	54	17	mediated	mediate	VERB
admet-322	54	18	transport	transport	NOUN
admet-322	54	19	.	.	PUNCT
admet-322	55	1	tki	tki	PROPN
admet-322	55	2	/	/	SYM
admet-322	55	3	akis	akis	PROPN
admet-322	55	4	are	be	AUX
admet-322	55	5	categorized	categorize	VERB
admet-322	55	6	by	by	ADP
admet-322	55	7	primary	primary	ADJ
admet-322	55	8	kinase	kinase	PROPN
admet-322	55	9	target	target	PROPN
admet-322	55	10	.	.	PUNCT
admet-322	56	1	egfr	egfr	ADJ
admet-322	56	2	,	,	PUNCT
admet-322	56	3	epidermal	epidermal	ADJ
admet-322	56	4	growth	growth	NOUN
admet-322	56	5	factor	factor	NOUN
admet-322	56	6	receptor	receptor	NOUN
admet-322	56	7	;	;	PUNCT
admet-322	56	8	vegfr	vegfr	ADJ
admet-322	56	9	,	,	PUNCT
admet-322	56	10	vascular	vascular	ADJ
admet-322	56	11	endothelial	endothelial	ADJ
admet-322	56	12	growth	growth	NOUN
admet-322	56	13	factor	factor	NOUN
admet-322	56	14	receptor	receptor	NOUN
admet-322	56	15	;	;	PUNCT
admet-322	56	16	pdgfr	pdgfr	ADJ
admet-322	56	17	,	,	PUNCT
admet-322	56	18	platelet	platelet	ADJ
admet-322	56	19	-	-	PUNCT
admet-322	56	20	derived	derive	VERB
admet-322	56	21	growth	growth	NOUN
admet-322	56	22	factor	factor	NOUN
admet-322	56	23	receptor	receptor	NOUN
admet-322	56	24	;	;	PUNCT
admet-322	56	25	bcr	bcr	PROPN
admet-322	56	26	/	/	SYM
admet-322	56	27	abl	abl	PROPN
admet-322	56	28	,	,	PUNCT
admet-322	56	29	breakpoint	breakpoint	NOUN
admet-322	56	30	cluster	cluster	NOUN
admet-322	56	31	region	region	NOUN
admet-322	56	32	/	/	SYM
admet-322	56	33	abelson	abelson	NOUN
admet-322	56	34	fusion	fusion	NOUN
admet-322	56	35	protein	protein	NOUN
admet-322	56	36	.	.	PUNCT
admet-322	57	1	primary	primary	ADJ
admet-322	57	2	target	target	NOUN
admet-322	57	3	inhibitors	inhibitor	NOUN
admet-322	57	4	egfr	egfr	VERB
admet-322	57	5	erlotinib	erlotinib	NOUN
admet-322	57	6	,	,	PUNCT
admet-322	57	7	gefitinib	gefitinib	NOUN
admet-322	57	8	,	,	PUNCT
admet-322	57	9	lapatinib	lapatinib	PROPN
admet-322	57	10	,	,	PUNCT
admet-322	57	11	neratinib	neratinib	NOUN
admet-322	57	12	,	,	PUNCT
admet-322	57	13	vandetanib	vandetanib	PROPN
admet-322	57	14	vegfr	vegfr	PROPN
admet-322	57	15	&	&	CCONJ
admet-322	57	16	pdgfr	pdgfr	ADJ
admet-322	57	17	axitinib	axitinib	NOUN
admet-322	57	18	,	,	PUNCT
admet-322	57	19	pazopanib	pazopanib	NOUN
admet-322	57	20	,	,	PUNCT
admet-322	57	21	sorafenib	sorafenib	NOUN
admet-322	57	22	,	,	PUNCT
admet-322	57	23	sunitinib	sunitinib	NOUN
admet-322	57	24	bcr	bcr	PROPN
admet-322	57	25	/	/	SYM
admet-322	57	26	abl	abl	NOUN
admet-322	57	27	bosutinib	bosutinib	NOUN
admet-322	57	28	,	,	PUNCT
admet-322	57	29	dasatinib	dasatinib	NOUN
admet-322	57	30	,	,	PUNCT
admet-322	57	31	imatinib	imatinib	NOUN
admet-322	57	32	,	,	PUNCT
admet-322	57	33	nilotinib	nilotinib	NOUN
admet-322	57	34	miscellaneous	miscellaneous	ADJ
admet-322	57	35	crizotinib	crizotinib	NOUN
admet-322	57	36	(	(	PUNCT
admet-322	57	37	anaplastic	anaplastic	ADJ
admet-322	57	38	lymphoma	lymphoma	NOUN
admet-322	57	39	kinase	kinase	PROPN
admet-322	57	40	)	)	PUNCT
admet-322	57	41	,	,	PUNCT
admet-322	57	42	enzastaurin	enzastaurin	NOUN
admet-322	57	43	(	(	PUNCT
admet-322	57	44	protein	protein	NOUN
admet-322	57	45	kinase	kinase	NOUN
admet-322	57	46	c	c	PROPN
admet-322	57	47	isoforms	isoform	NOUN
admet-322	57	48	)	)	PUNCT
admet-322	57	49	,	,	PUNCT
admet-322	57	50	selumetinib	selumetinib	PROPN
admet-322	57	51	(	(	PUNCT
admet-322	57	52	mitogen	mitogen	NOUN
admet-322	57	53	-	-	PUNCT
admet-322	57	54	activated	activate	VERB
admet-322	57	55	protein	protein	NOUN
admet-322	57	56	kinase	kinase	NOUN
admet-322	57	57	1	1	NUM
admet-322	57	58	)	)	PUNCT
admet-322	57	59	aurora	aurora	PROPN
admet-322	57	60	alisertib	alisertib	PROPN
admet-322	57	61	(	(	PUNCT
admet-322	57	62	aurora	aurora	PROPN
admet-322	57	63	a	a	PROPN
admet-322	57	64	)	)	PUNCT
admet-322	57	65	,	,	PUNCT
admet-322	57	66	barasertib	barasertib	PROPN
admet-322	57	67	(	(	PUNCT
admet-322	57	68	aurora	aurora	PROPN
admet-322	57	69	b	b	PROPN
admet-322	57	70	)	)	PUNCT
admet-322	57	71	,	,	PUNCT
admet-322	57	72	danusertib	danusertib	PROPN
admet-322	57	73	(	(	PUNCT
admet-322	57	74	aurora	aurora	PROPN
admet-322	57	75	a	a	PROPN
admet-322	57	76	/	/	SYM
admet-322	57	77	b	b	PROPN
admet-322	57	78	/	/	SYM
admet-322	57	79	c	c	NOUN
admet-322	57	80	)	)	PUNCT
admet-322	57	81	,	,	PUNCT
admet-322	57	82	tozasertib	tozasertib	PROPN
admet-322	57	83	(	(	PUNCT
admet-322	57	84	aurora	aurora	PROPN
admet-322	57	85	a	a	PROPN
admet-322	57	86	/	/	SYM
admet-322	57	87	b	b	NOUN
admet-322	57	88	/	/	SYM
admet-322	57	89	c	c	NOUN
admet-322	57	90	)	)	PUNCT
admet-322	57	91	experimental	experimental	ADJ
admet-322	57	92	materials	material	NOUN
admet-322	57	93	cell	cell	NOUN
admet-322	57	94	culture	culture	NOUN
admet-322	57	95	supplies	supply	NOUN
admet-322	57	96	were	be	AUX
admet-322	57	97	obtained	obtain	VERB
admet-322	57	98	from	from	ADP
admet-322	57	99	gibco	gibco	NOUN
admet-322	57	100	(	(	PUNCT
admet-322	57	101	life	life	NOUN
admet-322	57	102	technologies	technology	NOUN
admet-322	57	103	,	,	PUNCT
admet-322	57	104	grand	grand	ADJ
admet-322	57	105	island	island	NOUN
admet-322	57	106	,	,	PUNCT
admet-322	57	107	ny	ny	PROPN
admet-322	57	108	)	)	PUNCT
admet-322	57	109	,	,	PUNCT
admet-322	57	110	and	and	CCONJ
admet-322	57	111	hygromycin	hygromycin	PROPN
admet-322	57	112	b	b	PROPN
admet-322	57	113	from	from	ADP
admet-322	57	114	roche	roche	PROPN
admet-322	57	115	life	life	NOUN
admet-322	57	116	sciences	sciences	PROPN
admet-322	57	117	(	(	PUNCT
admet-322	57	118	indianapolis	indianapolis	PROPN
admet-322	57	119	,	,	PUNCT
admet-322	57	120	in	in	ADP
admet-322	57	121	)	)	PUNCT
admet-322	57	122	.	.	PUNCT
admet-322	58	1	microscint-20	microscint-20	PROPN
admet-322	58	2	,	,	PUNCT
admet-322	58	3	[	[	X
admet-322	58	4	3h]-dehydroepiandrosterone	3h]-dehydroepiandrosterone	NUM
admet-322	58	5	-	-	PUNCT
admet-322	58	6	sulfate	sulfate	NOUN
admet-322	58	7	(	(	PUNCT
admet-322	58	8	dheas	dheas	ADJ
admet-322	58	9	;	;	PUNCT
admet-322	58	10	70.5	70.5	NUM
admet-322	58	11	ci	ci	NOUN
admet-322	58	12	/	/	SYM
admet-322	58	13	mmol	mmol	NOUN
admet-322	58	14	)	)	PUNCT
admet-322	58	15	and	and	CCONJ
admet-322	58	16	[	[	X
admet-322	58	17	3h]-estrone	3h]-estrone	NUM
admet-322	58	18	sulfate	sulfate	NOUN
admet-322	58	19	(	(	PUNCT
admet-322	58	20	e1s	e1s	PROPN
admet-322	58	21	;	;	PUNCT
admet-322	58	22	45	45	NUM
admet-322	58	23	ci	ci	NOUN
admet-322	58	24	/	/	SYM
admet-322	58	25	mmol	mmol	NOUN
admet-322	58	26	)	)	PUNCT
admet-322	58	27	were	be	AUX
admet-322	58	28	purchased	purchase	VERB
admet-322	58	29	from	from	ADP
admet-322	58	30	perkin	perkin	PROPN
admet-322	58	31	elmer	elmer	PROPN
admet-322	58	32	life	life	PROPN
admet-322	58	33	and	and	CCONJ
admet-322	58	34	analytical	analytical	ADJ
admet-322	58	35	sciences	science	NOUN
admet-322	58	36	(	(	PUNCT
admet-322	58	37	waltham	waltham	PROPN
admet-322	58	38	,	,	PUNCT
admet-322	58	39	ma	ma	PROPN
admet-322	58	40	)	)	PUNCT
admet-322	58	41	.	.	PUNCT
admet-322	59	1	dmso	dmso	NOUN
admet-322	59	2	(	(	PUNCT
admet-322	59	3	dimethylsulfoxide	dimethylsulfoxide	ADV
admet-322	59	4	)	)	PUNCT
admet-322	59	5	was	be	AUX
admet-322	59	6	obtained	obtain	VERB
admet-322	59	7	from	from	ADP
admet-322	59	8	fisher	fisher	PROPN
admet-322	59	9	scientific	scientific	PROPN
admet-322	59	10	(	(	PUNCT
admet-322	59	11	fairlawn	fairlawn	NOUN
admet-322	59	12	,	,	PUNCT
admet-322	59	13	nh	nh	PROPN
admet-322	59	14	)	)	PUNCT
admet-322	59	15	.	.	PUNCT
admet-322	60	1	compounds	compound	NOUN
admet-322	60	2	were	be	AUX
admet-322	60	3	purchased	purchase	VERB
admet-322	60	4	from	from	ADP
admet-322	60	5	selleckchem	selleckchem	NOUN
admet-322	60	6	(	(	PUNCT
admet-322	60	7	houston	houston	PROPN
admet-322	60	8	,	,	PUNCT
admet-322	60	9	tx	tx	PROPN
admet-322	60	10	)	)	PUNCT
admet-322	60	11	or	or	CCONJ
admet-322	60	12	cayman	cayman	PROPN
admet-322	60	13	chemical	chemical	PROPN
admet-322	60	14	(	(	PUNCT
admet-322	60	15	ann	ann	PROPN
admet-322	60	16	arbor	arbor	PROPN
admet-322	60	17	,	,	PUNCT
admet-322	60	18	mi	mi	PROPN
admet-322	60	19	)	)	PUNCT
admet-322	60	20	.	.	PUNCT
admet-322	61	1	admet	admet	PROPN
admet-322	61	2	&	&	CCONJ
admet-322	61	3	dmpk	dmpk	PROPN
admet-322	61	4	4(4	4(4	NUM
admet-322	61	5	)	)	PUNCT
admet-322	61	6	(	(	PUNCT
admet-322	61	7	2016	2016	NUM
admet-322	61	8	)	)	PUNCT
admet-322	61	9	302	302	NUM
admet-322	61	10	-	-	SYM
admet-322	61	11	313	313	NUM
admet-322	61	12	tkis	tki	NOUN
admet-322	61	13	and	and	CCONJ
admet-322	61	14	akis	akis	PROPN
admet-322	61	15	diminish	diminish	VERB
admet-322	61	16	transport	transport	NOUN
admet-322	61	17	of	of	ADP
admet-322	61	18	function	function	NOUN
admet-322	61	19	of	of	ADP
admet-322	61	20	mrp4	mrp4	NOUN
admet-322	61	21	and	and	CCONJ
admet-322	61	22	bcrp	bcrp	PROPN
admet-322	61	23	doi	doi	PROPN
admet-322	61	24	:	:	PUNCT
admet-322	61	25	10.5599	10.5599	NUM
admet-322	61	26	/	/	SYM
admet-322	61	27	admet.4.4.322	admet.4.4.322	ADP
admet-322	61	28	305	305	NUM
admet-322	61	29	cell	cell	NOUN
admet-322	61	30	culture	culture	NOUN
admet-322	61	31	and	and	CCONJ
admet-322	61	32	membrane	membrane	NOUN
admet-322	61	33	vesicle	vesicle	NOUN
admet-322	61	34	preparation	preparation	NOUN
admet-322	61	35	hek293	hek293	PROPN
admet-322	61	36	t	t	PROPN
admet-322	61	37	cells	cell	NOUN
admet-322	61	38	stably	stably	ADV
admet-322	61	39	overexpressing	overexpresse	VERB
admet-322	61	40	mrp4	mrp4	NOUN
admet-322	61	41	(	(	PUNCT
admet-322	61	42	hek	hek	NOUN
admet-322	61	43	-	-	PUNCT
admet-322	61	44	mrp4	mrp4	PROPN
admet-322	61	45	)	)	PUNCT
admet-322	61	46	,	,	PUNCT
admet-322	61	47	hek293	hek293	PROPN
admet-322	61	48	t	t	PROPN
admet-322	61	49	cells	cell	NOUN
admet-322	61	50	transfected	transfecte	VERB
admet-322	61	51	with	with	ADP
admet-322	61	52	empty	empty	ADJ
admet-322	61	53	vector	vector	NOUN
admet-322	61	54	(	(	PUNCT
admet-322	61	55	hek	hek	NOUN
admet-322	61	56	-	-	PUNCT
admet-322	61	57	mock	mock	NOUN
admet-322	61	58	)	)	PUNCT
admet-322	61	59	,	,	PUNCT
admet-322	61	60	mdckii	mdckii	PROPN
admet-322	61	61	cells	cell	NOUN
admet-322	61	62	stably	stably	ADV
admet-322	61	63	overexpressing	overexpresse	VERB
admet-322	61	64	bcrp	bcrp	PROPN
admet-322	61	65	(	(	PUNCT
admet-322	61	66	mdckii	mdckii	PROPN
admet-322	61	67	-	-	PUNCT
admet-322	61	68	bcrp	bcrp	NOUN
admet-322	61	69	)	)	PUNCT
admet-322	61	70	,	,	PUNCT
admet-322	61	71	and	and	CCONJ
admet-322	61	72	untransfected	untransfected	ADJ
admet-322	61	73	mdckii	mdckii	ADJ
admet-322	61	74	cells	cell	NOUN
admet-322	61	75	were	be	AUX
admet-322	61	76	cultured	cultured	ADJ
admet-322	61	77	in	in	ADP
admet-322	61	78	dmem	dmem	ADJ
admet-322	61	79	supplemented	supplement	VERB
admet-322	61	80	with	with	ADP
admet-322	61	81	10	10	NUM
admet-322	61	82	%	%	NOUN
admet-322	61	83	fbs	fb	VERB
admet-322	61	84	as	as	SCONJ
admet-322	61	85	previously	previously	ADV
admet-322	61	86	described	describe	VERB
admet-322	61	87	[	[	X
admet-322	61	88	29	29	NUM
admet-322	61	89	,	,	PUNCT
admet-322	61	90	31	31	NUM
admet-322	61	91	]	]	PUNCT
admet-322	61	92	.	.	PUNCT
admet-322	62	1	mrp4	mrp4	PROPN
admet-322	62	2	or	or	CCONJ
admet-322	62	3	bcrp	bcrp	PROPN
admet-322	62	4	overexpression	overexpression	NOUN
admet-322	62	5	was	be	AUX
admet-322	62	6	maintained	maintain	VERB
admet-322	62	7	by	by	ADP
admet-322	62	8	antibiotic	antibiotic	ADJ
admet-322	62	9	selection	selection	NOUN
admet-322	62	10	with	with	ADP
admet-322	62	11	hygromycin	hygromycin	PROPN
admet-322	62	12	b	b	PROPN
admet-322	63	1	[	[	X
admet-322	63	2	29	29	NUM
admet-322	63	3	]	]	PUNCT
admet-322	63	4	.	.	PUNCT
admet-322	64	1	cells	cell	NOUN
admet-322	64	2	were	be	AUX
admet-322	64	3	grown	grow	VERB
admet-322	64	4	to	to	ADP
admet-322	64	5	~85	~85	NOUN
admet-322	64	6	-	-	SYM
admet-322	64	7	95	95	NUM
admet-322	64	8	%	%	NOUN
admet-322	64	9	confluence	confluence	NOUN
admet-322	64	10	before	before	ADP
admet-322	64	11	membrane	membrane	NOUN
admet-322	64	12	vesicle	vesicle	NOUN
admet-322	64	13	preparation	preparation	NOUN
admet-322	64	14	.	.	PUNCT
admet-322	65	1	membrane	membrane	NOUN
admet-322	65	2	vesicles	vesicle	NOUN
admet-322	65	3	were	be	AUX
admet-322	65	4	prepared	prepare	VERB
admet-322	65	5	as	as	SCONJ
admet-322	65	6	previously	previously	ADV
admet-322	65	7	described	describe	VERB
admet-322	65	8	[	[	PUNCT
admet-322	65	9	31	31	NUM
admet-322	65	10	-	-	SYM
admet-322	65	11	34	34	NUM
admet-322	65	12	]	]	PUNCT
admet-322	65	13	.	.	PUNCT
admet-322	66	1	vesicles	vesicle	NOUN
admet-322	66	2	were	be	AUX
admet-322	66	3	validated	validate	VERB
admet-322	66	4	for	for	ADP
admet-322	66	5	maximal	maximal	ADJ
admet-322	66	6	activity	activity	NOUN
admet-322	66	7	and	and	CCONJ
admet-322	66	8	used	use	VERB
admet-322	66	9	in	in	ADP
admet-322	66	10	transport	transport	NOUN
admet-322	66	11	studies	study	NOUN
admet-322	66	12	within	within	ADP
admet-322	66	13	1	1	NUM
admet-322	66	14	-	-	SYM
admet-322	66	15	2	2	NUM
admet-322	66	16	weeks	week	NOUN
admet-322	66	17	of	of	ADP
admet-322	66	18	preparation	preparation	NOUN
admet-322	66	19	.	.	PUNCT
admet-322	67	1	western	western	ADJ
admet-322	67	2	blot	blot	NOUN
admet-322	67	3	analysis	analysis	NOUN
admet-322	67	4	of	of	ADP
admet-322	67	5	transporter	transporter	NOUN
admet-322	67	6	expression	expression	NOUN
admet-322	67	7	transporter	transporter	NOUN
admet-322	67	8	over	over	ADP
admet-322	67	9	-	-	PUNCT
admet-322	67	10	expression	expression	NOUN
admet-322	67	11	was	be	AUX
admet-322	67	12	verified	verify	VERB
admet-322	67	13	in	in	ADP
admet-322	67	14	control	control	NOUN
admet-322	67	15	and	and	CCONJ
admet-322	67	16	transporter	transporter	VERB
admet-322	67	17	over	over	ADP
admet-322	67	18	-	-	PUNCT
admet-322	67	19	expressing	express	VERB
admet-322	67	20	membrane	membrane	NOUN
admet-322	67	21	vesicles	vesicle	NOUN
admet-322	67	22	via	via	ADP
admet-322	67	23	western	western	ADJ
admet-322	67	24	blot	blot	NOUN
admet-322	67	25	analysis	analysis	NOUN
admet-322	67	26	.	.	PUNCT
admet-322	68	1	lysates	lysate	NOUN
admet-322	68	2	of	of	ADP
admet-322	68	3	membrane	membrane	NOUN
admet-322	68	4	vesicles	vesicle	NOUN
admet-322	68	5	(	(	PUNCT
admet-322	68	6	15	15	NUM
admet-322	68	7	μg	μg	NOUN
admet-322	68	8	/	/	SYM
admet-322	68	9	well	well	NOUN
admet-322	68	10	)	)	PUNCT
admet-322	68	11	were	be	AUX
admet-322	68	12	prepared	prepare	VERB
admet-322	68	13	in	in	ADP
admet-322	68	14	tris	tris	ADJ
admet-322	68	15	-	-	PUNCT
admet-322	68	16	glycine	glycine	NOUN
admet-322	68	17	sds	sds	NOUN
admet-322	68	18	sample	sample	NOUN
admet-322	68	19	buffer	buffer	NOUN
admet-322	68	20	(	(	PUNCT
admet-322	68	21	life	life	NOUN
admet-322	68	22	technologies	technology	NOUN
admet-322	68	23	)	)	PUNCT
admet-322	68	24	and	and	CCONJ
admet-322	68	25	separated	separate	VERB
admet-322	68	26	by	by	ADP
admet-322	68	27	sds	sds	PROPN
admet-322	68	28	-	-	PUNCT
admet-322	68	29	polyacrylamide	polyacrylamide	NOUN
admet-322	68	30	gel	gel	NOUN
admet-322	68	31	electrophoresis	electrophoresis	NOUN
admet-322	68	32	(	(	PUNCT
admet-322	68	33	sds	sds	NOUN
admet-322	68	34	-	-	PUNCT
admet-322	68	35	page	page	NOUN
admet-322	68	36	)	)	PUNCT
admet-322	68	37	using	use	VERB
admet-322	68	38	4	4	NUM
admet-322	68	39	-	-	SYM
admet-322	68	40	12	12	NUM
admet-322	68	41	%	%	NOUN
admet-322	68	42	tris	tris	ADJ
admet-322	68	43	-	-	PUNCT
admet-322	68	44	glycine	glycine	NOUN
admet-322	68	45	gels	gel	NOUN
admet-322	68	46	(	(	PUNCT
admet-322	68	47	life	life	NOUN
admet-322	68	48	technologies	technology	NOUN
admet-322	68	49	)	)	PUNCT
admet-322	68	50	.	.	PUNCT
admet-322	69	1	proteins	protein	NOUN
admet-322	69	2	separated	separate	VERB
admet-322	69	3	by	by	ADP
admet-322	69	4	sds	sds	PROPN
admet-322	69	5	-	-	PUNCT
admet-322	69	6	page	page	NOUN
admet-322	69	7	were	be	AUX
admet-322	69	8	transferred	transfer	VERB
admet-322	69	9	to	to	ADP
admet-322	69	10	polyvinylidene	polyvinylidene	NOUN
admet-322	69	11	difluoride	difluoride	NOUN
admet-322	69	12	(	(	PUNCT
admet-322	69	13	pvdf	pvdf	NOUN
admet-322	69	14	)	)	PUNCT
admet-322	69	15	membranes	membrane	NOUN
admet-322	69	16	overnight	overnight	ADV
admet-322	69	17	.	.	PUNCT
admet-322	70	1	protein	protein	NOUN
admet-322	70	2	levels	level	NOUN
admet-322	70	3	on	on	ADP
admet-322	70	4	membranes	membrane	NOUN
admet-322	70	5	were	be	AUX
admet-322	70	6	determined	determine	VERB
admet-322	70	7	by	by	ADP
admet-322	70	8	incubation	incubation	NOUN
admet-322	70	9	with	with	ADP
admet-322	70	10	antibodies	antibody	NOUN
admet-322	70	11	directed	direct	VERB
admet-322	70	12	against	against	ADP
admet-322	70	13	mrp4	mrp4	NOUN
admet-322	70	14	(	(	PUNCT
admet-322	70	15	m4i-10	m4i-10	NOUN
admet-322	70	16	,	,	PUNCT
admet-322	70	17	generously	generously	ADV
admet-322	70	18	provided	provide	VERB
admet-322	70	19	by	by	ADP
admet-322	70	20	george	george	PROPN
admet-322	70	21	l.	l.	PROPN
admet-322	70	22	scheffer	scheffer	PROPN
admet-322	70	23	,	,	PUNCT
admet-322	70	24	amsterdam	amsterdam	PROPN
admet-322	70	25	,	,	PUNCT
admet-322	70	26	the	the	DET
admet-322	70	27	netherlands	netherlands	PROPN
admet-322	70	28	)	)	PUNCT
admet-322	70	29	or	or	CCONJ
admet-322	70	30	bcrp	bcrp	ADV
admet-322	70	31	(	(	PUNCT
admet-322	70	32	bxp-21	bxp-21	PROPN
admet-322	70	33	,	,	PUNCT
admet-322	70	34	kamiya	kamiya	PROPN
admet-322	70	35	biomedical	biomedical	ADJ
admet-322	70	36	company	company	NOUN
admet-322	70	37	)	)	PUNCT
admet-322	70	38	.	.	PUNCT
admet-322	71	1	membrane	membrane	NOUN
admet-322	71	2	vesicle	vesicle	NOUN
admet-322	71	3	transport	transport	NOUN
admet-322	71	4	assay	assay	PROPN
admet-322	71	5	tkiand	tkiand	PROPN
admet-322	71	6	aki	aki	PROPN
admet-322	71	7	-	-	PUNCT
admet-322	71	8	mediated	mediate	VERB
admet-322	71	9	inhibition	inhibition	NOUN
admet-322	71	10	of	of	ADP
admet-322	71	11	transport	transport	NOUN
admet-322	71	12	function	function	NOUN
admet-322	71	13	was	be	AUX
admet-322	71	14	investigated	investigate	VERB
admet-322	71	15	in	in	ADP
admet-322	71	16	membrane	membrane	NOUN
admet-322	71	17	vesicles	vesicle	NOUN
admet-322	71	18	so	so	SCONJ
admet-322	71	19	as	as	SCONJ
admet-322	71	20	to	to	PART
admet-322	71	21	study	study	VERB
admet-322	71	22	the	the	DET
admet-322	71	23	function	function	NOUN
admet-322	71	24	of	of	ADP
admet-322	71	25	a	a	DET
admet-322	71	26	single	single	ADJ
admet-322	71	27	transporter	transporter	NOUN
admet-322	71	28	in	in	ADP
admet-322	71	29	isolation	isolation	NOUN
admet-322	71	30	without	without	ADP
admet-322	71	31	confounding	confound	VERB
admet-322	71	32	variables	variable	NOUN
admet-322	71	33	such	such	ADJ
admet-322	71	34	as	as	ADP
admet-322	71	35	cellular	cellular	ADJ
admet-322	71	36	uptake	uptake	NOUN
admet-322	71	37	or	or	CCONJ
admet-322	71	38	protein	protein	NOUN
admet-322	71	39	binding	bind	VERB
admet-322	71	40	.	.	PUNCT
admet-322	72	1	to	to	PART
admet-322	72	2	confirm	confirm	VERB
admet-322	72	3	transport	transport	NOUN
admet-322	72	4	based	base	VERB
admet-322	72	5	on	on	ADP
admet-322	72	6	previously	previously	ADV
admet-322	72	7	developed	develop	VERB
admet-322	72	8	assays	assay	NOUN
admet-322	72	9	,	,	PUNCT
admet-322	72	10	transport	transport	NOUN
admet-322	72	11	of	of	ADP
admet-322	72	12	[	[	X
admet-322	72	13	3h]dheas	3h]dheas	NUM
admet-322	72	14	(	(	PUNCT
admet-322	72	15	2	2	NUM
admet-322	72	16	µm	µm	NOUN
admet-322	72	17	,	,	PUNCT
admet-322	72	18	0.7	0.7	NUM
admet-322	72	19	µci	µci	PROPN
admet-322	72	20	/	/	SYM
admet-322	72	21	ml	ml	VERB
admet-322	72	22	)	)	PUNCT
admet-322	72	23	by	by	ADP
admet-322	72	24	mrp4	mrp4	NOUN
admet-322	72	25	or	or	CCONJ
admet-322	72	26	[	[	X
admet-322	72	27	3h]e1s	3h]e1s	NUM
admet-322	72	28	(	(	PUNCT
admet-322	72	29	1	1	NUM
admet-322	72	30	µm	µm	NUM
admet-322	72	31	;	;	PUNCT
admet-322	72	32	0.4	0.4	NUM
admet-322	72	33	µci	µci	PROPN
admet-322	72	34	/	/	SYM
admet-322	72	35	ml	ml	VERB
admet-322	72	36	)	)	PUNCT
admet-322	72	37	by	by	ADP
admet-322	72	38	bcrp	bcrp	PROPN
admet-322	72	39	was	be	AUX
admet-322	72	40	measured	measure	VERB
admet-322	72	41	over	over	ADP
admet-322	72	42	time	time	NOUN
admet-322	72	43	via	via	ADP
admet-322	72	44	incubation	incubation	NOUN
admet-322	72	45	of	of	ADP
admet-322	72	46	control	control	NOUN
admet-322	72	47	(	(	PUNCT
admet-322	72	48	hek	hek	NOUN
admet-322	72	49	-	-	PUNCT
admet-322	72	50	mock	mock	PROPN
admet-322	72	51	or	or	CCONJ
admet-322	72	52	mdckii	mdckii	ADJ
admet-322	72	53	)	)	PUNCT
admet-322	72	54	and	and	CCONJ
admet-322	72	55	transporter	transporter	VERB
admet-322	72	56	over	over	ADP
admet-322	72	57	-	-	PUNCT
admet-322	72	58	expressing	express	VERB
admet-322	72	59	(	(	PUNCT
admet-322	72	60	hek	hek	PROPN
admet-322	72	61	-	-	PUNCT
admet-322	72	62	mrp4	mrp4	PROPN
admet-322	72	63	or	or	CCONJ
admet-322	72	64	mdckii	mdckii	PROPN
admet-322	72	65	-	-	PUNCT
admet-322	72	66	bcrp	bcrp	ADJ
admet-322	72	67	)	)	PUNCT
admet-322	72	68	membrane	membrane	ADJ
admet-322	72	69	vesicles	vesicle	NOUN
admet-322	72	70	in	in	ADP
admet-322	72	71	tris	tris	NOUN
admet-322	72	72	-	-	PUNCT
admet-322	72	73	sucrose	sucrose	VERB
admet-322	72	74	buffer	buffer	NOUN
admet-322	72	75	(	(	PUNCT
admet-322	72	76	50	50	NUM
admet-322	72	77	mm	mm	NOUN
admet-322	72	78	tris	tris	PROPN
admet-322	72	79	/	/	SYM
admet-322	72	80	hcl	hcl	PROPN
admet-322	72	81	and	and	CCONJ
admet-322	72	82	250	250	NUM
admet-322	72	83	mm	mm	NOUN
admet-322	72	84	sucrose	sucrose	NOUN
admet-322	72	85	,	,	PUNCT
admet-322	72	86	ph	ph	NOUN
admet-322	72	87	7.4	7.4	NUM
admet-322	72	88	)	)	PUNCT
admet-322	72	89	in	in	ADP
admet-322	72	90	the	the	DET
admet-322	72	91	presence	presence	NOUN
admet-322	72	92	or	or	CCONJ
admet-322	72	93	absence	absence	NOUN
admet-322	72	94	of	of	ADP
admet-322	72	95	an	an	DET
admet-322	72	96	atp	atp	NOUN
admet-322	72	97	-	-	PUNCT
admet-322	72	98	regenerating	regenerate	VERB
admet-322	72	99	system	system	NOUN
admet-322	72	100	(	(	PUNCT
admet-322	72	101	4	4	NUM
admet-322	72	102	mm	mm	PROPN
admet-322	72	103	atp	atp	PROPN
admet-322	72	104	,	,	PUNCT
admet-322	72	105	10	10	NUM
admet-322	72	106	mm	mm	NOUN
admet-322	72	107	mgcl2	mgcl2	PROPN
admet-322	72	108	,	,	PUNCT
admet-322	72	109	10	10	NUM
admet-322	72	110	mm	mm	NUM
admet-322	72	111	creatine	creatine	NOUN
admet-322	72	112	phosphate	phosphate	NOUN
admet-322	72	113	,	,	PUNCT
admet-322	72	114	and	and	CCONJ
admet-322	72	115	0.1	0.1	NUM
admet-322	72	116	mg	mg	NUM
admet-322	72	117	/	/	SYM
admet-322	72	118	ml	ml	PROPN
admet-322	72	119	creatine	creatine	PROPN
admet-322	72	120	kinase	kinase	PROPN
admet-322	72	121	)	)	PUNCT
admet-322	72	122	.	.	PUNCT
admet-322	73	1	transporter	transporter	NOUN
admet-322	73	2	substrate	substrate	NOUN
admet-322	73	3	concentrations	concentration	NOUN
admet-322	73	4	were	be	AUX
admet-322	73	5	selected	select	VERB
admet-322	73	6	based	base	VERB
admet-322	73	7	on	on	ADP
admet-322	73	8	km	km	PROPN
admet-322	73	9	values	value	NOUN
admet-322	73	10	[	[	X
admet-322	73	11	29	29	NUM
admet-322	73	12	,	,	PUNCT
admet-322	73	13	34	34	NUM
admet-322	73	14	]	]	PUNCT
admet-322	73	15	.	.	PUNCT
admet-322	74	1	amp	amp	PROPN
admet-322	74	2	was	be	AUX
admet-322	74	3	replaced	replace	VERB
admet-322	74	4	with	with	ADP
admet-322	74	5	atp	atp	PROPN
admet-322	74	6	for	for	ADP
admet-322	74	7	incubations	incubation	NOUN
admet-322	74	8	conducted	conduct	VERB
admet-322	74	9	in	in	ADP
admet-322	74	10	the	the	DET
admet-322	74	11	absence	absence	NOUN
admet-322	74	12	of	of	ADP
admet-322	74	13	an	an	DET
admet-322	74	14	atp	atp	NOUN
admet-322	74	15	-	-	PUNCT
admet-322	74	16	regenerating	regenerate	VERB
admet-322	74	17	system	system	NOUN
admet-322	74	18	.	.	PUNCT
admet-322	75	1	the	the	DET
admet-322	75	2	difference	difference	NOUN
admet-322	75	3	between	between	ADP
admet-322	75	4	uptake	uptake	NOUN
admet-322	75	5	with	with	ADP
admet-322	75	6	atp	atp	PROPN
admet-322	75	7	versus	versus	ADP
admet-322	75	8	amp	amp	PROPN
admet-322	75	9	was	be	AUX
admet-322	75	10	used	use	VERB
admet-322	75	11	to	to	PART
admet-322	75	12	determine	determine	VERB
admet-322	75	13	the	the	DET
admet-322	75	14	atp	atp	NOUN
admet-322	75	15	-	-	PUNCT
admet-322	75	16	dependent	dependent	ADJ
admet-322	75	17	uptake	uptake	NOUN
admet-322	75	18	of	of	ADP
admet-322	75	19	[	[	NOUN
admet-322	75	20	3h]-dheas	3h]-dheas	NUM
admet-322	75	21	and	and	CCONJ
admet-322	75	22	[	[	X
admet-322	75	23	3h]-e1s	3h]-e1s	NUM
admet-322	75	24	in	in	ADP
admet-322	75	25	mrp4	mrp4	PROPN
admet-322	75	26	and	and	CCONJ
admet-322	75	27	bcrp	bcrp	ADV
admet-322	75	28	membrane	membrane	ADJ
admet-322	75	29	vesicles	vesicle	NOUN
admet-322	75	30	,	,	PUNCT
admet-322	75	31	respectively	respectively	ADV
admet-322	75	32	.	.	PUNCT
admet-322	76	1	for	for	ADP
admet-322	76	2	transport	transport	NOUN
admet-322	76	3	inhibition	inhibition	NOUN
admet-322	76	4	assays	assay	NOUN
admet-322	76	5	,	,	PUNCT
admet-322	76	6	20	20	NUM
admet-322	76	7	different	different	ADJ
admet-322	76	8	tkior	tkior	ADJ
admet-322	76	9	aki	aki	NOUN
admet-322	76	10	-	-	PUNCT
admet-322	76	11	test	test	NOUN
admet-322	76	12	compounds	compound	NOUN
admet-322	76	13	(	(	PUNCT
admet-322	76	14	alisertib	alisertib	ADJ
admet-322	76	15	,	,	PUNCT
admet-322	76	16	axitinib	axitinib	NOUN
admet-322	76	17	,	,	PUNCT
admet-322	76	18	barasertib	barasertib	PROPN
admet-322	76	19	,	,	PUNCT
admet-322	76	20	bosutinib	bosutinib	NOUN
admet-322	76	21	,	,	PUNCT
admet-322	76	22	crizotinib	crizotinib	NOUN
admet-322	76	23	,	,	PUNCT
admet-322	76	24	danusertib	danusertib	NOUN
admet-322	76	25	,	,	PUNCT
admet-322	76	26	dasatinib	dasatinib	NOUN
admet-322	76	27	,	,	PUNCT
admet-322	76	28	enzastaurin	enzastaurin	NOUN
admet-322	76	29	,	,	PUNCT
admet-322	76	30	erlotinib	erlotinib	NOUN
admet-322	76	31	,	,	PUNCT
admet-322	76	32	gefitinib	gefitinib	NOUN
admet-322	76	33	,	,	PUNCT
admet-322	76	34	imatinib	imatinib	NOUN
admet-322	76	35	,	,	PUNCT
admet-322	76	36	lapatinib	lapatinib	PROPN
admet-322	76	37	,	,	PUNCT
admet-322	76	38	neratinib	neratinib	NOUN
admet-322	76	39	,	,	PUNCT
admet-322	76	40	nilotinib	nilotinib	NOUN
admet-322	76	41	,	,	PUNCT
admet-322	76	42	pazopanib	pazopanib	NOUN
admet-322	76	43	,	,	PUNCT
admet-322	76	44	selumetinib	selumetinib	NOUN
admet-322	76	45	,	,	PUNCT
admet-322	76	46	sorafenib	sorafenib	NOUN
admet-322	76	47	,	,	PUNCT
admet-322	76	48	sunitinib	sunitinib	NOUN
admet-322	76	49	,	,	PUNCT
admet-322	76	50	tozasertib	tozasertib	NOUN
admet-322	76	51	,	,	PUNCT
admet-322	76	52	or	or	CCONJ
admet-322	76	53	vandetanib	vandetanib	NOUN
admet-322	76	54	)	)	PUNCT
admet-322	76	55	solubilized	solubilize	VERB
admet-322	76	56	in	in	ADP
admet-322	76	57	dmso	dmso	NOUN
admet-322	76	58	(	(	PUNCT
admet-322	76	59	1	1	NUM
admet-322	76	60	%	%	NOUN
admet-322	76	61	dmso	dmso	ADJ
admet-322	76	62	final	final	ADJ
admet-322	76	63	reaction	reaction	NOUN
admet-322	76	64	concentration	concentration	NOUN
admet-322	76	65	)	)	PUNCT
admet-322	76	66	were	be	AUX
admet-322	76	67	added	add	VERB
admet-322	76	68	in	in	ADP
admet-322	76	69	separate	separate	ADJ
admet-322	76	70	experiments	experiment	NOUN
admet-322	76	71	to	to	ADP
admet-322	76	72	the	the	DET
admet-322	76	73	reaction	reaction	NOUN
admet-322	76	74	mixture	mixture	NOUN
admet-322	76	75	containing	contain	VERB
admet-322	76	76	control	control	NOUN
admet-322	76	77	or	or	CCONJ
admet-322	76	78	transporter	transporter	VERB
admet-322	76	79	over	over	ADP
admet-322	76	80	-	-	PUNCT
admet-322	76	81	expressing	express	VERB
admet-322	76	82	membrane	membrane	NOUN
admet-322	76	83	vesicles	vesicle	NOUN
admet-322	76	84	in	in	ADP
admet-322	76	85	tris	tris	NOUN
admet-322	76	86	-	-	PUNCT
admet-322	76	87	sucrose	sucrose	VERB
admet-322	76	88	buffer	buffer	NOUN
admet-322	76	89	with	with	ADP
admet-322	76	90	the	the	DET
admet-322	76	91	atp	atp	NOUN
admet-322	76	92	-	-	PUNCT
admet-322	76	93	regenerating	regenerate	VERB
admet-322	76	94	system	system	NOUN
admet-322	76	95	.	.	PUNCT
admet-322	77	1	test	test	NOUN
admet-322	77	2	compounds	compound	NOUN
admet-322	77	3	were	be	AUX
admet-322	77	4	examined	examine	VERB
admet-322	77	5	at	at	ADP
admet-322	77	6	a	a	DET
admet-322	77	7	concentration	concentration	NOUN
admet-322	77	8	range	range	NOUN
admet-322	77	9	of	of	ADP
admet-322	77	10	0.316	0.316	NUM
admet-322	77	11	-	-	SYM
admet-322	77	12	100	100	NUM
admet-322	77	13	μm	μm	NOUN
admet-322	77	14	.	.	PUNCT
admet-322	78	1	for	for	ADP
admet-322	78	2	potent	potent	ADJ
admet-322	78	3	bcrp	bcrp	ADJ
admet-322	78	4	inhibitors	inhibitor	NOUN
admet-322	78	5	,	,	PUNCT
admet-322	78	6	the	the	DET
admet-322	78	7	concentration	concentration	NOUN
admet-322	78	8	range	range	NOUN
admet-322	78	9	was	be	AUX
admet-322	78	10	reduced	reduce	VERB
admet-322	78	11	to	to	ADP
admet-322	78	12	0.00316	0.00316	NUM
admet-322	78	13	μm	μm	NOUN
admet-322	78	14	.	.	PUNCT
admet-322	79	1	for	for	ADP
admet-322	79	2	control	control	NOUN
admet-322	79	3	samples	sample	NOUN
admet-322	79	4	,	,	PUNCT
admet-322	79	5	identical	identical	ADJ
admet-322	79	6	concentrations	concentration	NOUN
admet-322	79	7	of	of	ADP
admet-322	79	8	the	the	DET
admet-322	79	9	solvent	solvent	NOUN
admet-322	79	10	(	(	PUNCT
admet-322	79	11	1	1	NUM
admet-322	79	12	%	%	NOUN
admet-322	79	13	dmso	dmso	NOUN
admet-322	79	14	)	)	PUNCT
admet-322	79	15	were	be	AUX
admet-322	79	16	used	use	VERB
admet-322	79	17	.	.	PUNCT
admet-322	80	1	all	all	DET
admet-322	80	2	uptake	uptake	ADJ
admet-322	80	3	studies	study	NOUN
admet-322	80	4	were	be	AUX
admet-322	80	5	performed	perform	VERB
admet-322	80	6	at	at	ADP
admet-322	80	7	37	37	NUM
admet-322	80	8	°	°	NOUN
admet-322	80	9	c	c	NOUN
admet-322	80	10	.	.	PUNCT
admet-322	81	1	uptake	uptake	NOUN
admet-322	81	2	was	be	AUX
admet-322	81	3	stopped	stop	VERB
admet-322	81	4	by	by	ADP
admet-322	81	5	addition	addition	NOUN
admet-322	81	6	of	of	ADP
admet-322	81	7	ice	ice	NOUN
admet-322	81	8	cold	cold	ADJ
admet-322	81	9	tris	tris	NOUN
admet-322	81	10	-	-	PUNCT
admet-322	81	11	sucrose	sucrose	VERB
admet-322	81	12	buffer	buffer	NOUN
admet-322	81	13	followed	follow	VERB
admet-322	81	14	by	by	ADP
admet-322	81	15	rapid	rapid	ADJ
admet-322	81	16	vacuum	vacuum	NOUN
admet-322	81	17	filtration	filtration	NOUN
admet-322	81	18	through	through	ADP
admet-322	81	19	glass	glass	NOUN
admet-322	81	20	fiber	fiber	NOUN
admet-322	81	21	96	96	NUM
admet-322	81	22	-	-	PUNCT
admet-322	81	23	well	well	NOUN
admet-322	81	24	plates	plate	NOUN
admet-322	81	25	pre	pre	ADJ
admet-322	81	26	-	-	ADJ
admet-322	81	27	soaked	soaked	ADJ
admet-322	81	28	in	in	ADP
admet-322	81	29	tris	tris	NOUN
admet-322	81	30	-	-	PUNCT
admet-322	81	31	sucrose	sucrose	VERB
admet-322	81	32	buffer	buffer	NOUN
admet-322	81	33	(	(	PUNCT
admet-322	81	34	bcrp	bcrp	NOUN
admet-322	81	35	reactions	reaction	NOUN
admet-322	81	36	)	)	PUNCT
admet-322	81	37	or	or	CCONJ
admet-322	81	38	tris	tris	NOUN
admet-322	81	39	-	-	PUNCT
admet-322	81	40	sucrose	sucrose	VERB
admet-322	81	41	buffer	buffer	NOUN
admet-322	81	42	with	with	ADP
admet-322	81	43	3	3	NUM
admet-322	81	44	mm	mm	NOUN
admet-322	81	45	glutathione	glutathione	NOUN
admet-322	81	46	and	and	CCONJ
admet-322	81	47	10	10	NUM
admet-322	81	48	mm	mm	PROPN
admet-322	81	49	dithiothreitol	dithiothreitol	NOUN
admet-322	81	50	(	(	PUNCT
admet-322	81	51	mrp4	mrp4	PROPN
admet-322	81	52	)	)	PUNCT
admet-322	81	53	.	.	PUNCT
admet-322	82	1	microscint-20	microscint-20	PROPN
admet-322	82	2	(	(	PUNCT
admet-322	82	3	75	75	NUM
admet-322	82	4	μl	μl	PRON
admet-322	82	5	)	)	PUNCT
admet-322	82	6	was	be	AUX
admet-322	82	7	added	add	VERB
admet-322	82	8	to	to	ADP
admet-322	82	9	each	each	DET
admet-322	82	10	well	well	ADV
admet-322	82	11	and	and	CCONJ
admet-322	82	12	the	the	DET
admet-322	82	13	plate	plate	NOUN
admet-322	82	14	was	be	AUX
admet-322	82	15	allowed	allow	VERB
admet-322	82	16	to	to	PART
admet-322	82	17	rotate	rotate	VERB
admet-322	82	18	on	on	ADP
admet-322	82	19	an	an	DET
admet-322	82	20	orbital	orbital	ADJ
admet-322	82	21	shaker	shaker	NOUN
admet-322	82	22	for	for	ADP
admet-322	82	23	15	15	NUM
admet-322	82	24	minutes	minute	NOUN
admet-322	82	25	.	.	PUNCT
admet-322	83	1	radioactivity	radioactivity	NOUN
admet-322	83	2	was	be	AUX
admet-322	83	3	quantified	quantify	VERB
admet-322	83	4	by	by	ADP
admet-322	83	5	liquid	liquid	ADJ
admet-322	83	6	scintillation	scintillation	NOUN
admet-322	83	7	counting	counting	NOUN
admet-322	83	8	in	in	ADP
admet-322	83	9	a	a	DET
admet-322	83	10	topcount	topcount	NOUN
admet-322	83	11	nxt	nxt	PROPN
admet-322	83	12	instrument	instrument	NOUN
admet-322	83	13	(	(	PUNCT
admet-322	83	14	perkin	perkin	PROPN
admet-322	83	15	elmer	elmer	PROPN
admet-322	83	16	)	)	PUNCT
admet-322	83	17	.	.	PUNCT
admet-322	84	1	incubations	incubation	NOUN
admet-322	84	2	with	with	ADP
admet-322	84	3	test	test	NOUN
admet-322	84	4	compounds	compound	NOUN
admet-322	84	5	were	be	AUX
admet-322	84	6	completed	complete	VERB
admet-322	84	7	in	in	ADP
admet-322	84	8	at	at	ADV
admet-322	84	9	least	least	ADV
admet-322	84	10	three	three	NUM
admet-322	84	11	independent	independent	ADJ
admet-322	84	12	experiments	experiment	NOUN
admet-322	84	13	with	with	ADP
admet-322	84	14	no	no	DET
admet-322	84	15	replicates	replicate	NOUN
admet-322	84	16	in	in	ADP
admet-322	84	17	individual	individual	ADJ
admet-322	84	18	experiments	experiment	NOUN
admet-322	84	19	.	.	PUNCT
admet-322	85	1	positive	positive	ADJ
admet-322	85	2	control	control	NOUN
admet-322	85	3	inhibitors	inhibitor	NOUN
admet-322	85	4	(	(	PUNCT
admet-322	85	5	mk571	mk571	PROPN
admet-322	85	6	r.n	r.n	PROPN
admet-322	85	7	.	.	PROPN
admet-322	85	8	hardwick	hardwick	PROPN
admet-322	85	9	et	et	PROPN
admet-322	85	10	al	al	PROPN
admet-322	85	11	.	.	PROPN
admet-322	85	12	admet	admet	PROPN
admet-322	85	13	&	&	CCONJ
admet-322	85	14	dmpk	dmpk	PROPN
admet-322	85	15	4(4	4(4	NUM
admet-322	85	16	)	)	PUNCT
admet-322	85	17	(	(	PUNCT
admet-322	85	18	2016	2016	NUM
admet-322	85	19	)	)	PUNCT
admet-322	85	20	302	302	NUM
admet-322	85	21	-	-	SYM
admet-322	85	22	313	313	NUM
admet-322	85	23	306	306	NUM
admet-322	85	24	for	for	ADP
admet-322	85	25	mrp4	mrp4	NOUN
admet-322	85	26	;	;	PUNCT
admet-322	85	27	sulfasalazine	sulfasalazine	NOUN
admet-322	85	28	and	and	CCONJ
admet-322	85	29	promethazine	promethazine	PROPN
admet-322	85	30	for	for	ADP
admet-322	85	31	bcrp	bcrp	ADV
admet-322	85	32	)	)	PUNCT
admet-322	85	33	were	be	AUX
admet-322	85	34	included	include	VERB
admet-322	85	35	in	in	ADP
admet-322	85	36	each	each	DET
admet-322	85	37	individual	individual	ADJ
admet-322	85	38	experiment	experiment	NOUN
admet-322	85	39	for	for	ADP
admet-322	85	40	quality	quality	NOUN
admet-322	85	41	control	control	NOUN
admet-322	85	42	.	.	PUNCT
admet-322	86	1	data	datum	NOUN
admet-322	86	2	analysis	analysis	NOUN
admet-322	86	3	and	and	CCONJ
admet-322	86	4	statistics	statistic	NOUN
admet-322	86	5	substrate	substrate	NOUN
admet-322	86	6	uptake	uptake	ADJ
admet-322	86	7	into	into	ADP
admet-322	86	8	vesicles	vesicle	NOUN
admet-322	86	9	was	be	AUX
admet-322	86	10	calculated	calculate	VERB
admet-322	86	11	as	as	ADP
admet-322	86	12	pmol	pmol	NOUN
admet-322	86	13	/	/	SYM
admet-322	86	14	mg	mg	PROPN
admet-322	86	15	protein	protein	NOUN
admet-322	86	16	/	/	SYM
admet-322	86	17	min	min	NOUN
admet-322	86	18	before	before	ADP
admet-322	86	19	conversion	conversion	NOUN
admet-322	86	20	to	to	ADP
admet-322	86	21	percent	percent	NOUN
admet-322	86	22	of	of	ADP
admet-322	86	23	control	control	NOUN
admet-322	86	24	inhibition	inhibition	NOUN
admet-322	86	25	.	.	PUNCT
admet-322	87	1	inhibition	inhibition	NOUN
admet-322	87	2	by	by	ADP
admet-322	87	3	tki	tki	NOUN
admet-322	87	4	/	/	SYM
admet-322	87	5	akis	akis	PROPN
admet-322	87	6	as	as	ADP
admet-322	87	7	a	a	DET
admet-322	87	8	percentage	percentage	NOUN
admet-322	87	9	of	of	ADP
admet-322	87	10	control	control	NOUN
admet-322	87	11	was	be	AUX
admet-322	87	12	calculated	calculate	VERB
admet-322	87	13	as	as	ADP
admet-322	87	14	the	the	DET
admet-322	87	15	difference	difference	NOUN
admet-322	87	16	between	between	ADP
admet-322	87	17	substrate	substrate	NOUN
admet-322	87	18	uptake	uptake	NOUN
admet-322	87	19	in	in	ADP
admet-322	87	20	control	control	NOUN
admet-322	87	21	and	and	CCONJ
admet-322	87	22	transporter	transporter	NOUN
admet-322	87	23	-	-	PUNCT
admet-322	87	24	overexpressing	overexpresse	VERB
admet-322	87	25	membrane	membrane	NOUN
admet-322	87	26	vesicles	vesicle	NOUN
admet-322	87	27	compared	compare	VERB
admet-322	87	28	to	to	ADP
admet-322	87	29	vehicle	vehicle	NOUN
admet-322	87	30	-	-	PUNCT
admet-322	87	31	treated	treat	VERB
admet-322	87	32	membrane	membrane	NOUN
admet-322	87	33	vesicles	vesicle	NOUN
admet-322	87	34	(	(	PUNCT
admet-322	87	35	mean	mean	NOUN
admet-322	87	36	±	±	NUM
admet-322	87	37	standard	standard	ADJ
admet-322	87	38	deviation	deviation	NOUN
admet-322	87	39	,	,	PUNCT
admet-322	87	40	sd	sd	NOUN
admet-322	87	41	)	)	PUNCT
admet-322	87	42	.	.	PUNCT
admet-322	88	1	dose	dose	NOUN
admet-322	88	2	-	-	PUNCT
admet-322	88	3	response	response	NOUN
admet-322	88	4	ic50	ic50	PROPN
admet-322	88	5	curves	curve	NOUN
admet-322	88	6	were	be	AUX
admet-322	88	7	fit	fit	ADJ
admet-322	88	8	via	via	ADP
admet-322	88	9	nonlinear	nonlinear	ADJ
admet-322	88	10	regression	regression	NOUN
admet-322	88	11	analysis	analysis	NOUN
admet-322	88	12	according	accord	VERB
admet-322	88	13	to	to	ADP
admet-322	88	14	the	the	DET
admet-322	88	15	four	four	NUM
admet-322	88	16	-	-	PUNCT
admet-322	88	17	parameter	parameter	NOUN
admet-322	88	18	logistic	logistic	ADJ
admet-322	88	19	model	model	NOUN
admet-322	88	20	(	(	PUNCT
admet-322	88	21	4pl	4pl	NOUN
admet-322	88	22	)	)	PUNCT
admet-322	88	23	with	with	ADP
admet-322	88	24	the	the	DET
admet-322	88	25	bottom	bottom	ADJ
admet-322	88	26	constraint	constraint	NOUN
admet-322	88	27	set	set	VERB
admet-322	88	28	to	to	ADP
admet-322	88	29	>	>	X
admet-322	88	30	0	0	PUNCT
admet-322	88	31	using	use	VERB
admet-322	88	32	graphpad	graphpad	NOUN
admet-322	88	33	prism	prism	NOUN
admet-322	88	34	5	5	NUM
admet-322	88	35	.	.	PUNCT
admet-322	89	1	for	for	ADP
admet-322	89	2	analysis	analysis	NOUN
admet-322	89	3	of	of	ADP
admet-322	89	4	potential	potential	ADJ
admet-322	89	5	clinical	clinical	ADJ
admet-322	89	6	relevance	relevance	NOUN
admet-322	89	7	of	of	ADP
admet-322	89	8	transporter	transporter	NOUN
admet-322	89	9	inhibition	inhibition	NOUN
admet-322	89	10	,	,	PUNCT
admet-322	89	11	steady	steady	ADJ
admet-322	89	12	-	-	PUNCT
admet-322	89	13	state	state	NOUN
admet-322	89	14	total	total	ADJ
admet-322	89	15	plasma	plasma	NOUN
admet-322	89	16	css	css	NOUN
admet-322	89	17	values	value	NOUN
admet-322	89	18	for	for	ADP
admet-322	89	19	each	each	DET
admet-322	89	20	tki	tki	PROPN
admet-322	89	21	/	/	SYM
admet-322	89	22	aki	aki	NOUN
admet-322	89	23	were	be	AUX
admet-322	89	24	extracted	extract	VERB
admet-322	89	25	from	from	ADP
admet-322	89	26	micromedex	micromedex	NOUN
admet-322	89	27	and	and	CCONJ
admet-322	89	28	manufacturer	manufacturer	NOUN
admet-322	89	29	package	package	NOUN
admet-322	89	30	inserts	insert	NOUN
admet-322	89	31	.	.	PUNCT
admet-322	90	1	results	result	NOUN
admet-322	90	2	and	and	CCONJ
admet-322	90	3	discussion	discussion	NOUN
admet-322	90	4	mrp4	mrp4	VERB
admet-322	90	5	over	over	ADP
admet-322	90	6	-	-	PUNCT
admet-322	90	7	expression	expression	NOUN
admet-322	90	8	was	be	AUX
admet-322	90	9	confirmed	confirm	VERB
admet-322	90	10	in	in	ADP
admet-322	90	11	hek	hek	PROPN
admet-322	90	12	-	-	PUNCT
admet-322	90	13	mrp4	mrp4	PROPN
admet-322	90	14	membrane	membrane	NOUN
admet-322	90	15	vesicles	vesicle	NOUN
admet-322	90	16	,	,	PUNCT
admet-322	90	17	and	and	CCONJ
admet-322	90	18	was	be	AUX
admet-322	90	19	significantly	significantly	ADV
admet-322	90	20	higher	high	ADJ
admet-322	90	21	than	than	ADP
admet-322	90	22	hek	hek	NOUN
admet-322	90	23	-	-	PUNCT
admet-322	90	24	mock	mock	ADJ
admet-322	90	25	membrane	membrane	NOUN
admet-322	90	26	vesicles	vesicle	NOUN
admet-322	90	27	(	(	PUNCT
admet-322	90	28	figure	figure	NOUN
admet-322	90	29	1a	1a	NOUN
admet-322	90	30	)	)	PUNCT
admet-322	90	31	.	.	PUNCT
admet-322	91	1	the	the	DET
admet-322	91	2	timeand	timeand	NOUN
admet-322	91	3	atp	atp	PROPN
admet-322	91	4	-	-	PUNCT
admet-322	91	5	dependent	dependent	ADJ
admet-322	91	6	uptake	uptake	NOUN
admet-322	91	7	of	of	ADP
admet-322	91	8	[	[	PUNCT
admet-322	91	9	3	3	NUM
admet-322	91	10	h]-dheas	h]-dheas	NOUN
admet-322	91	11	in	in	ADP
admet-322	91	12	hek	hek	PROPN
admet-322	91	13	-	-	PUNCT
admet-322	91	14	mrp4	mrp4	PROPN
admet-322	91	15	vesicles	vesicle	NOUN
admet-322	91	16	was	be	AUX
admet-322	91	17	linear	linear	ADJ
admet-322	91	18	up	up	ADP
admet-322	91	19	to	to	PART
admet-322	91	20	10	10	NUM
admet-322	91	21	minutes	minute	NOUN
admet-322	91	22	(	(	PUNCT
admet-322	91	23	figure	figure	NOUN
admet-322	91	24	1a	1a	NOUN
admet-322	91	25	)	)	PUNCT
admet-322	91	26	,	,	PUNCT
admet-322	91	27	similar	similar	ADJ
admet-322	91	28	to	to	ADP
admet-322	91	29	previous	previous	ADJ
admet-322	91	30	studies	study	NOUN
admet-322	91	31	[	[	X
admet-322	91	32	29	29	NUM
admet-322	91	33	]	]	PUNCT
admet-322	91	34	.	.	PUNCT
admet-322	92	1	[	[	X
admet-322	92	2	3h]-dheas	3h]-dheas	NUM
admet-322	92	3	uptake	uptake	NOUN
admet-322	92	4	in	in	ADP
admet-322	92	5	hek	hek	PROPN
admet-322	92	6	-	-	PUNCT
admet-322	92	7	mrp4	mrp4	PROPN
admet-322	92	8	vesicles	vesicle	NOUN
admet-322	92	9	was	be	AUX
admet-322	92	10	at	at	ADV
admet-322	92	11	least	least	ADJ
admet-322	92	12	75	75	NUM
admet-322	92	13	-	-	NUM
admet-322	92	14	fold	fold	VERB
admet-322	92	15	greater	great	ADJ
admet-322	92	16	than	than	ADP
admet-322	92	17	in	in	ADP
admet-322	92	18	hek	hek	NOUN
admet-322	92	19	-	-	PUNCT
admet-322	92	20	mock	mock	ADJ
admet-322	92	21	vesicles	vesicle	NOUN
admet-322	92	22	.	.	PUNCT
admet-322	93	1	an	an	DET
admet-322	93	2	incubation	incubation	NOUN
admet-322	93	3	time	time	NOUN
admet-322	93	4	of	of	ADP
admet-322	93	5	3.5	3.5	NUM
admet-322	93	6	minutes	minute	NOUN
admet-322	93	7	was	be	AUX
admet-322	93	8	chosen	choose	VERB
admet-322	93	9	for	for	ADP
admet-322	93	10	experiments	experiment	NOUN
admet-322	93	11	with	with	ADP
admet-322	93	12	hek	hek	PROPN
admet-322	93	13	-	-	PUNCT
admet-322	93	14	mrp4	mrp4	PROPN
admet-322	93	15	vesicles	vesicle	NOUN
admet-322	93	16	to	to	PART
admet-322	93	17	evaluate	evaluate	VERB
admet-322	93	18	the	the	DET
admet-322	93	19	inhibition	inhibition	NOUN
admet-322	93	20	potential	potential	NOUN
admet-322	93	21	of	of	ADP
admet-322	93	22	test	test	NOUN
admet-322	93	23	compounds	compound	NOUN
admet-322	93	24	,	,	PUNCT
admet-322	93	25	similar	similar	ADJ
admet-322	93	26	to	to	ADP
admet-322	93	27	previous	previous	ADJ
admet-322	93	28	studies	study	NOUN
admet-322	93	29	[	[	X
admet-322	93	30	29	29	NUM
admet-322	93	31	]	]	PUNCT
admet-322	93	32	.	.	PUNCT
admet-322	94	1	the	the	DET
admet-322	94	2	pan	pan	PROPN
admet-322	94	3	-	-	ADJ
admet-322	94	4	mrp	mrp	NOUN
admet-322	94	5	inhibitor	inhibitor	NOUN
admet-322	94	6	mk571	mk571	PROPN
admet-322	94	7	was	be	AUX
admet-322	94	8	assessed	assess	VERB
admet-322	94	9	across	across	ADP
admet-322	94	10	a	a	DET
admet-322	94	11	concentration	concentration	NOUN
admet-322	94	12	range	range	NOUN
admet-322	94	13	of	of	ADP
admet-322	94	14	0.316	0.316	NUM
admet-322	94	15	-	-	SYM
admet-322	94	16	100	100	NUM
admet-322	94	17	μm	μm	NOUN
admet-322	94	18	.	.	PUNCT
admet-322	95	1	mk571	mk571	PROPN
admet-322	95	2	produced	produce	VERB
admet-322	95	3	a	a	DET
admet-322	95	4	prototypical	prototypical	ADJ
admet-322	95	5	dose	dose	NOUN
admet-322	95	6	-	-	PUNCT
admet-322	95	7	response	response	NOUN
admet-322	95	8	curve	curve	NOUN
admet-322	95	9	ranging	range	VERB
admet-322	95	10	from	from	ADP
admet-322	95	11	nearly	nearly	ADV
admet-322	95	12	full	full	ADJ
admet-322	95	13	activity	activity	NOUN
admet-322	95	14	to	to	PART
admet-322	95	15	complete	complete	VERB
admet-322	95	16	inhibition	inhibition	NOUN
admet-322	95	17	(	(	PUNCT
admet-322	95	18	figure	figure	NOUN
admet-322	95	19	1b	1b	NUM
admet-322	95	20	)	)	PUNCT
admet-322	95	21	with	with	ADP
admet-322	95	22	an	an	DET
admet-322	95	23	ic50	ic50	PROPN
admet-322	95	24	value	value	NOUN
admet-322	95	25	of	of	ADP
admet-322	95	26	2.04	2.04	NUM
admet-322	95	27	μm	μm	NOUN
admet-322	95	28	(	(	PUNCT
admet-322	95	29	95	95	NUM
admet-322	95	30	%	%	NOUN
admet-322	95	31	confidence	confidence	NOUN
admet-322	95	32	interval	interval	NOUN
admet-322	95	33	:	:	PUNCT
admet-322	95	34	1.31	1.31	NUM
admet-322	95	35	-	-	SYM
admet-322	95	36	3.19	3.19	NUM
admet-322	95	37	μm	μm	NUM
admet-322	95	38	)	)	PUNCT
admet-322	95	39	.	.	PUNCT
admet-322	96	1	morgan	morgan	PROPN
admet-322	96	2	,	,	PUNCT
admet-322	96	3	et	et	PROPN
admet-322	96	4	al	al	PROPN
admet-322	96	5	.	.	PROPN
admet-322	96	6	previously	previously	ADV
admet-322	96	7	reported	report	VERB
admet-322	96	8	an	an	DET
admet-322	96	9	ic50	ic50	PROPN
admet-322	96	10	value	value	NOUN
admet-322	96	11	of	of	ADP
admet-322	96	12	6	6	NUM
admet-322	96	13	µm	µm	NOUN
admet-322	96	14	for	for	ADP
admet-322	96	15	mk571	mk571	PROPN
admet-322	96	16	-	-	PUNCT
admet-322	96	17	mediated	mediate	VERB
admet-322	96	18	inhibition	inhibition	NOUN
admet-322	96	19	of	of	ADP
admet-322	96	20	3	3	NUM
admet-322	96	21	h	h	NOUN
admet-322	96	22	-	-	PUNCT
admet-322	96	23	estradiol-17β	estradiol-17β	PROPN
admet-322	96	24	-	-	PUNCT
admet-322	96	25	d	d	NOUN
admet-322	96	26	-	-	ADJ
admet-322	96	27	glucuronide	glucuronide	ADJ
admet-322	96	28	uptake	uptake	NOUN
admet-322	96	29	in	in	ADP
admet-322	96	30	mrp4	mrp4	NOUN
admet-322	96	31	membrane	membrane	NOUN
admet-322	96	32	vesicles	vesicle	NOUN
admet-322	96	33	derived	derive	VERB
admet-322	96	34	from	from	ADP
admet-322	96	35	sf9	sf9	NOUN
admet-322	96	36	cells	cell	NOUN
admet-322	96	37	[	[	X
admet-322	96	38	35	35	NUM
admet-322	96	39	]	]	PUNCT
admet-322	96	40	.	.	PUNCT
admet-322	97	1	mk571	mk571	PROPN
admet-322	97	2	was	be	AUX
admet-322	97	3	included	include	VERB
admet-322	97	4	as	as	ADP
admet-322	97	5	a	a	DET
admet-322	97	6	positive	positive	ADJ
admet-322	97	7	control	control	NOUN
admet-322	97	8	with	with	ADP
admet-322	97	9	all	all	DET
admet-322	97	10	subsequent	subsequent	ADJ
admet-322	97	11	test	test	NOUN
admet-322	97	12	compound	compound	NOUN
admet-322	97	13	experiments	experiment	NOUN
admet-322	97	14	for	for	ADP
admet-322	97	15	quality	quality	NOUN
admet-322	97	16	assurance	assurance	NOUN
admet-322	97	17	of	of	ADP
admet-322	97	18	the	the	DET
admet-322	97	19	mrp4	mrp4	NOUN
admet-322	97	20	vesicle	vesicle	NOUN
admet-322	97	21	assay	assay	VERB
admet-322	97	22	.	.	PUNCT
admet-322	98	1	figure	figure	NOUN
admet-322	98	2	1	1	NUM
admet-322	98	3	.	.	PUNCT
admet-322	98	4	characterization	characterization	NOUN
admet-322	98	5	of	of	ADP
admet-322	98	6	the	the	DET
admet-322	98	7	mrp4	mrp4	NOUN
admet-322	98	8	membrane	membrane	NOUN
admet-322	98	9	vesicle	vesicle	NOUN
admet-322	98	10	assay	assay	VERB
admet-322	98	11	.	.	PUNCT
admet-322	99	1	(	(	PUNCT
admet-322	99	2	a	a	X
admet-322	99	3	)	)	PUNCT
admet-322	99	4	mrp4	mrp4	NOUN
admet-322	99	5	expression	expression	NOUN
admet-322	99	6	in	in	ADP
admet-322	99	7	hek	hek	PROPN
admet-322	99	8	-	-	PUNCT
admet-322	99	9	mock	mock	PROPN
admet-322	99	10	and	and	CCONJ
admet-322	99	11	hek	hek	PROPN
admet-322	99	12	-	-	PUNCT
admet-322	99	13	mrp4	mrp4	PROPN
admet-322	99	14	cells	cell	NOUN
admet-322	99	15	.	.	PUNCT
admet-322	100	1	also	also	ADV
admet-322	100	2	shown	show	VERB
admet-322	100	3	is	be	AUX
admet-322	100	4	atp	atp	NOUN
admet-322	100	5	-	-	PUNCT
admet-322	100	6	dependent	dependent	ADJ
admet-322	100	7	,	,	PUNCT
admet-322	100	8	time	time	NOUN
admet-322	100	9	-	-	PUNCT
admet-322	100	10	dependent	dependent	ADJ
admet-322	100	11	uptake	uptake	NOUN
admet-322	100	12	of	of	ADP
admet-322	100	13	2	2	NUM
admet-322	100	14	μm	μm	NOUN
admet-322	100	15	[	[	PUNCT
admet-322	100	16	3	3	NUM
admet-322	100	17	h]-dehydroepiandrosterone	h]-dehydroepiandrosterone	NOUN
admet-322	100	18	(	(	PUNCT
admet-322	100	19	dheas	dheas	ADJ
admet-322	100	20	)	)	PUNCT
admet-322	100	21	in	in	ADP
admet-322	100	22	membrane	membrane	NOUN
admet-322	100	23	vesicles	vesicle	NOUN
admet-322	100	24	.	.	PUNCT
admet-322	101	1	data	datum	NOUN
admet-322	101	2	are	be	AUX
admet-322	101	3	presented	present	VERB
admet-322	101	4	as	as	ADP
admet-322	101	5	mean	mean	NOUN
admet-322	101	6	±	±	NUM
admet-322	101	7	sd	sd	NOUN
admet-322	101	8	,	,	PUNCT
admet-322	101	9	n=3	n=3	PUNCT
admet-322	101	10	independent	independent	ADJ
admet-322	101	11	experiments	experiment	NOUN
admet-322	101	12	.	.	PUNCT
admet-322	102	1	(	(	PUNCT
admet-322	102	2	b	b	X
admet-322	102	3	)	)	PUNCT
admet-322	102	4	doseresponse	doseresponse	NOUN
admet-322	102	5	ic50	ic50	PROPN
admet-322	102	6	curve	curve	NOUN
admet-322	102	7	of	of	ADP
admet-322	102	8	the	the	DET
admet-322	102	9	mrp4	mrp4	NOUN
admet-322	102	10	positive	positive	ADJ
admet-322	102	11	control	control	NOUN
admet-322	102	12	inhibitor	inhibitor	NOUN
admet-322	102	13	mk571	mk571	PROPN
admet-322	102	14	(	(	PUNCT
admet-322	102	15	3.5	3.5	NUM
admet-322	102	16	min	min	NOUN
admet-322	102	17	incubation	incubation	NOUN
admet-322	102	18	)	)	PUNCT
admet-322	102	19	.	.	PUNCT
admet-322	103	1	data	datum	NOUN
admet-322	103	2	are	be	AUX
admet-322	103	3	presented	present	VERB
admet-322	103	4	as	as	ADP
admet-322	103	5	mean	mean	ADJ
admet-322	103	6	%	%	NOUN
admet-322	103	7	of	of	ADP
admet-322	103	8	control	control	NOUN
admet-322	103	9	uptake	uptake	ADJ
admet-322	103	10	±	±	NOUN
admet-322	103	11	sd	sd	NOUN
admet-322	103	12	,	,	PUNCT
admet-322	103	13	n=7	n=7	PROPN
admet-322	103	14	independent	independent	ADJ
admet-322	103	15	experiments	experiment	NOUN
admet-322	103	16	.	.	PUNCT
admet-322	104	1	the	the	DET
admet-322	104	2	inhibition	inhibition	NOUN
admet-322	104	3	potential	potential	NOUN
admet-322	104	4	of	of	ADP
admet-322	104	5	20	20	NUM
admet-322	104	6	tki	tki	NOUN
admet-322	104	7	/	/	SYM
admet-322	104	8	akis	akis	PROPN
admet-322	104	9	was	be	AUX
admet-322	104	10	assessed	assess	VERB
admet-322	104	11	in	in	ADP
admet-322	104	12	control	control	NOUN
admet-322	104	13	and	and	CCONJ
admet-322	104	14	mrp4	mrp4	NOUN
admet-322	104	15	over	over	ADP
admet-322	104	16	-	-	PUNCT
admet-322	104	17	expressing	express	VERB
admet-322	104	18	membrane	membrane	NOUN
admet-322	104	19	vesicles	vesicle	NOUN
admet-322	104	20	.	.	PUNCT
admet-322	105	1	dose	dose	NOUN
admet-322	105	2	-	-	PUNCT
admet-322	105	3	response	response	NOUN
admet-322	105	4	curves	curve	NOUN
admet-322	105	5	of	of	ADP
admet-322	105	6	tkis	tkis	NOUN
admet-322	105	7	are	be	AUX
admet-322	105	8	shown	show	VERB
admet-322	105	9	in	in	ADP
admet-322	105	10	figure	figure	NOUN
admet-322	105	11	2	2	NUM
admet-322	105	12	.	.	PUNCT
admet-322	105	13	of	of	ADP
admet-322	105	14	the	the	DET
admet-322	105	15	16	16	NUM
admet-322	105	16	tkis	tkis	NOUN
admet-322	105	17	examined	examine	VERB
admet-322	105	18	,	,	PUNCT
admet-322	105	19	6	6	NUM
admet-322	105	20	exhibited	exhibit	VERB
admet-322	105	21	ic50	ic50	PROPN
admet-322	105	22	values	value	NOUN
admet-322	105	23	<	<	X
admet-322	105	24	10	10	NUM
admet-322	105	25	μm	μm	NUM
admet-322	105	26	(	(	PUNCT
admet-322	105	27	table	table	NOUN
admet-322	105	28	2	2	NUM
admet-322	105	29	)	)	PUNCT
admet-322	105	30	,	,	PUNCT
admet-322	105	31	namely	namely	ADV
admet-322	105	32	,	,	PUNCT
admet-322	105	33	the	the	DET
admet-322	105	34	egfr	egfr	ADJ
admet-322	105	35	inhibitors	inhibitor	NOUN
admet-322	105	36	erlotinib	erlotinib	NOUN
admet-322	105	37	,	,	PUNCT
admet-322	105	38	gefitinib	gefitinib	NOUN
admet-322	105	39	,	,	PUNCT
admet-322	105	40	lapatinib	lapatinib	NOUN
admet-322	105	41	and	and	CCONJ
admet-322	105	42	neratinib	neratinib	NOUN
admet-322	105	43	;	;	PUNCT
admet-322	105	44	the	the	DET
admet-322	105	45	vegfr	vegfr	PROPN
admet-322	105	46	&	&	CCONJ
admet-322	105	47	pdgfr	pdgfr	ADJ
admet-322	105	48	inhibitor	inhibitor	NOUN
admet-322	105	49	sorafenib	sorafenib	NOUN
admet-322	105	50	;	;	PUNCT
admet-322	105	51	and	and	CCONJ
admet-322	105	52	the	the	DET
admet-322	105	53	bcr	bcr	PROPN
admet-322	105	54	/	/	SYM
admet-322	105	55	abl	abl	PROPN
admet-322	105	56	inhibitor	inhibitor	NOUN
admet-322	105	57	nilotinib	nilotinib	NOUN
admet-322	105	58	.	.	PUNCT
admet-322	106	1	others	other	NOUN
admet-322	106	2	have	have	AUX
admet-322	106	3	reported	report	VERB
admet-322	106	4	the	the	DET
admet-322	106	5	inhibitory	inhibitory	ADJ
admet-322	106	6	admet	admet	NOUN
admet-322	106	7	&	&	CCONJ
admet-322	106	8	dmpk	dmpk	PROPN
admet-322	106	9	4(4	4(4	NUM
admet-322	106	10	)	)	PUNCT
admet-322	106	11	(	(	PUNCT
admet-322	106	12	2016	2016	NUM
admet-322	106	13	)	)	PUNCT
admet-322	106	14	302	302	NUM
admet-322	106	15	-	-	SYM
admet-322	106	16	313	313	NUM
admet-322	106	17	tkis	tki	NOUN
admet-322	106	18	and	and	CCONJ
admet-322	106	19	akis	akis	PROPN
admet-322	106	20	diminish	diminish	VERB
admet-322	106	21	transport	transport	NOUN
admet-322	106	22	of	of	ADP
admet-322	106	23	function	function	NOUN
admet-322	106	24	of	of	ADP
admet-322	106	25	mrp4	mrp4	NOUN
admet-322	106	26	and	and	CCONJ
admet-322	106	27	bcrp	bcrp	PROPN
admet-322	106	28	doi	doi	PROPN
admet-322	106	29	:	:	PUNCT
admet-322	106	30	10.5599	10.5599	NUM
admet-322	106	31	/	/	SYM
admet-322	106	32	admet.4.4.322	admet.4.4.322	NUM
admet-322	106	33	307	307	NUM
admet-322	106	34	potency	potency	NOUN
admet-322	106	35	of	of	ADP
admet-322	106	36	some	some	DET
admet-322	106	37	tkis	tkis	NOUN
admet-322	106	38	against	against	ADP
admet-322	106	39	mrp4	mrp4	NOUN
admet-322	106	40	-	-	PUNCT
admet-322	106	41	mediated	mediate	VERB
admet-322	106	42	transport	transport	NOUN
admet-322	106	43	,	,	PUNCT
admet-322	106	44	particularly	particularly	ADV
admet-322	106	45	dasatinib	dasatinib	NOUN
admet-322	106	46	,	,	PUNCT
admet-322	106	47	gefitinib	gefitinib	NOUN
admet-322	106	48	,	,	PUNCT
admet-322	106	49	imatinib	imatinib	NOUN
admet-322	106	50	,	,	PUNCT
admet-322	106	51	lapatinib	lapatinib	PROPN
admet-322	106	52	,	,	PUNCT
admet-322	106	53	neratinib	neratinib	NOUN
admet-322	106	54	,	,	PUNCT
admet-322	106	55	pazopanib	pazopanib	NOUN
admet-322	106	56	,	,	PUNCT
admet-322	106	57	and	and	CCONJ
admet-322	106	58	sunitinib	sunitinib	NOUN
admet-322	106	59	[	[	X
admet-322	106	60	35	35	NUM
admet-322	106	61	]	]	PUNCT
admet-322	106	62	.	.	PUNCT
admet-322	107	1	we	we	PRON
admet-322	107	2	found	find	VERB
admet-322	107	3	a	a	DET
admet-322	107	4	similar	similar	ADJ
admet-322	107	5	ic50	ic50	PROPN
admet-322	107	6	for	for	ADP
admet-322	107	7	gefinitib	gefinitib	ADJ
admet-322	107	8	inhibition	inhibition	NOUN
admet-322	107	9	of	of	ADP
admet-322	107	10	mrp4	mrp4	NOUN
admet-322	107	11	(	(	PUNCT
admet-322	107	12	4.48	4.48	NUM
admet-322	107	13	μm	μm	NUM
admet-322	107	14	)	)	PUNCT
admet-322	107	15	to	to	ADP
admet-322	107	16	that	that	PRON
admet-322	107	17	of	of	ADP
admet-322	107	18	morgan	morgan	PROPN
admet-322	107	19	,	,	PUNCT
admet-322	107	20	et	et	PROPN
admet-322	107	21	al	al	PROPN
admet-322	107	22	.	.	PUNCT
admet-322	108	1	(	(	PUNCT
admet-322	108	2	4.6	4.6	NUM
admet-322	108	3	μm	μm	NUM
admet-322	108	4	)	)	PUNCT
admet-322	108	5	,	,	PUNCT
admet-322	108	6	and	and	CCONJ
admet-322	108	7	a	a	DET
admet-322	108	8	somewhat	somewhat	ADV
admet-322	108	9	comparable	comparable	ADJ
admet-322	108	10	ic50	ic50	PROPN
admet-322	108	11	for	for	ADP
admet-322	108	12	dasatanib	dasatanib	NOUN
admet-322	108	13	(	(	PUNCT
admet-322	108	14	18.03	18.03	NUM
admet-322	108	15	μm	μm	NOUN
admet-322	108	16	in	in	ADP
admet-322	108	17	the	the	DET
admet-322	108	18	present	present	ADJ
admet-322	108	19	study	study	NOUN
admet-322	108	20	versus	versus	ADP
admet-322	108	21	27.3	27.3	NUM
admet-322	108	22	μm	μm	NUM
admet-322	108	23	)	)	PUNCT
admet-322	108	24	.	.	PUNCT
admet-322	109	1	however	however	ADV
admet-322	109	2	,	,	PUNCT
admet-322	109	3	the	the	DET
admet-322	109	4	ic50	ic50	PROPN
admet-322	109	5	values	value	NOUN
admet-322	109	6	for	for	ADP
admet-322	109	7	the	the	DET
admet-322	109	8	remaining	remain	VERB
admet-322	109	9	tkis	tkis	NOUN
admet-322	109	10	evaluated	evaluate	VERB
admet-322	109	11	by	by	ADP
admet-322	109	12	morgan	morgan	PROPN
admet-322	109	13	,	,	PUNCT
admet-322	109	14	et	et	PROPN
admet-322	109	15	al	al	PROPN
admet-322	109	16	.	.	PROPN
admet-322	109	17	were	be	AUX
admet-322	109	18	notably	notably	ADV
admet-322	109	19	different	different	ADJ
admet-322	109	20	,	,	PUNCT
admet-322	109	21	which	which	PRON
admet-322	109	22	may	may	AUX
admet-322	109	23	reflect	reflect	VERB
admet-322	109	24	differences	difference	NOUN
admet-322	109	25	in	in	ADP
admet-322	109	26	the	the	DET
admet-322	109	27	experimental	experimental	ADJ
admet-322	109	28	conditions	condition	NOUN
admet-322	109	29	such	such	ADJ
admet-322	109	30	as	as	ADP
admet-322	109	31	the	the	DET
admet-322	109	32	specific	specific	ADJ
admet-322	109	33	transporter	transporter	NOUN
admet-322	109	34	substrate	substrate	NOUN
admet-322	109	35	and	and	CCONJ
admet-322	109	36	range	range	NOUN
admet-322	109	37	of	of	ADP
admet-322	109	38	inhibitor	inhibitor	NOUN
admet-322	109	39	concentrations	concentration	NOUN
admet-322	109	40	selected	select	VERB
admet-322	109	41	for	for	ADP
admet-322	109	42	investigation	investigation	NOUN
admet-322	109	43	(	(	PUNCT
admet-322	109	44	e.g.	e.g.	ADV
admet-322	109	45	extrapolation	extrapolation	NOUN
admet-322	109	46	of	of	ADP
admet-322	109	47	an	an	DET
admet-322	109	48	ic50	ic50	PROPN
admet-322	109	49	value	value	NOUN
admet-322	109	50	beyond	beyond	ADP
admet-322	109	51	the	the	DET
admet-322	109	52	tested	test	VERB
admet-322	109	53	concentrations	concentration	NOUN
admet-322	109	54	)	)	PUNCT
admet-322	110	1	[	[	X
admet-322	110	2	35	35	NUM
admet-322	110	3	,	,	PUNCT
admet-322	110	4	36	36	NUM
admet-322	110	5	]	]	PUNCT
admet-322	110	6	.	.	PUNCT
admet-322	111	1	the	the	DET
admet-322	111	2	majority	majority	NOUN
admet-322	111	3	of	of	ADP
admet-322	111	4	the	the	DET
admet-322	111	5	potent	potent	ADJ
admet-322	111	6	mrp4	mrp4	NOUN
admet-322	111	7	inhibitors	inhibitor	NOUN
admet-322	111	8	fell	fall	VERB
admet-322	111	9	within	within	ADP
admet-322	111	10	the	the	DET
admet-322	111	11	egfr	egfr	ADJ
admet-322	111	12	tki	tki	X
admet-322	111	13	class	class	NOUN
admet-322	111	14	with	with	ADP
admet-322	111	15	only	only	ADV
admet-322	111	16	one	one	NUM
admet-322	111	17	potent	potent	ADJ
admet-322	111	18	inhibitor	inhibitor	NOUN
admet-322	111	19	each	each	PRON
admet-322	111	20	in	in	ADP
admet-322	111	21	the	the	DET
admet-322	111	22	dual	dual	ADJ
admet-322	111	23	vegfr	vegfr	NOUN
admet-322	111	24	&	&	CCONJ
admet-322	111	25	pdgfr	pdgfr	PROPN
admet-322	111	26	and	and	CCONJ
admet-322	111	27	the	the	DET
admet-322	111	28	bcr	bcr	PROPN
admet-322	111	29	/	/	SYM
admet-322	111	30	abl	abl	PROPN
admet-322	111	31	classes	class	NOUN
admet-322	111	32	.	.	PUNCT
admet-322	112	1	four	four	NUM
admet-322	112	2	akis	akis	PROPN
admet-322	112	3	were	be	AUX
admet-322	112	4	tested	test	VERB
admet-322	112	5	for	for	ADP
admet-322	112	6	their	their	PRON
admet-322	112	7	potential	potential	NOUN
admet-322	112	8	to	to	PART
admet-322	112	9	inhibit	inhibit	VERB
admet-322	112	10	mrp4	mrp4	NOUN
admet-322	112	11	(	(	PUNCT
admet-322	112	12	figure	figure	NOUN
admet-322	112	13	3	3	NUM
admet-322	112	14	)	)	PUNCT
admet-322	112	15	.	.	PUNCT
admet-322	113	1	two	two	NUM
admet-322	113	2	akis	akis	PROPN
admet-322	113	3	,	,	PUNCT
admet-322	113	4	danusertib	danusertib	NOUN
admet-322	113	5	and	and	CCONJ
admet-322	113	6	tozasertib	tozasertib	NOUN
admet-322	113	7	,	,	PUNCT
admet-322	113	8	produced	produce	VERB
admet-322	113	9	ic50	ic50	PROPN
admet-322	113	10	values	value	NOUN
admet-322	113	11	<	<	X
admet-322	113	12	10	10	NUM
admet-322	113	13	μm	μm	NUM
admet-322	113	14	(	(	PUNCT
admet-322	113	15	table	table	NOUN
admet-322	113	16	2	2	NUM
admet-322	113	17	)	)	PUNCT
admet-322	113	18	.	.	PUNCT
admet-322	114	1	in	in	ADP
admet-322	114	2	particular	particular	ADJ
admet-322	114	3	,	,	PUNCT
admet-322	114	4	tozasertib	tozasertib	PROPN
admet-322	114	5	exhibited	exhibit	VERB
admet-322	114	6	comparable	comparable	ADJ
admet-322	114	7	inhibitory	inhibitory	ADJ
admet-322	114	8	potency	potency	NOUN
admet-322	114	9	to	to	ADP
admet-322	114	10	mk571	mk571	PROPN
admet-322	114	11	(	(	PUNCT
admet-322	114	12	1.87	1.87	NUM
admet-322	114	13	±	±	NUM
admet-322	114	14	0.81	0.81	NUM
admet-322	114	15	μm	μm	NOUN
admet-322	114	16	versus	versus	ADP
admet-322	114	17	2.04	2.04	NUM
admet-322	114	18	μm	μm	NUM
admet-322	114	19	,	,	PUNCT
admet-322	114	20	respectively	respectively	ADV
admet-322	114	21	)	)	PUNCT
admet-322	114	22	.	.	PUNCT
admet-322	115	1	in	in	ADP
admet-322	115	2	total	total	NOUN
admet-322	115	3	,	,	PUNCT
admet-322	115	4	eight	eight	NUM
admet-322	115	5	of	of	ADP
admet-322	115	6	the	the	DET
admet-322	115	7	20	20	NUM
admet-322	115	8	tki	tki	NOUN
admet-322	115	9	/	/	SYM
admet-322	115	10	akis	akis	PROPN
admet-322	115	11	assessed	assess	VERB
admet-322	115	12	were	be	AUX
admet-322	115	13	identified	identify	VERB
admet-322	115	14	as	as	ADP
admet-322	115	15	potent	potent	ADJ
admet-322	115	16	inhibitors	inhibitor	NOUN
admet-322	115	17	(	(	PUNCT
admet-322	115	18	ic50	ic50	PROPN
admet-322	115	19	≤	≤	NUM
admet-322	115	20	10	10	NUM
admet-322	115	21	μm	μm	NOUN
admet-322	115	22	)	)	PUNCT
admet-322	115	23	of	of	ADP
admet-322	115	24	mrp4	mrp4	PROPN
admet-322	115	25	.	.	PUNCT
admet-322	116	1	figure	figure	NOUN
admet-322	116	2	2	2	NUM
admet-322	116	3	.	.	PUNCT
admet-322	116	4	mrp4	mrp4	NOUN
admet-322	116	5	inhibition	inhibition	NOUN
admet-322	116	6	by	by	ADP
admet-322	116	7	tyrosine	tyrosine	PROPN
admet-322	116	8	kinase	kinase	PROPN
admet-322	116	9	inhibitors	inhibitor	NOUN
admet-322	116	10	.	.	PUNCT
admet-322	117	1	inhibition	inhibition	NOUN
admet-322	117	2	of	of	ADP
admet-322	117	3	mrp4	mrp4	NOUN
admet-322	117	4	-	-	PUNCT
admet-322	117	5	mediated	mediate	VERB
admet-322	117	6	[	[	PUNCT
admet-322	117	7	3	3	NUM
admet-322	117	8	h]-dheas	h]-dheas	NOUN
admet-322	117	9	(	(	PUNCT
admet-322	117	10	2	2	NUM
admet-322	117	11	μm	μm	NUM
admet-322	117	12	;	;	PUNCT
admet-322	117	13	3.5	3.5	NUM
admet-322	117	14	min	min	NOUN
admet-322	117	15	)	)	PUNCT
admet-322	117	16	uptake	uptake	ADJ
admet-322	117	17	across	across	ADP
admet-322	117	18	an	an	DET
admet-322	117	19	inhibitor	inhibitor	NOUN
admet-322	117	20	concentration	concentration	NOUN
admet-322	117	21	range	range	NOUN
admet-322	117	22	of	of	ADP
admet-322	117	23	0.316	0.316	NUM
admet-322	117	24	-	-	SYM
admet-322	117	25	100	100	NUM
admet-322	117	26	μm	μm	NUM
admet-322	117	27	by	by	ADP
admet-322	117	28	egfr	egfr	ADJ
admet-322	117	29	,	,	PUNCT
admet-322	117	30	vegfr	vegfr	NOUN
admet-322	117	31	/	/	SYM
admet-322	117	32	pdgfr	pdgfr	ADJ
admet-322	117	33	,	,	PUNCT
admet-322	117	34	bcr	bcr	PROPN
admet-322	117	35	/	/	SYM
admet-322	117	36	abl	abl	NOUN
admet-322	117	37	inhibitors	inhibitor	NOUN
admet-322	117	38	,	,	PUNCT
admet-322	117	39	and	and	CCONJ
admet-322	117	40	inhibitors	inhibitor	NOUN
admet-322	117	41	with	with	ADP
admet-322	117	42	miscellaneous	miscellaneous	ADJ
admet-322	117	43	targets	target	NOUN
admet-322	117	44	is	be	AUX
admet-322	117	45	shown	show	VERB
admet-322	117	46	.	.	PUNCT
admet-322	118	1	data	datum	NOUN
admet-322	118	2	are	be	AUX
admet-322	118	3	presented	present	VERB
admet-322	118	4	as	as	ADP
admet-322	118	5	mean	mean	ADJ
admet-322	118	6	%	%	NOUN
admet-322	118	7	of	of	ADP
admet-322	118	8	control	control	NOUN
admet-322	118	9	uptake	uptake	ADJ
admet-322	118	10	±	±	NOUN
admet-322	118	11	sd	sd	NOUN
admet-322	118	12	,	,	PUNCT
admet-322	118	13	n=3	n=3	NOUN
admet-322	118	14	-	-	SYM
admet-322	118	15	6	6	NUM
admet-322	118	16	independent	independent	ADJ
admet-322	118	17	experiments	experiment	NOUN
admet-322	118	18	.	.	PUNCT
admet-322	119	1	bcrp	bcrp	ADV
admet-322	119	2	over	over	ADP
admet-322	119	3	-	-	PUNCT
admet-322	119	4	expression	expression	NOUN
admet-322	119	5	in	in	ADP
admet-322	119	6	mdckii	mdckii	ADJ
admet-322	119	7	-	-	ADJ
admet-322	119	8	bcrp	bcrp	ADJ
admet-322	119	9	membrane	membrane	NOUN
admet-322	119	10	vesicles	vesicle	NOUN
admet-322	119	11	was	be	AUX
admet-322	119	12	determined	determine	VERB
admet-322	119	13	via	via	ADP
admet-322	119	14	western	western	ADJ
admet-322	119	15	blot	blot	NOUN
admet-322	119	16	analysis	analysis	NOUN
admet-322	119	17	and	and	CCONJ
admet-322	119	18	compared	compare	VERB
admet-322	119	19	to	to	PART
admet-322	119	20	control	control	VERB
admet-322	119	21	mdckii	mdckii	ADJ
admet-322	119	22	vesicles	vesicle	NOUN
admet-322	119	23	(	(	PUNCT
admet-322	119	24	figure	figure	NOUN
admet-322	119	25	4a	4a	NUM
admet-322	119	26	)	)	PUNCT
admet-322	119	27	.	.	PUNCT
admet-322	120	1	bcrp	bcrp	ADV
admet-322	120	2	over	over	ADP
admet-322	120	3	-	-	PUNCT
admet-322	120	4	expression	expression	NOUN
admet-322	120	5	was	be	AUX
admet-322	120	6	confirmed	confirm	VERB
admet-322	120	7	to	to	PART
admet-322	120	8	be	be	AUX
admet-322	120	9	substantially	substantially	ADV
admet-322	120	10	greater	great	ADJ
admet-322	120	11	in	in	ADP
admet-322	120	12	mdckii	mdckii	ADJ
admet-322	120	13	-	-	ADJ
admet-322	120	14	bcrp	bcrp	ADJ
admet-322	120	15	vesicles	vesicle	NOUN
admet-322	120	16	.	.	PUNCT
admet-322	121	1	to	to	PART
admet-322	121	2	establish	establish	VERB
admet-322	121	3	the	the	DET
admet-322	121	4	bcrp	bcrp	ADJ
admet-322	121	5	membrane	membrane	NOUN
admet-322	121	6	vesicle	vesicle	NOUN
admet-322	121	7	transport	transport	NOUN
admet-322	121	8	assay	assay	VERB
admet-322	121	9	,	,	PUNCT
admet-322	121	10	the	the	DET
admet-322	121	11	timeand	timeand	NOUN
admet-322	121	12	atp	atp	NOUN
admet-322	121	13	-	-	PUNCT
admet-322	121	14	dependent	dependent	ADJ
admet-322	121	15	uptake	uptake	NOUN
admet-322	121	16	of	of	ADP
admet-322	121	17	[	[	X
admet-322	121	18	3h]-e1s	3h]-e1s	NUM
admet-322	121	19	was	be	AUX
admet-322	121	20	measured	measure	VERB
admet-322	121	21	in	in	ADP
admet-322	121	22	mdckii	mdckii	ADJ
admet-322	121	23	and	and	CCONJ
admet-322	121	24	mdckii	mdckii	ADJ
admet-322	121	25	-	-	ADJ
admet-322	121	26	bcrp	bcrp	ADJ
admet-322	121	27	vesicles	vesicle	NOUN
admet-322	121	28	(	(	PUNCT
admet-322	121	29	figure	figure	NOUN
admet-322	121	30	4a	4a	NUM
admet-322	121	31	)	)	PUNCT
admet-322	121	32	.	.	PUNCT
admet-322	122	1	the	the	DET
admet-322	122	2	uptake	uptake	NOUN
admet-322	122	3	of	of	ADP
admet-322	122	4	[	[	X
admet-322	122	5	3h]-e1s	3h]-e1s	NUM
admet-322	122	6	was	be	AUX
admet-322	122	7	linear	linear	ADJ
admet-322	122	8	up	up	ADP
admet-322	122	9	to	to	PART
admet-322	122	10	1.5	1.5	NUM
admet-322	122	11	minutes	minute	NOUN
admet-322	122	12	and	and	CCONJ
admet-322	122	13	appeared	appear	VERB
admet-322	122	14	to	to	PART
admet-322	122	15	saturate	saturate	VERB
admet-322	122	16	by	by	ADP
admet-322	122	17	3	3	NUM
admet-322	122	18	minutes	minute	NOUN
admet-322	122	19	.	.	PUNCT
admet-322	123	1	an	an	DET
admet-322	123	2	incubation	incubation	NOUN
admet-322	123	3	time	time	NOUN
admet-322	123	4	of	of	ADP
admet-322	123	5	1.5	1.5	NUM
admet-322	123	6	minutes	minute	NOUN
admet-322	123	7	was	be	AUX
admet-322	123	8	chosen	choose	VERB
admet-322	123	9	for	for	ADP
admet-322	123	10	subsequent	subsequent	ADJ
admet-322	123	11	assessment	assessment	NOUN
admet-322	123	12	of	of	ADP
admet-322	123	13	potential	potential	ADJ
admet-322	123	14	bcrp	bcrp	ADJ
admet-322	123	15	inhibitors	inhibitor	NOUN
admet-322	123	16	.	.	PUNCT
admet-322	124	1	there	there	PRON
admet-322	124	2	was	be	VERB
admet-322	124	3	at	at	ADP
admet-322	124	4	least	least	ADJ
admet-322	124	5	a	a	DET
admet-322	124	6	35fold	35fold	NUM
admet-322	124	7	increase	increase	NOUN
admet-322	124	8	in	in	ADP
admet-322	124	9	[	[	X
admet-322	124	10	3h]-e1s	3h]-e1s	NUM
admet-322	124	11	uptake	uptake	ADJ
admet-322	124	12	in	in	ADP
admet-322	124	13	mdckii	mdckii	ADJ
admet-322	124	14	-	-	ADJ
admet-322	124	15	bcrp	bcrp	ADV
admet-322	124	16	versus	versus	ADP
admet-322	124	17	mdckii	mdckii	ADJ
admet-322	124	18	vesicles	vesicle	NOUN
admet-322	124	19	.	.	PUNCT
admet-322	125	1	several	several	ADJ
admet-322	125	2	compounds	compound	NOUN
admet-322	125	3	ascribed	ascribe	VERB
admet-322	125	4	as	as	SCONJ
admet-322	125	5	bcrp	bcrp	ADJ
admet-322	125	6	inhibitors	inhibitor	NOUN
admet-322	125	7	were	be	AUX
admet-322	125	8	assessed	assess	VERB
admet-322	125	9	for	for	ADP
admet-322	125	10	their	their	PRON
admet-322	125	11	potential	potential	NOUN
admet-322	125	12	as	as	ADP
admet-322	125	13	positive	positive	ADJ
admet-322	125	14	controls	control	NOUN
admet-322	125	15	in	in	ADP
admet-322	125	16	the	the	DET
admet-322	125	17	membrane	membrane	NOUN
admet-322	125	18	vesicle	vesicle	NOUN
admet-322	125	19	inhibition	inhibition	NOUN
admet-322	125	20	assay	assay	ADV
admet-322	125	21	.	.	PUNCT
admet-322	126	1	sulfasalazine	sulfasalazine	NOUN
admet-322	126	2	and	and	CCONJ
admet-322	126	3	promethazine	promethazine	PROPN
admet-322	126	4	were	be	AUX
admet-322	126	5	discovered	discover	VERB
admet-322	126	6	to	to	PART
admet-322	126	7	have	have	VERB
admet-322	126	8	the	the	DET
admet-322	126	9	most	most	ADV
admet-322	126	10	consistent	consistent	ADJ
admet-322	126	11	inhibition	inhibition	NOUN
admet-322	126	12	profile	profile	NOUN
admet-322	126	13	across	across	ADP
admet-322	126	14	multiple	multiple	ADJ
admet-322	126	15	independent	independent	ADJ
admet-322	126	16	experiments	experiment	NOUN
admet-322	126	17	(	(	PUNCT
admet-322	126	18	n=9	n=9	NOUN
admet-322	126	19	-	-	SYM
admet-322	126	20	12	12	NUM
admet-322	126	21	)	)	PUNCT
admet-322	126	22	.	.	PUNCT
admet-322	127	1	the	the	DET
admet-322	127	2	dose	dose	NOUN
admet-322	127	3	-	-	PUNCT
admet-322	127	4	response	response	NOUN
admet-322	127	5	curves	curve	NOUN
admet-322	127	6	for	for	ADP
admet-322	127	7	sulfasalazine	sulfasalazine	NOUN
admet-322	127	8	and	and	CCONJ
admet-322	127	9	r.n	r.n	PROPN
admet-322	127	10	.	.	PROPN
admet-322	127	11	hardwick	hardwick	PROPN
admet-322	127	12	et	et	PROPN
admet-322	127	13	al	al	PROPN
admet-322	127	14	.	.	PROPN
admet-322	127	15	admet	admet	PROPN
admet-322	127	16	&	&	CCONJ
admet-322	127	17	dmpk	dmpk	PROPN
admet-322	127	18	4(4	4(4	NUM
admet-322	127	19	)	)	PUNCT
admet-322	127	20	(	(	PUNCT
admet-322	127	21	2016	2016	NUM
admet-322	127	22	)	)	PUNCT
admet-322	127	23	302	302	NUM
admet-322	127	24	-	-	SYM
admet-322	127	25	313	313	NUM
admet-322	127	26	308	308	NUM
admet-322	127	27	promethazine	promethazine	NOUN
admet-322	127	28	are	be	AUX
admet-322	127	29	shown	show	VERB
admet-322	127	30	in	in	ADP
admet-322	127	31	figure	figure	NOUN
admet-322	127	32	4b	4b	PROPN
admet-322	127	33	.	.	PUNCT
admet-322	128	1	promethazine	promethazine	PROPN
admet-322	128	2	exhibited	exhibit	VERB
admet-322	128	3	an	an	DET
admet-322	128	4	ic50	ic50	PROPN
admet-322	128	5	value	value	NOUN
admet-322	128	6	of	of	ADP
admet-322	128	7	9.83	9.83	NUM
admet-322	128	8	μm	μm	NOUN
admet-322	128	9	(	(	PUNCT
admet-322	128	10	95	95	NUM
admet-322	128	11	%	%	NOUN
admet-322	128	12	confidence	confidence	NOUN
admet-322	128	13	interval	interval	NOUN
admet-322	128	14	:	:	PUNCT
admet-322	128	15	5.14	5.14	NUM
admet-322	128	16	-	-	SYM
admet-322	128	17	18.80	18.80	NUM
admet-322	128	18	μm	μm	NUM
admet-322	128	19	)	)	PUNCT
admet-322	128	20	,	,	PUNCT
admet-322	128	21	while	while	SCONJ
admet-322	128	22	sulfasalazine	sulfasalazine	NOUN
admet-322	128	23	proved	prove	VERB
admet-322	128	24	to	to	PART
admet-322	128	25	be	be	AUX
admet-322	128	26	a	a	DET
admet-322	128	27	much	much	ADV
admet-322	128	28	more	more	ADV
admet-322	128	29	potent	potent	ADJ
admet-322	128	30	inhibitor	inhibitor	NOUN
admet-322	128	31	of	of	ADP
admet-322	128	32	bcrp	bcrp	PROPN
admet-322	128	33	with	with	ADP
admet-322	128	34	an	an	DET
admet-322	128	35	ic50	ic50	PROPN
admet-322	128	36	value	value	NOUN
admet-322	128	37	of	of	ADP
admet-322	128	38	0.79	0.79	NUM
admet-322	128	39	μm	μm	NUM
admet-322	128	40	(	(	PUNCT
admet-322	128	41	95	95	NUM
admet-322	128	42	%	%	NOUN
admet-322	128	43	confidence	confidence	NOUN
admet-322	128	44	interval	interval	NOUN
admet-322	128	45	:	:	PUNCT
admet-322	128	46	0.64	0.64	NUM
admet-322	128	47	-	-	SYM
admet-322	128	48	0.99	0.99	NUM
admet-322	128	49	μm	μm	NUM
admet-322	128	50	)	)	PUNCT
admet-322	128	51	.	.	PUNCT
admet-322	129	1	others	other	NOUN
admet-322	129	2	have	have	AUX
admet-322	129	3	reported	report	VERB
admet-322	129	4	an	an	DET
admet-322	129	5	ic50	ic50	PROPN
admet-322	129	6	of	of	ADP
admet-322	129	7	0.6	0.6	NUM
admet-322	129	8	µm	µm	NOUN
admet-322	129	9	for	for	ADP
admet-322	129	10	sulfasalazine	sulfasalazine	NOUN
admet-322	129	11	-	-	PUNCT
admet-322	129	12	mediated	mediate	VERB
admet-322	129	13	inhibition	inhibition	NOUN
admet-322	129	14	of	of	ADP
admet-322	129	15	3	3	NUM
admet-322	129	16	h	h	NOUN
admet-322	129	17	-	-	PUNCT
admet-322	129	18	estrone-3	estrone-3	NOUN
admet-322	129	19	-	-	PUNCT
admet-322	129	20	sulfate	sulfate	NOUN
admet-322	129	21	uptake	uptake	NOUN
admet-322	129	22	in	in	ADP
admet-322	129	23	bcrp	bcrp	ADJ
admet-322	129	24	membrane	membrane	NOUN
admet-322	129	25	vesicles	vesicle	NOUN
admet-322	129	26	derived	derive	VERB
admet-322	129	27	from	from	ADP
admet-322	129	28	hek	hek	PROPN
admet-322	129	29	-	-	PUNCT
admet-322	129	30	bcrp	bcrp	PROPN
admet-322	129	31	cells	cell	NOUN
admet-322	129	32	[	[	X
admet-322	129	33	37	37	NUM
admet-322	129	34	]	]	PUNCT
admet-322	129	35	.	.	PUNCT
admet-322	130	1	figure	figure	NOUN
admet-322	130	2	3	3	NUM
admet-322	130	3	.	.	PUNCT
admet-322	130	4	mrp4	mrp4	NOUN
admet-322	130	5	inhibition	inhibition	NOUN
admet-322	130	6	by	by	ADP
admet-322	130	7	aurora	aurora	PROPN
admet-322	130	8	kinase	kinase	PROPN
admet-322	130	9	inhibitors	inhibitor	NOUN
admet-322	130	10	.	.	PUNCT
admet-322	131	1	inhibition	inhibition	NOUN
admet-322	131	2	of	of	ADP
admet-322	131	3	mrp4	mrp4	NOUN
admet-322	131	4	-	-	PUNCT
admet-322	131	5	mediated	mediate	VERB
admet-322	131	6	[	[	PUNCT
admet-322	131	7	3	3	NUM
admet-322	131	8	h]-dheas	h]-dheas	NOUN
admet-322	131	9	(	(	PUNCT
admet-322	131	10	2	2	NUM
admet-322	131	11	μm	μm	NUM
admet-322	131	12	;	;	PUNCT
admet-322	131	13	3.5	3.5	NUM
admet-322	131	14	min	min	NOUN
admet-322	131	15	)	)	PUNCT
admet-322	131	16	uptake	uptake	ADJ
admet-322	131	17	across	across	ADP
admet-322	131	18	an	an	DET
admet-322	131	19	inhibitor	inhibitor	NOUN
admet-322	131	20	concentration	concentration	NOUN
admet-322	131	21	range	range	NOUN
admet-322	131	22	of	of	ADP
admet-322	131	23	0.316	0.316	NUM
admet-322	131	24	-	-	SYM
admet-322	131	25	100	100	NUM
admet-322	131	26	μm	μm	NOUN
admet-322	131	27	is	be	AUX
admet-322	131	28	shown	show	VERB
admet-322	131	29	.	.	PUNCT
admet-322	132	1	data	datum	NOUN
admet-322	132	2	are	be	AUX
admet-322	132	3	presented	present	VERB
admet-322	132	4	as	as	ADP
admet-322	132	5	mean	mean	ADJ
admet-322	132	6	%	%	NOUN
admet-322	132	7	of	of	ADP
admet-322	132	8	control	control	NOUN
admet-322	132	9	uptake	uptake	ADJ
admet-322	132	10	±	±	NOUN
admet-322	132	11	sd	sd	NOUN
admet-322	132	12	,	,	PUNCT
admet-322	132	13	n=3	n=3	NOUN
admet-322	132	14	-	-	SYM
admet-322	132	15	6	6	NUM
admet-322	132	16	independent	independent	ADJ
admet-322	132	17	experiments	experiment	NOUN
admet-322	132	18	.	.	PUNCT
admet-322	133	1	figure	figure	VERB
admet-322	133	2	4	4	NUM
admet-322	133	3	.	.	PUNCT
admet-322	133	4	characterization	characterization	NOUN
admet-322	133	5	of	of	ADP
admet-322	133	6	the	the	DET
admet-322	133	7	bcrp	bcrp	ADJ
admet-322	133	8	membrane	membrane	NOUN
admet-322	133	9	vesicle	vesicle	NOUN
admet-322	133	10	assay	assay	VERB
admet-322	133	11	.	.	PUNCT
admet-322	134	1	(	(	PUNCT
admet-322	134	2	a	a	X
admet-322	134	3	)	)	PUNCT
admet-322	134	4	bcrp	bcrp	ADJ
admet-322	134	5	expression	expression	NOUN
admet-322	134	6	in	in	ADP
admet-322	134	7	mdckii	mdckii	ADJ
admet-322	134	8	and	and	CCONJ
admet-322	134	9	mdckiibcrp	mdckiibcrp	ADJ
admet-322	134	10	cells	cell	NOUN
admet-322	134	11	.	.	PUNCT
admet-322	135	1	also	also	ADV
admet-322	135	2	shown	show	VERB
admet-322	135	3	is	be	AUX
admet-322	135	4	atp	atp	NOUN
admet-322	135	5	-	-	PUNCT
admet-322	135	6	dependent	dependent	ADJ
admet-322	135	7	,	,	PUNCT
admet-322	135	8	time	time	NOUN
admet-322	135	9	-	-	PUNCT
admet-322	135	10	dependent	dependent	ADJ
admet-322	135	11	uptake	uptake	NOUN
admet-322	135	12	of	of	ADP
admet-322	135	13	1	1	NUM
admet-322	135	14	μm	μm	NOUN
admet-322	135	15	[	[	PUNCT
admet-322	135	16	3	3	NUM
admet-322	135	17	h]-estrone	h]-estrone	NOUN
admet-322	135	18	sulfate	sulfate	NOUN
admet-322	135	19	(	(	PUNCT
admet-322	135	20	e1s	e1s	PROPN
admet-322	135	21	)	)	PUNCT
admet-322	135	22	in	in	ADP
admet-322	135	23	membrane	membrane	NOUN
admet-322	135	24	vesicles	vesicle	NOUN
admet-322	135	25	.	.	PUNCT
admet-322	136	1	data	datum	NOUN
admet-322	136	2	are	be	AUX
admet-322	136	3	presented	present	VERB
admet-322	136	4	as	as	ADP
admet-322	136	5	mean	mean	NOUN
admet-322	136	6	±	±	NUM
admet-322	136	7	sd	sd	NOUN
admet-322	136	8	,	,	PUNCT
admet-322	136	9	n=3	n=3	PUNCT
admet-322	136	10	independent	independent	ADJ
admet-322	136	11	experiments	experiment	NOUN
admet-322	136	12	.	.	PUNCT
admet-322	137	1	(	(	PUNCT
admet-322	137	2	b	b	X
admet-322	137	3	)	)	PUNCT
admet-322	137	4	dose	dose	NOUN
admet-322	137	5	-	-	PUNCT
admet-322	137	6	response	response	NOUN
admet-322	137	7	ic50	ic50	PROPN
admet-322	137	8	curves	curve	NOUN
admet-322	137	9	of	of	ADP
admet-322	137	10	the	the	DET
admet-322	137	11	bcrp	bcrp	ADJ
admet-322	137	12	positive	positive	ADJ
admet-322	137	13	control	control	NOUN
admet-322	137	14	inhibitors	inhibitor	NOUN
admet-322	137	15	sulfasalazine	sulfasalazine	NOUN
admet-322	137	16	and	and	CCONJ
admet-322	137	17	promethazine	promethazine	PROPN
admet-322	137	18	are	be	AUX
admet-322	137	19	shown	show	VERB
admet-322	137	20	(	(	PUNCT
admet-322	137	21	1.5	1.5	NUM
admet-322	137	22	min	min	NOUN
admet-322	137	23	incubation	incubation	NOUN
admet-322	137	24	)	)	PUNCT
admet-322	137	25	.	.	PUNCT
admet-322	138	1	data	datum	NOUN
admet-322	138	2	are	be	AUX
admet-322	138	3	presented	present	VERB
admet-322	138	4	as	as	ADP
admet-322	138	5	mean	mean	ADJ
admet-322	138	6	%	%	NOUN
admet-322	138	7	of	of	ADP
admet-322	138	8	control	control	NOUN
admet-322	138	9	uptake	uptake	ADJ
admet-322	138	10	±	±	NOUN
admet-322	138	11	sd	sd	NOUN
admet-322	138	12	,	,	PUNCT
admet-322	138	13	n=9	n=9	NOUN
admet-322	138	14	-	-	PUNCT
admet-322	138	15	12	12	NUM
admet-322	138	16	independent	independent	ADJ
admet-322	138	17	experiments	experiment	NOUN
admet-322	138	18	.	.	PUNCT
admet-322	139	1	of	of	ADP
admet-322	139	2	the	the	DET
admet-322	139	3	16	16	NUM
admet-322	139	4	tkis	tkis	NOUN
admet-322	139	5	assessed	assess	VERB
admet-322	139	6	,	,	PUNCT
admet-322	139	7	the	the	DET
admet-322	139	8	majority	majority	NOUN
admet-322	139	9	(	(	PUNCT
admet-322	139	10	the	the	DET
admet-322	139	11	egfr	egfr	ADJ
admet-322	139	12	inhibitors	inhibitor	NOUN
admet-322	139	13	erlotinib	erlotinib	NOUN
admet-322	139	14	,	,	PUNCT
admet-322	139	15	gefitinib	gefitinib	NOUN
admet-322	139	16	,	,	PUNCT
admet-322	139	17	neratinib	neratinib	NOUN
admet-322	139	18	and	and	CCONJ
admet-322	139	19	vandetanib	vandetanib	PROPN
admet-322	139	20	;	;	PUNCT
admet-322	139	21	the	the	DET
admet-322	139	22	vegfr	vegfr	PROPN
admet-322	139	23	&	&	CCONJ
admet-322	139	24	pdgfr	pdgfr	ADJ
admet-322	139	25	inhibitors	inhibitor	NOUN
admet-322	139	26	axitinib	axitinib	NOUN
admet-322	139	27	,	,	PUNCT
admet-322	139	28	pazopanib	pazopanib	NOUN
admet-322	139	29	,	,	PUNCT
admet-322	139	30	sorafenib	sorafenib	NOUN
admet-322	139	31	and	and	CCONJ
admet-322	139	32	sunitinib	sunitinib	NOUN
admet-322	139	33	;	;	PUNCT
admet-322	139	34	the	the	DET
admet-322	139	35	bcr	bcr	PROPN
admet-322	139	36	/	/	SYM
admet-322	139	37	abl	abl	PROPN
admet-322	139	38	inhibitors	inhibitor	NOUN
admet-322	139	39	bosutinib	bosutinib	NOUN
admet-322	139	40	,	,	PUNCT
admet-322	139	41	imatinib	imatinib	NOUN
admet-322	139	42	and	and	CCONJ
admet-322	139	43	nilotinib	nilotinib	NOUN
admet-322	139	44	;	;	PUNCT
admet-322	139	45	and	and	CCONJ
admet-322	139	46	the	the	DET
admet-322	139	47	protein	protein	NOUN
admet-322	139	48	kinase	kinase	PROPN
admet-322	139	49	c	c	PROPN
admet-322	139	50	isoform	isoform	PROPN
admet-322	139	51	inhibitor	inhibitor	PROPN
admet-322	139	52	enzastaurin	enzastaurin	PROPN
admet-322	139	53	)	)	PUNCT
admet-322	139	54	were	be	AUX
admet-322	139	55	found	find	VERB
admet-322	139	56	to	to	PART
admet-322	139	57	be	be	AUX
admet-322	139	58	potent	potent	ADJ
admet-322	139	59	inhibitors	inhibitor	NOUN
admet-322	139	60	of	of	ADP
admet-322	139	61	bcrp	bcrp	ADV
admet-322	139	62	with	with	ADP
admet-322	139	63	ic50	ic50	PROPN
admet-322	139	64	values	value	NOUN
admet-322	139	65	<	<	X
admet-322	139	66	10	10	NUM
admet-322	139	67	μm	μm	NOUN
admet-322	139	68	(	(	PUNCT
admet-322	139	69	figure	figure	NOUN
admet-322	139	70	5	5	NUM
admet-322	139	71	)	)	PUNCT
admet-322	139	72	.	.	PUNCT
admet-322	140	1	notably	notably	ADV
admet-322	140	2	,	,	PUNCT
admet-322	140	3	erlotinib	erlotinib	NOUN
admet-322	140	4	,	,	PUNCT
admet-322	140	5	gefitinib	gefitinib	NOUN
admet-322	140	6	,	,	PUNCT
admet-322	140	7	sorafenib	sorafenib	NOUN
admet-322	140	8	,	,	PUNCT
admet-322	140	9	imatinib	imatinib	NOUN
admet-322	140	10	,	,	PUNCT
admet-322	140	11	nilotinib	nilotinib	NOUN
admet-322	140	12	,	,	PUNCT
admet-322	140	13	and	and	CCONJ
admet-322	140	14	enzaustaurin	enzaustaurin	NOUN
admet-322	140	15	produced	produce	VERB
admet-322	140	16	ic50	ic50	PROPN
admet-322	140	17	values	value	NOUN
admet-322	140	18	<	<	X
admet-322	140	19	1	1	NUM
admet-322	140	20	μm	μm	NUM
admet-322	140	21	.	.	PUNCT
admet-322	141	1	a	a	DET
admet-322	141	2	previous	previous	ADJ
admet-322	141	3	report	report	NOUN
admet-322	141	4	identified	identify	VERB
admet-322	141	5	axitinib	axitinib	NOUN
admet-322	141	6	as	as	ADP
admet-322	141	7	admet	admet	PROPN
admet-322	141	8	&	&	CCONJ
admet-322	141	9	dmpk	dmpk	PROPN
admet-322	141	10	4(4	4(4	NUM
admet-322	141	11	)	)	PUNCT
admet-322	141	12	(	(	PUNCT
admet-322	141	13	2016	2016	NUM
admet-322	141	14	)	)	PUNCT
admet-322	141	15	302	302	NUM
admet-322	141	16	-	-	SYM
admet-322	141	17	313	313	NUM
admet-322	141	18	tkis	tki	NOUN
admet-322	141	19	and	and	CCONJ
admet-322	141	20	akis	akis	PROPN
admet-322	141	21	diminish	diminish	VERB
admet-322	141	22	transport	transport	NOUN
admet-322	141	23	of	of	ADP
admet-322	141	24	function	function	NOUN
admet-322	141	25	of	of	ADP
admet-322	141	26	mrp4	mrp4	NOUN
admet-322	141	27	and	and	CCONJ
admet-322	141	28	bcrp	bcrp	PROPN
admet-322	141	29	doi	doi	PROPN
admet-322	141	30	:	:	PUNCT
admet-322	141	31	10.5599	10.5599	NUM
admet-322	141	32	/	/	SYM
admet-322	141	33	admet.4.4.322	admet.4.4.322	ADP
admet-322	141	34	309	309	NUM
admet-322	141	35	only	only	ADV
admet-322	141	36	a	a	DET
admet-322	141	37	partial	partial	ADJ
admet-322	141	38	inhibitor	inhibitor	NOUN
admet-322	141	39	of	of	ADP
admet-322	141	40	bcrp	bcrp	PROPN
admet-322	141	41	with	with	ADP
admet-322	141	42	an	an	DET
admet-322	141	43	ic50	ic50	PROPN
admet-322	141	44	value	value	NOUN
admet-322	141	45	of	of	ADP
admet-322	141	46	4.4	4.4	NUM
admet-322	141	47	μm	μm	NOUN
admet-322	141	48	;	;	PUNCT
admet-322	141	49	however	however	ADV
admet-322	141	50	the	the	DET
admet-322	141	51	experiments	experiment	NOUN
admet-322	141	52	were	be	AUX
admet-322	141	53	performed	perform	VERB
admet-322	141	54	in	in	ADP
admet-322	141	55	mcdk	mcdk	NOUN
admet-322	141	56	-	-	PUNCT
admet-322	141	57	bcrp	bcrp	NOUN
admet-322	141	58	cell	cell	NOUN
admet-322	141	59	monolayers	monolayer	NOUN
admet-322	141	60	and	and	CCONJ
admet-322	141	61	may	may	AUX
admet-322	141	62	not	not	PART
admet-322	141	63	be	be	AUX
admet-322	141	64	directly	directly	ADV
admet-322	141	65	comparable	comparable	ADJ
admet-322	141	66	to	to	ADP
admet-322	141	67	isolated	isolated	ADJ
admet-322	141	68	membrane	membrane	NOUN
admet-322	141	69	vesicle	vesicle	NOUN
admet-322	141	70	systems	system	NOUN
admet-322	141	71	[	[	X
admet-322	141	72	14	14	NUM
admet-322	141	73	]	]	PUNCT
admet-322	141	74	.	.	PUNCT
admet-322	142	1	tki	tki	NOUN
admet-322	142	2	inhibition	inhibition	NOUN
admet-322	142	3	potency	potency	NOUN
admet-322	142	4	towards	towards	ADP
admet-322	142	5	bcrp	bcrp	ADV
admet-322	142	6	was	be	AUX
admet-322	142	7	not	not	PART
admet-322	142	8	overrepresented	overrepresente	VERB
admet-322	142	9	in	in	ADP
admet-322	142	10	one	one	NUM
admet-322	142	11	inhibitor	inhibitor	NOUN
admet-322	142	12	class	class	NOUN
admet-322	142	13	versus	versus	ADP
admet-322	142	14	another	another	PRON
admet-322	142	15	as	as	SCONJ
admet-322	142	16	was	be	AUX
admet-322	142	17	seen	see	VERB
admet-322	142	18	for	for	ADP
admet-322	142	19	egfr	egfr	ADJ
admet-322	142	20	inhibitors	inhibitor	NOUN
admet-322	142	21	with	with	ADP
admet-322	142	22	respect	respect	NOUN
admet-322	142	23	to	to	ADP
admet-322	142	24	mrp4	mrp4	PROPN
admet-322	142	25	.	.	PUNCT
admet-322	143	1	one	one	NUM
admet-322	143	2	tki	tki	NOUN
admet-322	143	3	,	,	PUNCT
admet-322	143	4	lapatinib	lapatinib	PROPN
admet-322	143	5	,	,	PUNCT
admet-322	143	6	did	do	AUX
admet-322	143	7	not	not	PART
admet-322	143	8	produce	produce	VERB
admet-322	143	9	a	a	DET
admet-322	143	10	dose	dose	NOUN
admet-322	143	11	-	-	PUNCT
admet-322	143	12	response	response	NOUN
admet-322	143	13	curve	curve	NOUN
admet-322	143	14	and	and	CCONJ
admet-322	143	15	was	be	AUX
admet-322	143	16	deemed	deem	VERB
admet-322	143	17	to	to	PART
admet-322	143	18	not	not	PART
admet-322	143	19	be	be	AUX
admet-322	143	20	an	an	DET
admet-322	143	21	inhibitor	inhibitor	NOUN
admet-322	143	22	of	of	ADP
admet-322	143	23	bcrp	bcrp	PROPN
admet-322	143	24	.	.	PUNCT
admet-322	144	1	dose	dose	NOUN
admet-322	144	2	-	-	PUNCT
admet-322	144	3	response	response	NOUN
admet-322	144	4	curves	curve	NOUN
admet-322	144	5	for	for	ADP
admet-322	144	6	aki	aki	NOUN
admet-322	144	7	inhibition	inhibition	NOUN
admet-322	144	8	of	of	ADP
admet-322	144	9	bcrpmediated	bcrpmediated	ADJ
admet-322	144	10	transport	transport	NOUN
admet-322	144	11	are	be	AUX
admet-322	144	12	shown	show	VERB
admet-322	144	13	in	in	ADP
admet-322	144	14	figure	figure	NOUN
admet-322	144	15	6	6	NUM
admet-322	144	16	.	.	PUNCT
admet-322	145	1	in	in	ADP
admet-322	145	2	the	the	DET
admet-322	145	3	aki	aki	NOUN
admet-322	145	4	class	class	NOUN
admet-322	145	5	,	,	PUNCT
admet-322	145	6	alisertib	alisertib	ADJ
admet-322	145	7	,	,	PUNCT
admet-322	145	8	barasertib	barasertib	ADJ
admet-322	145	9	,	,	PUNCT
admet-322	145	10	and	and	CCONJ
admet-322	145	11	danusertib	danusertib	NOUN
admet-322	145	12	were	be	AUX
admet-322	145	13	identified	identify	VERB
admet-322	145	14	as	as	ADP
admet-322	145	15	potent	potent	ADJ
admet-322	145	16	inhibitors	inhibitor	NOUN
admet-322	145	17	of	of	ADP
admet-322	145	18	bcrp	bcrp	ADV
admet-322	145	19	with	with	ADP
admet-322	145	20	ic50	ic50	PROPN
admet-322	145	21	values	value	NOUN
admet-322	145	22	<	<	X
admet-322	145	23	10	10	NUM
admet-322	145	24	μm	μm	NUM
admet-322	145	25	(	(	PUNCT
admet-322	145	26	table	table	NOUN
admet-322	145	27	2	2	NUM
admet-322	145	28	)	)	PUNCT
admet-322	145	29	.	.	PUNCT
admet-322	146	1	unlike	unlike	ADP
admet-322	146	2	the	the	DET
admet-322	146	3	tkis	tkis	NOUN
admet-322	146	4	,	,	PUNCT
admet-322	146	5	none	none	NOUN
admet-322	146	6	of	of	ADP
admet-322	146	7	the	the	DET
admet-322	146	8	akis	akis	PROPN
admet-322	146	9	produced	produce	VERB
admet-322	146	10	ic50	ic50	PROPN
admet-322	146	11	values	value	NOUN
admet-322	146	12	<	<	X
admet-322	146	13	1	1	NUM
admet-322	146	14	μm	μm	NUM
admet-322	146	15	and	and	CCONJ
admet-322	146	16	thus	thus	ADV
admet-322	146	17	appeared	appear	VERB
admet-322	146	18	to	to	PART
admet-322	146	19	be	be	AUX
admet-322	146	20	slightly	slightly	ADV
admet-322	146	21	less	less	ADV
admet-322	146	22	potent	potent	ADJ
admet-322	146	23	inhibitors	inhibitor	NOUN
admet-322	146	24	of	of	ADP
admet-322	146	25	bcrp	bcrp	ADJ
admet-322	146	26	.	.	PUNCT
admet-322	147	1	figure	figure	VERB
admet-322	147	2	5	5	NUM
admet-322	147	3	.	.	PUNCT
admet-322	148	1	bcrp	bcrp	ADV
admet-322	148	2	inhibition	inhibition	NOUN
admet-322	148	3	by	by	ADP
admet-322	148	4	tyrosine	tyrosine	PROPN
admet-322	148	5	kinase	kinase	PROPN
admet-322	148	6	inhibitors	inhibitor	NOUN
admet-322	148	7	.	.	PUNCT
admet-322	149	1	inhibition	inhibition	NOUN
admet-322	149	2	of	of	ADP
admet-322	149	3	bcrp	bcrp	ADV
admet-322	149	4	-	-	PUNCT
admet-322	149	5	mediated	mediate	VERB
admet-322	149	6	[	[	PUNCT
admet-322	149	7	3	3	NUM
admet-322	149	8	h]-e1s	h]-e1	NOUN
admet-322	149	9	(	(	PUNCT
admet-322	149	10	1μm	1μm	NOUN
admet-322	149	11	;	;	PUNCT
admet-322	149	12	1.5	1.5	NUM
admet-322	149	13	min	min	NOUN
admet-322	149	14	)	)	PUNCT
admet-322	149	15	uptake	uptake	ADJ
admet-322	149	16	across	across	ADP
admet-322	149	17	an	an	DET
admet-322	149	18	inhibitor	inhibitor	NOUN
admet-322	149	19	concentration	concentration	NOUN
admet-322	149	20	range	range	NOUN
admet-322	149	21	of	of	ADP
admet-322	149	22	0.00316	0.00316	NUM
admet-322	149	23	-	-	SYM
admet-322	149	24	100	100	NUM
admet-322	149	25	μm	μm	NOUN
admet-322	149	26	(	(	PUNCT
admet-322	149	27	0.00316	0.00316	NUM
admet-322	149	28	-	-	SYM
admet-322	149	29	1	1	NUM
admet-322	149	30	μm	μm	NUM
admet-322	149	31	or	or	CCONJ
admet-322	149	32	0.0316	0.0316	NUM
admet-322	149	33	-	-	SYM
admet-322	149	34	10	10	NUM
admet-322	149	35	μm	μm	NOUN
admet-322	149	36	for	for	ADP
admet-322	149	37	potent	potent	ADJ
admet-322	149	38	inhibitors	inhibitor	NOUN
admet-322	149	39	)	)	PUNCT
admet-322	149	40	by	by	ADP
admet-322	149	41	egfr	egfr	ADJ
admet-322	149	42	,	,	PUNCT
admet-322	149	43	vegfr	vegfr	NOUN
admet-322	149	44	/	/	SYM
admet-322	149	45	pdgfr	pdgfr	ADJ
admet-322	149	46	,	,	PUNCT
admet-322	149	47	bcr	bcr	PROPN
admet-322	149	48	/	/	SYM
admet-322	149	49	abl	abl	NOUN
admet-322	149	50	inhibitors	inhibitor	NOUN
admet-322	149	51	,	,	PUNCT
admet-322	149	52	and	and	CCONJ
admet-322	149	53	inhibitors	inhibitor	NOUN
admet-322	149	54	with	with	ADP
admet-322	149	55	miscellaneous	miscellaneous	ADJ
admet-322	149	56	targets	target	NOUN
admet-322	149	57	is	be	AUX
admet-322	149	58	shown	show	VERB
admet-322	149	59	.	.	PUNCT
admet-322	150	1	data	datum	NOUN
admet-322	150	2	are	be	AUX
admet-322	150	3	presented	present	VERB
admet-322	150	4	as	as	ADP
admet-322	150	5	mean	mean	ADJ
admet-322	150	6	%	%	NOUN
admet-322	150	7	of	of	ADP
admet-322	150	8	control	control	NOUN
admet-322	150	9	uptake	uptake	ADJ
admet-322	150	10	±	±	NOUN
admet-322	150	11	sd	sd	NOUN
admet-322	150	12	,	,	PUNCT
admet-322	150	13	n=3	n=3	NOUN
admet-322	150	14	-	-	SYM
admet-322	150	15	7	7	NUM
admet-322	150	16	independent	independent	ADJ
admet-322	150	17	experiments	experiment	NOUN
admet-322	150	18	.	.	PUNCT
admet-322	151	1	r.n	r.n	PROPN
admet-322	151	2	.	.	PROPN
admet-322	151	3	hardwick	hardwick	PROPN
admet-322	151	4	et	et	PROPN
admet-322	151	5	al	al	PROPN
admet-322	151	6	.	.	PROPN
admet-322	151	7	admet	admet	PROPN
admet-322	151	8	&	&	CCONJ
admet-322	151	9	dmpk	dmpk	PROPN
admet-322	151	10	4(4	4(4	NUM
admet-322	151	11	)	)	PUNCT
admet-322	151	12	(	(	PUNCT
admet-322	151	13	2016	2016	NUM
admet-322	151	14	)	)	PUNCT
admet-322	151	15	302	302	NUM
admet-322	151	16	-	-	SYM
admet-322	151	17	313	313	NUM
admet-322	151	18	310	310	NUM
admet-322	151	19	figure	figure	NOUN
admet-322	151	20	6	6	NUM
admet-322	151	21	.	.	PUNCT
admet-322	152	1	bcrp	bcrp	ADV
admet-322	152	2	inhibition	inhibition	NOUN
admet-322	152	3	by	by	ADP
admet-322	152	4	aurora	aurora	PROPN
admet-322	152	5	kinase	kinase	PROPN
admet-322	152	6	inhibitors	inhibitor	NOUN
admet-322	152	7	.	.	PUNCT
admet-322	153	1	inhibition	inhibition	NOUN
admet-322	153	2	of	of	ADP
admet-322	153	3	bcrp	bcrp	ADV
admet-322	153	4	-	-	PUNCT
admet-322	153	5	mediated	mediate	VERB
admet-322	153	6	[	[	PUNCT
admet-322	153	7	3	3	NUM
admet-322	153	8	h]-e1s	h]-e1	NOUN
admet-322	153	9	(	(	PUNCT
admet-322	153	10	1	1	NUM
admet-322	153	11	μm	μm	NUM
admet-322	153	12	;	;	PUNCT
admet-322	153	13	1.5	1.5	NUM
admet-322	153	14	min	min	NOUN
admet-322	153	15	)	)	PUNCT
admet-322	153	16	uptake	uptake	ADJ
admet-322	153	17	across	across	ADP
admet-322	153	18	an	an	DET
admet-322	153	19	inhibitor	inhibitor	NOUN
admet-322	153	20	concentration	concentration	NOUN
admet-322	153	21	range	range	NOUN
admet-322	153	22	of	of	ADP
admet-322	153	23	0.316	0.316	NUM
admet-322	153	24	-	-	SYM
admet-322	153	25	100	100	NUM
admet-322	153	26	μm	μm	NOUN
admet-322	153	27	is	be	AUX
admet-322	153	28	shown	show	VERB
admet-322	153	29	.	.	PUNCT
admet-322	154	1	data	datum	NOUN
admet-322	154	2	are	be	AUX
admet-322	154	3	presented	present	VERB
admet-322	154	4	as	as	ADP
admet-322	154	5	mean	mean	ADJ
admet-322	154	6	%	%	NOUN
admet-322	154	7	of	of	ADP
admet-322	154	8	control	control	NOUN
admet-322	154	9	uptake	uptake	ADJ
admet-322	154	10	±	±	NOUN
admet-322	154	11	sd	sd	NOUN
admet-322	154	12	,	,	PUNCT
admet-322	154	13	n=3	n=3	NOUN
admet-322	154	14	-	-	SYM
admet-322	154	15	4	4	NUM
admet-322	154	16	independent	independent	ADJ
admet-322	154	17	experiments	experiment	NOUN
admet-322	154	18	.	.	PUNCT
admet-322	155	1	to	to	PART
admet-322	155	2	provide	provide	VERB
admet-322	155	3	insight	insight	NOUN
admet-322	155	4	to	to	ADP
admet-322	155	5	the	the	DET
admet-322	155	6	clinical	clinical	ADJ
admet-322	155	7	relevance	relevance	NOUN
admet-322	155	8	of	of	ADP
admet-322	155	9	tki	tki	PROPN
admet-322	155	10	/	/	SYM
admet-322	155	11	aki	aki	NOUN
admet-322	155	12	inhibition	inhibition	NOUN
admet-322	155	13	of	of	ADP
admet-322	155	14	mrp4and	mrp4and	NOUN
admet-322	155	15	bcrp	bcrp	ADV
admet-322	155	16	-	-	PUNCT
admet-322	155	17	mediated	mediate	VERB
admet-322	155	18	transport	transport	NOUN
admet-322	155	19	,	,	PUNCT
admet-322	155	20	steady	steady	ADJ
admet-322	155	21	-	-	PUNCT
admet-322	155	22	state	state	NOUN
admet-322	155	23	total	total	ADJ
admet-322	155	24	plasma	plasma	NOUN
admet-322	155	25	css	css	PROPN
admet-322	155	26	values	value	NOUN
admet-322	155	27	were	be	AUX
admet-322	155	28	extracted	extract	VERB
admet-322	155	29	from	from	ADP
admet-322	155	30	micromedex	micromedex	NOUN
admet-322	155	31	and	and	CCONJ
admet-322	155	32	manufacturer	manufacturer	NOUN
admet-322	155	33	package	package	NOUN
admet-322	155	34	inserts	insert	NOUN
admet-322	155	35	.	.	PUNCT
admet-322	156	1	the	the	DET
admet-322	156	2	css	css	PROPN
admet-322	156	3	values	value	NOUN
admet-322	156	4	were	be	AUX
admet-322	156	5	expressed	express	VERB
admet-322	156	6	as	as	ADP
admet-322	156	7	a	a	DET
admet-322	156	8	ratio	ratio	NOUN
admet-322	156	9	to	to	ADP
admet-322	156	10	the	the	DET
admet-322	156	11	ic50	ic50	PROPN
admet-322	156	12	for	for	ADP
admet-322	156	13	each	each	DET
admet-322	156	14	transporter	transporter	NOUN
admet-322	156	15	with	with	ADP
admet-322	156	16	a	a	DET
admet-322	156	17	css	css	PROPN
admet-322	156	18	/	/	SYM
admet-322	156	19	ic50	ic50	PROPN
admet-322	156	20	ratio	ratio	NOUN
admet-322	156	21	>	>	NOUN
admet-322	156	22	0.1	0.1	NUM
admet-322	156	23	regarded	regard	VERB
admet-322	156	24	as	as	ADP
admet-322	156	25	having	have	VERB
admet-322	156	26	potential	potential	NOUN
admet-322	156	27	for	for	ADP
admet-322	156	28	clinically	clinically	ADV
admet-322	156	29	relevant	relevant	ADJ
admet-322	156	30	transporter	transporter	NOUN
admet-322	156	31	inhibition	inhibition	NOUN
admet-322	156	32	[	[	X
admet-322	156	33	35	35	NUM
admet-322	156	34	,	,	PUNCT
admet-322	156	35	38	38	NUM
admet-322	156	36	]	]	PUNCT
admet-322	156	37	.	.	PUNCT
admet-322	157	1	although	although	SCONJ
admet-322	157	2	it	it	PRON
admet-322	157	3	is	be	AUX
admet-322	157	4	well	well	ADV
admet-322	157	5	-	-	PUNCT
admet-322	157	6	recognized	recognize	VERB
admet-322	157	7	that	that	SCONJ
admet-322	157	8	drug	drug	NOUN
admet-322	157	9	concentrations	concentration	NOUN
admet-322	157	10	within	within	ADP
admet-322	157	11	cells	cell	NOUN
admet-322	157	12	may	may	AUX
admet-322	157	13	become	become	VERB
admet-322	157	14	more	more	ADV
admet-322	157	15	concentrated	concentrated	ADJ
admet-322	157	16	than	than	ADP
admet-322	157	17	measured	measure	VERB
admet-322	157	18	css	css	PROPN
admet-322	157	19	in	in	ADP
admet-322	157	20	patient	patient	ADJ
admet-322	157	21	plasma	plasma	NOUN
admet-322	157	22	,	,	PUNCT
admet-322	157	23	either	either	CCONJ
admet-322	157	24	due	due	ADP
admet-322	157	25	to	to	ADP
admet-322	157	26	transporter	transporter	NOUN
admet-322	157	27	-	-	PUNCT
admet-322	157	28	mediated	mediate	VERB
admet-322	157	29	accumulation	accumulation	NOUN
admet-322	157	30	or	or	CCONJ
admet-322	157	31	organelle	organelle	NOUN
admet-322	157	32	binding	binding	NOUN
admet-322	157	33	,	,	PUNCT
admet-322	157	34	the	the	DET
admet-322	157	35	use	use	NOUN
admet-322	157	36	of	of	ADP
admet-322	157	37	total	total	ADJ
admet-322	157	38	plasma	plasma	NOUN
admet-322	157	39	css	css	PROPN
admet-322	157	40	values	value	NOUN
admet-322	157	41	have	have	AUX
admet-322	157	42	been	be	AUX
admet-322	157	43	recommended	recommend	VERB
admet-322	157	44	and	and	CCONJ
admet-322	157	45	are	be	AUX
admet-322	157	46	used	use	VERB
admet-322	157	47	herein	herein	NOUN
admet-322	157	48	in	in	ADP
admet-322	157	49	the	the	DET
admet-322	157	50	absence	absence	NOUN
admet-322	157	51	of	of	ADP
admet-322	157	52	unbound	unbound	NOUN
admet-322	157	53	intracellular	intracellular	ADJ
admet-322	157	54	drug	drug	NOUN
admet-322	157	55	concentration	concentration	NOUN
admet-322	157	56	data	datum	NOUN
admet-322	157	57	[	[	X
admet-322	157	58	35	35	NUM
admet-322	157	59	,	,	PUNCT
admet-322	157	60	38	38	NUM
admet-322	157	61	,	,	PUNCT
admet-322	157	62	39	39	NUM
admet-322	157	63	]	]	PUNCT
admet-322	157	64	.	.	PUNCT
admet-322	158	1	css	css	PROPN
admet-322	158	2	/	/	SYM
admet-322	158	3	ic50	ic50	PROPN
admet-322	158	4	ratios	ratio	NOUN
admet-322	158	5	are	be	AUX
admet-322	158	6	shown	show	VERB
admet-322	158	7	in	in	ADP
admet-322	158	8	table	table	NOUN
admet-322	158	9	2	2	NUM
admet-322	158	10	.	.	NOUN
admet-322	158	11	nine	nine	NUM
admet-322	158	12	of	of	ADP
admet-322	158	13	the	the	DET
admet-322	158	14	20	20	NUM
admet-322	158	15	tki	tki	NOUN
admet-322	158	16	/	/	SYM
admet-322	158	17	akis	akis	PROPN
admet-322	158	18	tested	tested	AUX
admet-322	158	19	exhibited	exhibit	VERB
admet-322	158	20	css	css	PROPN
admet-322	158	21	/	/	SYM
admet-322	158	22	ic50	ic50	PROPN
admet-322	158	23	ratios	ratio	NOUN
admet-322	158	24	>	>	X
admet-322	158	25	0.1	0.1	NUM
admet-322	158	26	for	for	ADP
admet-322	158	27	mrp4	mrp4	NOUN
admet-322	158	28	.	.	PUNCT
admet-322	159	1	in	in	ADP
admet-322	159	2	particular	particular	ADJ
admet-322	159	3	,	,	PUNCT
admet-322	159	4	alisertib	alisertib	ADJ
admet-322	159	5	,	,	PUNCT
admet-322	159	6	danusertib	danusertib	NOUN
admet-322	159	7	,	,	PUNCT
admet-322	159	8	erlotinib	erlotinib	PROPN
admet-322	159	9	,	,	PUNCT
admet-322	159	10	lapatinib	lapatinib	PROPN
admet-322	159	11	,	,	PUNCT
admet-322	159	12	neratinib	neratinib	NOUN
admet-322	159	13	,	,	PUNCT
admet-322	159	14	nilotinib	nilotinib	NOUN
admet-322	159	15	,	,	PUNCT
admet-322	159	16	pazopanib	pazopanib	NOUN
admet-322	159	17	,	,	PUNCT
admet-322	159	18	sorafenib	sorafenib	NOUN
admet-322	159	19	,	,	PUNCT
admet-322	159	20	and	and	CCONJ
admet-322	159	21	tozasertib	tozasertib	NOUN
admet-322	159	22	were	be	AUX
admet-322	159	23	identified	identify	VERB
admet-322	159	24	as	as	ADP
admet-322	159	25	having	have	VERB
admet-322	159	26	potential	potential	NOUN
admet-322	159	27	for	for	ADP
admet-322	159	28	clinically	clinically	ADV
admet-322	159	29	relevant	relevant	ADJ
admet-322	159	30	mrp4	mrp4	NOUN
admet-322	159	31	inhibition	inhibition	NOUN
admet-322	159	32	.	.	PUNCT
admet-322	160	1	although	although	SCONJ
admet-322	160	2	the	the	DET
admet-322	160	3	majority	majority	NOUN
admet-322	160	4	of	of	ADP
admet-322	160	5	potent	potent	ADJ
admet-322	160	6	mrp4	mrp4	NOUN
admet-322	160	7	inhibitors	inhibitor	NOUN
admet-322	160	8	(	(	PUNCT
admet-322	160	9	ic50	ic50	PROPN
admet-322	160	10	≤	≤	NUM
admet-322	160	11	10	10	NUM
admet-322	160	12	μm	μm	NUM
admet-322	160	13	)	)	PUNCT
admet-322	160	14	were	be	AUX
admet-322	160	15	found	find	VERB
admet-322	160	16	to	to	PART
admet-322	160	17	be	be	AUX
admet-322	160	18	in	in	ADP
admet-322	160	19	the	the	DET
admet-322	160	20	egfr	egfr	ADJ
admet-322	160	21	inhibitor	inhibitor	NOUN
admet-322	160	22	class	class	NOUN
admet-322	160	23	,	,	PUNCT
admet-322	160	24	the	the	DET
admet-322	160	25	tki	tki	PROPN
admet-322	160	26	/	/	SYM
admet-322	160	27	akis	akis	PROPN
admet-322	160	28	identified	identify	VERB
admet-322	160	29	as	as	ADP
admet-322	160	30	having	have	VERB
admet-322	160	31	potential	potential	NOUN
admet-322	160	32	for	for	ADP
admet-322	160	33	clinical	clinical	ADJ
admet-322	160	34	relevance	relevance	NOUN
admet-322	160	35	were	be	AUX
admet-322	160	36	primarily	primarily	ADV
admet-322	160	37	stratified	stratify	VERB
admet-322	160	38	across	across	ADP
admet-322	160	39	both	both	CCONJ
admet-322	160	40	egfr	egfr	NOUN
admet-322	160	41	and	and	CCONJ
admet-322	160	42	aurora	aurora	PROPN
admet-322	160	43	kinase	kinase	PROPN
admet-322	160	44	inhibitor	inhibitor	PROPN
admet-322	160	45	classes	class	NOUN
admet-322	160	46	.	.	PUNCT
admet-322	161	1	only	only	ADV
admet-322	161	2	2	2	NUM
admet-322	161	3	vegfr	vegfr	NOUN
admet-322	161	4	&	&	CCONJ
admet-322	161	5	pdgfr	pdgfr	ADJ
admet-322	161	6	and	and	CCONJ
admet-322	161	7	1	1	NUM
admet-322	161	8	bcr	bcr	VERB
admet-322	161	9	/	/	SYM
admet-322	161	10	abl	abl	PROPN
admet-322	161	11	kinase	kinase	PROPN
admet-322	161	12	inhibitors	inhibitor	NOUN
admet-322	161	13	were	be	AUX
admet-322	161	14	found	find	VERB
admet-322	161	15	to	to	PART
admet-322	161	16	be	be	AUX
admet-322	161	17	clinically	clinically	ADV
admet-322	161	18	relevant	relevant	ADJ
admet-322	161	19	.	.	PUNCT
admet-322	162	1	similar	similar	ADJ
admet-322	162	2	to	to	ADP
admet-322	162	3	the	the	DET
admet-322	162	4	report	report	NOUN
admet-322	162	5	of	of	ADP
admet-322	162	6	morgan	morgan	PROPN
admet-322	162	7	,	,	PUNCT
admet-322	162	8	et	et	PROPN
admet-322	162	9	al	al	PROPN
admet-322	162	10	.	.	PROPN
admet-322	162	11	,	,	PUNCT
admet-322	162	12	pazopanib	pazopanib	PROPN
admet-322	162	13	was	be	AUX
admet-322	162	14	identified	identify	VERB
admet-322	162	15	as	as	ADP
admet-322	162	16	having	have	VERB
admet-322	162	17	the	the	DET
admet-322	162	18	potential	potential	NOUN
admet-322	162	19	for	for	ADP
admet-322	162	20	clinically	clinically	ADV
admet-322	162	21	relevant	relevant	ADJ
admet-322	162	22	mrp4	mrp4	NOUN
admet-322	162	23	inhibition	inhibition	NOUN
admet-322	162	24	[	[	X
admet-322	162	25	35	35	NUM
admet-322	162	26	]	]	PUNCT
admet-322	162	27	.	.	PUNCT
admet-322	163	1	additionally	additionally	ADV
admet-322	163	2	,	,	PUNCT
admet-322	163	3	though	though	SCONJ
admet-322	163	4	the	the	DET
admet-322	163	5	studies	study	NOUN
admet-322	163	6	of	of	ADP
admet-322	163	7	morgan	morgan	PROPN
admet-322	163	8	,	,	PUNCT
admet-322	163	9	et	et	PROPN
admet-322	163	10	al	al	PROPN
admet-322	163	11	.	.	PROPN
admet-322	163	12	,	,	PUNCT
admet-322	163	13	also	also	ADV
admet-322	163	14	identified	identify	VERB
admet-322	163	15	gefitinib	gefitinib	NOUN
admet-322	163	16	as	as	ADP
admet-322	163	17	a	a	DET
admet-322	163	18	potent	potent	ADJ
admet-322	163	19	inhibitor	inhibitor	NOUN
admet-322	163	20	of	of	ADP
admet-322	163	21	mrp4	mrp4	PROPN
admet-322	163	22	,	,	PUNCT
admet-322	163	23	gefitinib	gefitinib	NOUN
admet-322	163	24	-	-	PUNCT
admet-322	163	25	mediated	mediate	VERB
admet-322	163	26	inhibition	inhibition	NOUN
admet-322	163	27	of	of	ADP
admet-322	163	28	mrp4	mrp4	NOUN
admet-322	163	29	transport	transport	NOUN
admet-322	163	30	activity	activity	NOUN
admet-322	163	31	was	be	AUX
admet-322	163	32	not	not	PART
admet-322	163	33	deemed	deem	VERB
admet-322	163	34	clinically	clinically	ADV
admet-322	163	35	relevant	relevant	ADJ
admet-322	163	36	[	[	X
admet-322	163	37	35	35	NUM
admet-322	163	38	]	]	PUNCT
admet-322	163	39	,	,	PUNCT
admet-322	163	40	which	which	PRON
admet-322	163	41	is	be	AUX
admet-322	163	42	similar	similar	ADJ
admet-322	163	43	to	to	ADP
admet-322	163	44	the	the	DET
admet-322	163	45	current	current	ADJ
admet-322	163	46	results	result	NOUN
admet-322	163	47	.	.	PUNCT
admet-322	164	1	the	the	DET
admet-322	164	2	majority	majority	NOUN
admet-322	164	3	of	of	ADP
admet-322	164	4	the	the	DET
admet-322	164	5	tki	tki	PROPN
admet-322	164	6	/	/	SYM
admet-322	164	7	akis	akis	PROPN
admet-322	164	8	investigated	investigate	VERB
admet-322	164	9	were	be	AUX
admet-322	164	10	found	find	VERB
admet-322	164	11	to	to	PART
admet-322	164	12	potentially	potentially	ADV
admet-322	164	13	be	be	AUX
admet-322	164	14	clinically	clinically	ADV
admet-322	164	15	relevant	relevant	ADJ
admet-322	164	16	inhibitors	inhibitor	NOUN
admet-322	164	17	of	of	ADP
admet-322	164	18	bcrp	bcrp	PROPN
admet-322	164	19	,	,	PUNCT
admet-322	164	20	with	with	ADP
admet-322	164	21	15	15	NUM
admet-322	164	22	of	of	ADP
admet-322	164	23	the	the	DET
admet-322	164	24	20	20	NUM
admet-322	164	25	compounds	compound	NOUN
admet-322	164	26	having	have	VERB
admet-322	164	27	a	a	DET
admet-322	164	28	css	css	PROPN
admet-322	164	29	/	/	SYM
admet-322	164	30	ic50	ic50	PROPN
admet-322	164	31	ratio	ratio	NOUN
admet-322	164	32	>	>	NOUN
admet-322	164	33	0.1	0.1	NUM
admet-322	164	34	.	.	PUNCT
admet-322	165	1	specific	specific	ADJ
admet-322	165	2	compounds	compound	NOUN
admet-322	165	3	identified	identify	VERB
admet-322	165	4	were	be	AUX
admet-322	165	5	alisertib	alisertib	ADJ
admet-322	165	6	,	,	PUNCT
admet-322	165	7	barasertib	barasertib	ADJ
admet-322	165	8	,	,	PUNCT
admet-322	165	9	danusertib	danusertib	NOUN
admet-322	165	10	,	,	PUNCT
admet-322	165	11	enzastaurin	enzastaurin	NOUN
admet-322	165	12	,	,	PUNCT
admet-322	165	13	erlotinib	erlotinib	NOUN
admet-322	165	14	,	,	PUNCT
admet-322	165	15	gefitinib	gefitinib	NOUN
admet-322	165	16	,	,	PUNCT
admet-322	165	17	imatinib	imatinib	NOUN
admet-322	165	18	,	,	PUNCT
admet-322	165	19	neratinib	neratinib	NOUN
admet-322	165	20	,	,	PUNCT
admet-322	165	21	nilotinb	nilotinb	PROPN
admet-322	165	22	,	,	PUNCT
admet-322	165	23	pazopanib	pazopanib	PROPN
admet-322	165	24	,	,	PUNCT
admet-322	165	25	selumetinib	selumetinib	NOUN
admet-322	165	26	,	,	PUNCT
admet-322	165	27	sorafenib	sorafenib	NOUN
admet-322	165	28	,	,	PUNCT
admet-322	165	29	sunitinib	sunitinib	NOUN
admet-322	165	30	,	,	PUNCT
admet-322	165	31	tozasertib	tozasertib	NOUN
admet-322	165	32	,	,	PUNCT
admet-322	165	33	and	and	CCONJ
admet-322	165	34	vandetanib	vandetanib	PROPN
admet-322	165	35	.	.	PUNCT
admet-322	166	1	several	several	ADJ
admet-322	166	2	compounds	compound	NOUN
admet-322	166	3	,	,	PUNCT
admet-322	166	4	notably	notably	ADV
admet-322	166	5	alisertib	alisertib	ADJ
admet-322	166	6	,	,	PUNCT
admet-322	166	7	danusertib	danusertib	NOUN
admet-322	166	8	,	,	PUNCT
admet-322	166	9	erlotinib	erlotinib	NOUN
admet-322	166	10	,	,	PUNCT
admet-322	166	11	neratinib	neratinib	NOUN
admet-322	166	12	,	,	PUNCT
admet-322	166	13	nilotinib	nilotinib	NOUN
admet-322	166	14	,	,	PUNCT
admet-322	166	15	pazopanib	pazopanib	NOUN
admet-322	166	16	,	,	PUNCT
admet-322	166	17	sorafenib	sorafenib	NOUN
admet-322	166	18	,	,	PUNCT
admet-322	166	19	and	and	CCONJ
admet-322	166	20	tozasertib	tozasertib	NOUN
admet-322	166	21	were	be	AUX
admet-322	166	22	found	find	VERB
admet-322	166	23	to	to	PART
admet-322	166	24	be	be	AUX
admet-322	166	25	dual	dual	ADJ
admet-322	166	26	inhibitors	inhibitor	NOUN
admet-322	166	27	of	of	ADP
admet-322	166	28	mrp4	mrp4	NOUN
admet-322	166	29	and	and	CCONJ
admet-322	166	30	bcrp	bcrp	ADV
admet-322	166	31	with	with	ADP
admet-322	166	32	potential	potential	ADJ
admet-322	166	33	clinical	clinical	ADJ
admet-322	166	34	relevance	relevance	NOUN
admet-322	166	35	for	for	ADP
admet-322	166	36	both	both	PRON
admet-322	166	37	.	.	PUNCT
admet-322	167	1	dual	dual	ADJ
admet-322	167	2	inhibition	inhibition	NOUN
admet-322	167	3	may	may	AUX
admet-322	167	4	further	far	ADV
admet-322	167	5	complicate	complicate	VERB
admet-322	167	6	drug	drug	NOUN
admet-322	167	7	-	-	PUNCT
admet-322	167	8	mediated	mediate	VERB
admet-322	167	9	transporter	transporter	NOUN
admet-322	167	10	inhibition	inhibition	NOUN
admet-322	167	11	by	by	ADP
admet-322	167	12	minimizing	minimize	VERB
admet-322	167	13	compensatory	compensatory	ADJ
admet-322	167	14	mechanisms	mechanism	NOUN
admet-322	167	15	for	for	ADP
admet-322	167	16	export	export	NOUN
admet-322	167	17	of	of	ADP
admet-322	167	18	compounds	compound	NOUN
admet-322	167	19	from	from	ADP
admet-322	167	20	within	within	ADP
admet-322	167	21	a	a	DET
admet-322	167	22	cell	cell	NOUN
admet-322	167	23	.	.	PUNCT
admet-322	168	1	in	in	ADP
admet-322	168	2	summation	summation	NOUN
admet-322	168	3	,	,	PUNCT
admet-322	168	4	the	the	DET
admet-322	168	5	analysis	analysis	NOUN
admet-322	168	6	of	of	ADP
admet-322	168	7	css	css	PROPN
admet-322	168	8	/	/	SYM
admet-322	168	9	ic50	ic50	PROPN
admet-322	168	10	ratios	ratio	NOUN
admet-322	168	11	revealed	reveal	VERB
admet-322	168	12	a	a	DET
admet-322	168	13	greater	great	ADJ
admet-322	168	14	potential	potential	NOUN
admet-322	168	15	for	for	ADP
admet-322	168	16	clinically	clinically	ADV
admet-322	168	17	relevant	relevant	ADJ
admet-322	168	18	bcrp	bcrp	ADJ
admet-322	168	19	inhibition	inhibition	VERB
admet-322	168	20	admet	admet	PROPN
admet-322	168	21	&	&	CCONJ
admet-322	168	22	dmpk	dmpk	PROPN
admet-322	168	23	4(4	4(4	NUM
admet-322	168	24	)	)	PUNCT
admet-322	168	25	(	(	PUNCT
admet-322	168	26	2016	2016	NUM
admet-322	168	27	)	)	PUNCT
admet-322	168	28	302	302	NUM
admet-322	168	29	-	-	SYM
admet-322	168	30	313	313	NUM
admet-322	168	31	tkis	tki	NOUN
admet-322	168	32	and	and	CCONJ
admet-322	168	33	akis	akis	PROPN
admet-322	168	34	diminish	diminish	VERB
admet-322	168	35	transport	transport	NOUN
admet-322	168	36	of	of	ADP
admet-322	168	37	function	function	NOUN
admet-322	168	38	of	of	ADP
admet-322	168	39	mrp4	mrp4	NOUN
admet-322	168	40	and	and	CCONJ
admet-322	168	41	bcrp	bcrp	PROPN
admet-322	168	42	doi	doi	PROPN
admet-322	168	43	:	:	PUNCT
admet-322	168	44	10.5599	10.5599	NUM
admet-322	168	45	/	/	SYM
admet-322	168	46	admet.4.4.322	admet.4.4.322	ADP
admet-322	168	47	311	311	NUM
admet-322	168	48	by	by	ADP
admet-322	168	49	tki	tki	NOUN
admet-322	168	50	/	/	SYM
admet-322	168	51	akis	akis	PROPN
admet-322	168	52	compared	compare	VERB
admet-322	168	53	to	to	ADP
admet-322	168	54	mrp4	mrp4	PROPN
admet-322	168	55	,	,	PUNCT
admet-322	168	56	though	though	SCONJ
admet-322	168	57	eight	eight	NUM
admet-322	168	58	tki	tki	NOUN
admet-322	168	59	/	/	SYM
admet-322	168	60	akis	akis	PROPN
admet-322	168	61	were	be	AUX
admet-322	168	62	found	find	VERB
admet-322	168	63	to	to	PART
admet-322	168	64	be	be	AUX
admet-322	168	65	dual	dual	ADJ
admet-322	168	66	inhibitors	inhibitor	NOUN
admet-322	168	67	of	of	ADP
admet-322	168	68	both	both	DET
admet-322	168	69	transporters	transporter	NOUN
admet-322	168	70	.	.	PUNCT
admet-322	169	1	table	table	NOUN
admet-322	169	2	2	2	NUM
admet-322	169	3	.	.	PUNCT
admet-322	170	1	summary	summary	NOUN
admet-322	170	2	of	of	ADP
admet-322	170	3	tki	tki	PROPN
admet-322	170	4	and	and	CCONJ
admet-322	170	5	aki	aki	NOUN
admet-322	170	6	inhibition	inhibition	NOUN
admet-322	170	7	of	of	ADP
admet-322	170	8	mrp4	mrp4	NOUN
admet-322	170	9	and	and	CCONJ
admet-322	170	10	bcrp	bcrp	ADV
admet-322	170	11	.	.	PUNCT
admet-322	171	1	data	datum	NOUN
admet-322	171	2	are	be	AUX
admet-322	171	3	presented	present	VERB
admet-322	171	4	as	as	ADP
admet-322	171	5	mean	mean	ADJ
admet-322	171	6	relative	relative	ADJ
admet-322	171	7	ic50	ic50	PROPN
admet-322	171	8	estimates	estimate	NOUN
admet-322	171	9	(	(	PUNCT
admet-322	171	10	μm	μm	NUM
admet-322	171	11	)	)	PUNCT
admet-322	171	12	.	.	PUNCT
admet-322	172	1	total	total	ADJ
admet-322	172	2	plasma	plasma	NOUN
admet-322	172	3	cmax	cmax	NOUN
admet-322	172	4	values	value	NOUN
admet-322	172	5	(	(	PUNCT
admet-322	172	6	μm	μm	NUM
admet-322	172	7	)	)	PUNCT
admet-322	172	8	were	be	AUX
admet-322	172	9	extracted	extract	VERB
admet-322	172	10	from	from	ADP
admet-322	172	11	micromedex	micromedex	PROPN
admet-322	172	12	2.0	2.0	NUM
admet-322	172	13	(	(	PUNCT
admet-322	172	14	truven	truven	NOUN
admet-322	172	15	health	health	NOUN
admet-322	172	16	analytics	analytic	NOUN
admet-322	172	17	)	)	PUNCT
admet-322	172	18	and	and	CCONJ
admet-322	172	19	manufacturer	manufacturer	NOUN
admet-322	172	20	package	package	NOUN
admet-322	172	21	inserts	insert	NOUN
admet-322	172	22	.	.	PUNCT
admet-322	173	1	n	n	CCONJ
admet-322	173	2	/	/	SYM
admet-322	173	3	a	a	DET
admet-322	173	4	=	=	NOUN
admet-322	173	5	data	datum	NOUN
admet-322	173	6	not	not	PART
admet-322	173	7	available	available	ADJ
admet-322	173	8	.	.	PUNCT
admet-322	174	1	asterisk	asterisk	NOUN
admet-322	174	2	(	(	PUNCT
admet-322	174	3	*	*	PUNCT
admet-322	174	4	)	)	PUNCT
admet-322	174	5	indicates	indicate	VERB
admet-322	174	6	cmax	cmax	NOUN
admet-322	174	7	/	/	SYM
admet-322	174	8	ic50	ic50	PROPN
admet-322	174	9	ratio	ratio	NOUN
admet-322	174	10	>	>	NOUN
admet-322	174	11	0.1	0.1	NUM
admet-322	174	12	for	for	ADP
admet-322	174	13	an	an	DET
admet-322	174	14	individual	individual	ADJ
admet-322	174	15	transporter	transporter	NOUN
admet-322	174	16	.	.	PUNCT
admet-322	175	1	tki	tki	PROPN
admet-322	175	2	/	/	SYM
admet-322	175	3	aki	aki	NOUN
admet-322	175	4	steady	steady	ADJ
admet-322	175	5	-	-	PUNCT
admet-322	175	6	state	state	NOUN
admet-322	175	7	total	total	ADJ
admet-322	175	8	css	css	PROPN
admet-322	175	9	(	(	PUNCT
admet-322	175	10	μm	μm	NOUN
admet-322	175	11	)	)	PUNCT
admet-322	175	12	mean	mean	NOUN
admet-322	175	13	relative	relative	ADJ
admet-322	175	14	mrp4	mrp4	NOUN
admet-322	175	15	ic50	ic50	PROPN
admet-322	175	16	estimate	estimate	NOUN
admet-322	175	17	(	(	PUNCT
admet-322	175	18	μm	μm	INTJ
admet-322	175	19	,	,	PUNCT
admet-322	175	20	±sd	±sd	ADJ
admet-322	175	21	)	)	PUNCT
admet-322	175	22	css	css	PROPN
admet-322	175	23	/	/	SYM
admet-322	175	24	ic50	ic50	PROPN
admet-322	175	25	mrp4	mrp4	NOUN
admet-322	175	26	mean	mean	VERB
admet-322	175	27	relative	relative	ADJ
admet-322	175	28	bcrp	bcrp	PROPN
admet-322	175	29	ic50	ic50	PROPN
admet-322	175	30	estimate	estimate	NOUN
admet-322	175	31	(	(	PUNCT
admet-322	175	32	μm	μm	INTJ
admet-322	175	33	,	,	PUNCT
admet-322	175	34	±sd	±sd	ADJ
admet-322	175	35	)	)	PUNCT
admet-322	175	36	css	css	PROPN
admet-322	175	37	/	/	SYM
admet-322	175	38	ic50	ic50	PROPN
admet-322	175	39	bcrp	bcrp	ADV
admet-322	175	40	alisertib	alisertib	VERB
admet-322	175	41	1.80	1.80	NUM
admet-322	175	42	16.54	16.54	NUM
admet-322	175	43	(	(	PUNCT
admet-322	175	44	±4.34	±4.34	PROPN
admet-322	175	45	)	)	PUNCT
admet-322	175	46	0.109	0.109	NUM
admet-322	176	1	*	*	SYM
admet-322	176	2	3.00	3.00	NUM
admet-322	176	3	(	(	PUNCT
admet-322	176	4	±0.38	±0.38	PROPN
admet-322	176	5	)	)	PUNCT
admet-322	176	6	0.600	0.600	NUM
admet-322	176	7	*	*	PUNCT
admet-322	176	8	axitinib	axitinib	NOUN
admet-322	176	9	0.07	0.07	NUM
admet-322	176	10	14.99	14.99	NUM
admet-322	176	11	(	(	PUNCT
admet-322	176	12	±5.29	±5.29	NOUN
admet-322	176	13	)	)	PUNCT
admet-322	176	14	0.005	0.005	NUM
admet-322	176	15	1.56	1.56	NUM
admet-322	176	16	(	(	PUNCT
admet-322	176	17	±1.07	±1.07	PROPN
admet-322	176	18	)	)	PUNCT
admet-322	176	19	0.045	0.045	NUM
admet-322	176	20	barasertib	barasertib	NOUN
admet-322	176	21	2.30	2.30	NUM
admet-322	176	22	86.30	86.30	NUM
admet-322	176	23	(	(	PUNCT
admet-322	176	24	±81.93	±81.93	PROPN
admet-322	176	25	)	)	PUNCT
admet-322	176	26	0.027	0.027	NUM
admet-322	176	27	7.62	7.62	NUM
admet-322	176	28	(	(	PUNCT
admet-322	176	29	±7.61	±7.61	NOUN
admet-322	176	30	)	)	PUNCT
admet-322	176	31	0.302	0.302	NUM
admet-322	176	32	*	*	PUNCT
admet-322	176	33	bosutinib	bosutinib	NOUN
admet-322	176	34	0.38	0.38	NUM
admet-322	176	35	16.75	16.75	NUM
admet-322	176	36	(	(	PUNCT
admet-322	176	37	±14.88	±14.88	PROPN
admet-322	176	38	)	)	PUNCT
admet-322	176	39	0.023	0.023	NUM
admet-322	176	40	9.11	9.11	NUM
admet-322	176	41	(	(	PUNCT
admet-322	176	42	±1.81	±1.81	PROPN
admet-322	176	43	)	)	PUNCT
admet-322	176	44	0.042	0.042	NUM
admet-322	176	45	crizotinib	crizotinib	VERB
admet-322	176	46	1.09	1.09	NUM
admet-322	176	47	n	n	NOUN
admet-322	176	48	/	/	SYM
admet-322	176	49	a	a	DET
admet-322	176	50	(	(	PUNCT
admet-322	176	51	outside	outside	ADJ
admet-322	176	52	concentration	concentration	NOUN
admet-322	176	53	range	range	NOUN
admet-322	176	54	)	)	PUNCT
admet-322	176	55	n	n	CCONJ
admet-322	176	56	/	/	SYM
admet-322	176	57	a	a	DET
admet-322	176	58	15.90	15.90	NUM
admet-322	176	59	(	(	PUNCT
admet-322	176	60	±8.23	±8.23	NOUN
admet-322	176	61	)	)	PUNCT
admet-322	176	62	0.069	0.069	NUM
admet-322	176	63	danusertib	danusertib	VERB
admet-322	176	64	9.34	9.34	NUM
admet-322	176	65	8.70	8.70	NUM
admet-322	176	66	(	(	PUNCT
admet-322	176	67	±5.18	±5.18	PROPN
admet-322	176	68	)	)	PUNCT
admet-322	176	69	1.074	1.074	NUM
admet-322	176	70	*	*	SYM
admet-322	176	71	7.49	7.49	NUM
admet-322	176	72	(	(	PUNCT
admet-322	176	73	±2.70	±2.70	X
admet-322	176	74	)	)	PUNCT
admet-322	176	75	1.248	1.248	NUM
admet-322	176	76	*	*	PUNCT
admet-322	176	77	dasatinib	dasatinib	NOUN
admet-322	176	78	0.13	0.13	NUM
admet-322	176	79	18.03	18.03	NUM
admet-322	176	80	(	(	PUNCT
admet-322	176	81	±4.42	±4.42	X
admet-322	176	82	)	)	PUNCT
admet-322	176	83	0.007	0.007	NUM
admet-322	176	84	13.17	13.17	NUM
admet-322	176	85	(	(	PUNCT
admet-322	176	86	±2.50	±2.50	PROPN
admet-322	176	87	)	)	PUNCT
admet-322	176	88	0.010	0.010	NUM
admet-322	176	89	enzastaurin	enzastaurin	NOUN
admet-322	176	90	2.19	2.19	NUM
admet-322	176	91	43.93	43.93	NUM
admet-322	176	92	(	(	PUNCT
admet-322	176	93	±23.77	±23.77	ADJ
admet-322	176	94	)	)	PUNCT
admet-322	176	95	0.050	0.050	NUM
admet-322	176	96	0.97	0.97	NUM
admet-322	176	97	(	(	PUNCT
admet-322	176	98	±0.34	±0.34	PROPN
admet-322	176	99	)	)	PUNCT
admet-322	176	100	2.266	2.266	NUM
admet-322	176	101	*	*	SYM
admet-322	176	102	erlotinib	erlotinib	NOUN
admet-322	176	103	3.95	3.95	NUM
admet-322	176	104	3.11	3.11	NUM
admet-322	176	105	(	(	PUNCT
admet-322	176	106	±1.16	±1.16	PROPN
admet-322	176	107	)	)	PUNCT
admet-322	176	108	1.270	1.270	NUM
admet-322	176	109	*	*	SYM
admet-322	176	110	0.11	0.11	NUM
admet-322	176	111	(	(	PUNCT
admet-322	176	112	±0.02	±0.02	PROPN
admet-322	176	113	)	)	PUNCT
admet-322	176	114	36.127	36.127	NUM
admet-322	176	115	*	*	SYM
admet-322	176	116	gefitinib	gefitinib	NOUN
admet-322	176	117	0.43	0.43	NUM
admet-322	176	118	4.48	4.48	NUM
admet-322	176	119	(	(	PUNCT
admet-322	176	120	±1.64	±1.64	NOUN
admet-322	176	121	)	)	PUNCT
admet-322	176	122	0.096	0.096	NUM
admet-322	176	123	0.12	0.12	NUM
admet-322	176	124	(	(	PUNCT
admet-322	176	125	±0.01	±0.01	PROPN
admet-322	176	126	)	)	PUNCT
admet-322	176	127	3.728	3.728	NUM
admet-322	176	128	*	*	PUNCT
admet-322	176	129	imatinib	imatinib	NOUN
admet-322	176	130	2.72	2.72	NUM
admet-322	176	131	n	n	NOUN
admet-322	176	132	/	/	SYM
admet-322	176	133	a	a	DET
admet-322	176	134	(	(	PUNCT
admet-322	176	135	partial	partial	ADJ
admet-322	176	136	inhibitor	inhibitor	NOUN
admet-322	176	137	)	)	PUNCT
admet-322	176	138	n	n	CCONJ
admet-322	176	139	/	/	SYM
admet-322	176	140	a	a	DET
admet-322	176	141	0.29	0.29	NUM
admet-322	176	142	(	(	PUNCT
admet-322	176	143	±0.15	±0.15	PROPN
admet-322	176	144	)	)	PUNCT
admet-322	176	145	9.292	9.292	NUM
admet-322	176	146	*	*	PUNCT
admet-322	176	147	lapatinib	lapatinib	VERB
admet-322	176	148	4.18	4.18	NUM
admet-322	176	149	8.33	8.33	NUM
admet-322	176	150	(	(	PUNCT
admet-322	176	151	±5.68	±5.68	PROPN
admet-322	176	152	)	)	PUNCT
admet-322	176	153	0.502	0.502	NUM
admet-322	176	154	*	*	SYM
admet-322	176	155	n	n	CCONJ
admet-322	176	156	/	/	SYM
admet-322	176	157	a	a	DET
admet-322	176	158	n	n	CCONJ
admet-322	176	159	/	/	SYM
admet-322	176	160	a	a	DET
admet-322	176	161	neratinib	neratinib	NOUN
admet-322	176	162	2.95	2.95	NUM
admet-322	176	163	6.65	6.65	NUM
admet-322	176	164	(	(	PUNCT
admet-322	176	165	±0.66	±0.66	NOUN
admet-322	176	166	)	)	PUNCT
admet-322	176	167	0.444	0.444	NUM
admet-322	176	168	*	*	SYM
admet-322	176	169	1.77	1.77	NUM
admet-322	176	170	(	(	PUNCT
admet-322	176	171	±1.44	±1.44	NOUN
admet-322	176	172	)	)	PUNCT
admet-322	176	173	1.669	1.669	NUM
admet-322	176	174	*	*	NOUN
admet-322	176	175	nilotinib	nilotinib	NOUN
admet-322	176	176	3.85	3.85	NUM
admet-322	176	177	6.18	6.18	NUM
admet-322	176	178	(	(	PUNCT
admet-322	176	179	±4.82	±4.82	PROPN
admet-322	176	180	)	)	PUNCT
admet-322	176	181	0.623	0.623	NUM
admet-322	176	182	*	*	NOUN
admet-322	177	1	0.05	0.05	NUM
admet-322	177	2	(	(	PUNCT
admet-322	177	3	±0.01	±0.01	PROPN
admet-322	177	4	)	)	PUNCT
admet-322	177	5	81.828	81.828	NUM
admet-322	177	6	*	*	PUNCT
admet-322	177	7	pazopanib	pazopanib	NOUN
admet-322	177	8	122.58	122.58	NUM
admet-322	177	9	22.92	22.92	NUM
admet-322	177	10	(	(	PUNCT
admet-322	177	11	±13.82	±13.82	PROPN
admet-322	177	12	)	)	PUNCT
admet-322	177	13	5.349	5.349	NUM
admet-322	177	14	*	*	SYM
admet-322	177	15	9.43	9.43	NUM
admet-322	177	16	(	(	PUNCT
admet-322	177	17	±2.85	±2.85	PROPN
admet-322	177	18	)	)	PUNCT
admet-322	177	19	13.000	13.000	NUM
admet-322	177	20	*	*	PUNCT
admet-322	177	21	selumetinib	selumetinib	NOUN
admet-322	177	22	2.08	2.08	NUM
admet-322	177	23	103.61	103.61	NUM
admet-322	177	24	(	(	PUNCT
admet-322	177	25	±18.42	±18.42	NOUN
admet-322	177	26	)	)	PUNCT
admet-322	177	27	0.020	0.020	NUM
admet-322	177	28	15.04	15.04	NUM
admet-322	177	29	(	(	PUNCT
admet-322	177	30	±6.21	±6.21	PROPN
admet-322	177	31	)	)	PUNCT
admet-322	177	32	0.138	0.138	NUM
admet-322	177	33	*	*	PUNCT
admet-322	177	34	sorafenib	sorafenib	NOUN
admet-322	177	35	21.51	21.51	NUM
admet-322	177	36	2.60	2.60	NUM
admet-322	177	37	(	(	PUNCT
admet-322	177	38	±0.33	±0.33	NOUN
admet-322	177	39	)	)	PUNCT
admet-322	177	40	8.261	8.261	NUM
admet-322	177	41	*	*	SYM
admet-322	177	42	0.26	0.26	NUM
admet-322	177	43	(	(	PUNCT
admet-322	177	44	±0.08	±0.08	PROPN
admet-322	177	45	)	)	PUNCT
admet-322	177	46	82.078	82.078	NUM
admet-322	177	47	*	*	PUNCT
admet-322	177	48	sunitinib	sunitinib	NOUN
admet-322	177	49	0.23	0.23	NUM
admet-322	177	50	91.53	91.53	NUM
admet-322	177	51	(	(	PUNCT
admet-322	177	52	±40.46	±40.46	ADP
admet-322	177	53	)	)	PUNCT
admet-322	177	54	0.003	0.003	NUM
admet-322	177	55	1.93	1.93	NUM
admet-322	177	56	(	(	PUNCT
admet-322	177	57	±0.37	±0.37	PROPN
admet-322	177	58	)	)	PUNCT
admet-322	177	59	0.119	0.119	NUM
admet-322	177	60	*	*	PUNCT
admet-322	177	61	tozasertib	tozasertib	NOUN
admet-322	177	62	2.67	2.67	NUM
admet-322	177	63	1.87	1.87	NUM
admet-322	177	64	(	(	PUNCT
admet-322	177	65	±0.81	±0.81	PROPN
admet-322	177	66	)	)	PUNCT
admet-322	177	67	1.427	1.427	NUM
admet-322	177	68	*	*	SYM
admet-322	177	69	13.74	13.74	NUM
admet-322	177	70	(	(	PUNCT
admet-322	177	71	±3.98	±3.98	ADV
admet-322	177	72	)	)	PUNCT
admet-322	177	73	0.194	0.194	NUM
admet-322	177	74	*	*	PUNCT
admet-322	177	75	vandetanib	vandetanib	PROPN
admet-322	177	76	1.93	1.93	NUM
admet-322	177	77	33.18	33.18	NUM
admet-322	177	78	(	(	PUNCT
admet-322	177	79	±18.90	±18.90	NOUN
admet-322	177	80	)	)	PUNCT
admet-322	177	81	0.058	0.058	NUM
admet-322	177	82	8.70	8.70	NUM
admet-322	177	83	(	(	PUNCT
admet-322	177	84	±3.20	±3.20	PROPN
admet-322	177	85	)	)	PUNCT
admet-322	177	86	0.222	0.222	NUM
admet-322	177	87	*	*	NOUN
admet-322	177	88	conclusions	conclusion	NOUN
admet-322	177	89	together	together	ADV
admet-322	177	90	,	,	PUNCT
admet-322	177	91	these	these	DET
admet-322	177	92	data	datum	NOUN
admet-322	177	93	represent	represent	VERB
admet-322	177	94	the	the	DET
admet-322	177	95	first	first	ADJ
admet-322	177	96	analysis	analysis	NOUN
admet-322	177	97	of	of	ADP
admet-322	177	98	the	the	DET
admet-322	177	99	inhibitory	inhibitory	ADJ
admet-322	177	100	potential	potential	NOUN
admet-322	177	101	of	of	ADP
admet-322	177	102	multiple	multiple	ADJ
admet-322	177	103	tki	tki	NOUN
admet-322	177	104	/	/	SYM
admet-322	177	105	akis	akis	PROPN
admet-322	177	106	against	against	ADP
admet-322	177	107	both	both	DET
admet-322	177	108	mrp4	mrp4	PROPN
admet-322	177	109	and	and	CCONJ
admet-322	177	110	bcrp	bcrp	ADV
admet-322	177	111	,	,	PUNCT
admet-322	177	112	along	along	ADP
admet-322	177	113	with	with	ADP
admet-322	177	114	estimation	estimation	NOUN
admet-322	177	115	of	of	ADP
admet-322	177	116	the	the	DET
admet-322	177	117	clinical	clinical	ADJ
admet-322	177	118	relevance	relevance	NOUN
admet-322	177	119	of	of	ADP
admet-322	177	120	tki	tki	PROPN
admet-322	177	121	/	/	SYM
admet-322	177	122	aki	aki	NOUN
admet-322	177	123	-	-	PUNCT
admet-322	177	124	facilitated	facilitate	VERB
admet-322	177	125	transport	transport	NOUN
admet-322	177	126	inhibition	inhibition	NOUN
admet-322	177	127	.	.	PUNCT
admet-322	178	1	the	the	DET
admet-322	178	2	data	data	NOUN
admet-322	178	3	herein	herein	NOUN
admet-322	178	4	may	may	AUX
admet-322	178	5	enable	enable	VERB
admet-322	178	6	greater	great	ADJ
admet-322	178	7	predictive	predictive	ADJ
admet-322	178	8	power	power	NOUN
admet-322	178	9	of	of	ADP
admet-322	178	10	the	the	DET
admet-322	178	11	pharmacokinetic	pharmacokinetic	ADJ
admet-322	178	12	/	/	SYM
admet-322	178	13	pharmacodynamic	pharmacodynamic	ADJ
admet-322	178	14	and	and	CCONJ
admet-322	178	15	potential	potential	ADJ
admet-322	178	16	hepatotoxic	hepatotoxic	ADJ
admet-322	178	17	effects	effect	NOUN
admet-322	178	18	of	of	ADP
admet-322	178	19	tki	tki	NOUN
admet-322	178	20	/	/	SYM
admet-322	178	21	aki	aki	NOUN
admet-322	178	22	use	use	NOUN
admet-322	178	23	in	in	ADP
admet-322	178	24	co	co	ADJ
admet-322	178	25	-	-	NOUN
admet-322	178	26	treatment	treatment	NOUN
admet-322	178	27	regimens	regimen	NOUN
admet-322	178	28	.	.	PUNCT
admet-322	179	1	acknowledgements	acknowledgement	NOUN
admet-322	179	2	this	this	DET
admet-322	179	3	work	work	NOUN
admet-322	179	4	was	be	AUX
admet-322	179	5	supported	support	VERB
admet-322	179	6	by	by	ADP
admet-322	179	7	the	the	DET
admet-322	179	8	national	national	PROPN
admet-322	179	9	institute	institute	PROPN
admet-322	179	10	of	of	ADP
admet-322	179	11	general	general	PROPN
admet-322	179	12	medical	medical	PROPN
admet-322	179	13	sciences	science	NOUN
admet-322	179	14	of	of	ADP
admet-322	179	15	the	the	DET
admet-322	179	16	national	national	PROPN
admet-322	179	17	institutes	institutes	PROPN
admet-322	179	18	of	of	ADP
admet-322	179	19	health	health	PROPN
admet-322	179	20	(	(	PUNCT
admet-322	179	21	nih	nih	PROPN
admet-322	179	22	)	)	PUNCT
admet-322	179	23	under	under	ADP
admet-322	179	24	award	award	NOUN
admet-322	179	25	number	number	NOUN
admet-322	179	26	r01	r01	PROPN
admet-322	179	27	gm041935	gm041935	PROPN
admet-322	179	28	.	.	PUNCT
admet-322	180	1	dr	dr	PROPN
admet-322	180	2	.	.	PROPN
admet-322	180	3	hardwick	hardwick	PROPN
admet-322	180	4	was	be	AUX
admet-322	180	5	supported	support	VERB
admet-322	180	6	by	by	ADP
admet-322	180	7	the	the	DET
admet-322	180	8	national	national	PROPN
admet-322	180	9	institute	institute	PROPN
admet-322	180	10	of	of	ADP
admet-322	180	11	environmental	environmental	PROPN
admet-322	180	12	health	health	PROPN
admet-322	180	13	sciences	science	NOUN
admet-322	180	14	under	under	ADP
admet-322	180	15	award	award	NOUN
admet-322	180	16	number	number	NOUN
admet-322	180	17	t32	t32	NOUN
admet-322	180	18	es007126	es007126	PROPN
admet-322	180	19	.	.	PUNCT
admet-322	181	1	dr	dr	PROPN
admet-322	181	2	.	.	PROPN
admet-322	181	3	ferslew	ferslew	PROPN
admet-322	181	4	was	be	AUX
admet-322	181	5	supported	support	VERB
admet-322	181	6	by	by	ADP
admet-322	181	7	an	an	DET
admet-322	181	8	amgen	amgen	PROPN
admet-322	181	9	predoctoral	predoctoral	ADJ
admet-322	181	10	fellowship	fellowship	NOUN
admet-322	181	11	in	in	ADP
admet-322	181	12	pharmacokinetics	pharmacokinetic	NOUN
admet-322	181	13	and	and	CCONJ
admet-322	181	14	drug	drug	NOUN
admet-322	181	15	disposition	disposition	NOUN
admet-322	181	16	.	.	PUNCT
admet-322	182	1	mdckii	mdckii	ADJ
admet-322	182	2	and	and	CCONJ
admet-322	182	3	mdckii	mdckii	ADJ
admet-322	182	4	-	-	ADJ
admet-322	182	5	bcrp	bcrp	PROPN
admet-322	182	6	cell	cell	NOUN
admet-322	182	7	lines	line	NOUN
admet-322	182	8	were	be	AUX
admet-322	182	9	a	a	DET
admet-322	182	10	generous	generous	ADJ
admet-322	182	11	gift	gift	NOUN
admet-322	182	12	from	from	ADP
admet-322	182	13	dr	dr	PROPN
admet-322	182	14	.	.	PROPN
admet-322	182	15	markus	markus	PROPN
admet-322	182	16	grube	grube	PROPN
admet-322	182	17	,	,	PUNCT
admet-322	182	18	ernst	ernst	PROPN
admet-322	182	19	moritz	moritz	PROPN
admet-322	182	20	arndt	arndt	PROPN
admet-322	182	21	university	university	PROPN
admet-322	182	22	of	of	ADP
admet-322	182	23	greifswald	greifswald	PROPN
admet-322	182	24	,	,	PUNCT
admet-322	182	25	greifswald	greifswald	PROPN
admet-322	182	26	,	,	PUNCT
admet-322	182	27	germany	germany	PROPN
admet-322	182	28	.	.	PUNCT
admet-322	183	1	hek	hek	PROPN
admet-322	183	2	-	-	PUNCT
admet-322	183	3	mock	mock	PROPN
admet-322	183	4	and	and	CCONJ
admet-322	183	5	hek	hek	PROPN
admet-322	183	6	-	-	PUNCT
admet-322	183	7	mrp4	mrp4	PROPN
admet-322	183	8	cell	cell	NOUN
admet-322	183	9	lines	line	NOUN
admet-322	183	10	were	be	AUX
admet-322	183	11	created	create	VERB
admet-322	183	12	by	by	ADP
admet-322	183	13	dr	dr	PROPN
admet-322	183	14	.	.	PROPN
admet-322	183	15	kathleen	kathleen	PROPN
admet-322	183	16	kӧck	kӧck	PROPN
admet-322	183	17	,	,	PUNCT
admet-322	183	18	unc	unc	PROPN
admet-322	183	19	-	-	PUNCT
admet-322	183	20	ch	ch	NOUN
admet-322	183	21	,	,	PUNCT
admet-322	183	22	using	use	VERB
admet-322	183	23	plasmids	plasmid	NOUN
admet-322	183	24	generously	generously	ADV
admet-322	183	25	donated	donate	VERB
admet-322	183	26	by	by	ADP
admet-322	183	27	dr	dr	PROPN
admet-322	183	28	.	.	PROPN
admet-322	183	29	dietrich	dietrich	PROPN
admet-322	183	30	keppler	keppler	PROPN
admet-322	183	31	,	,	PUNCT
admet-322	183	32	german	german	ADJ
admet-322	183	33	cancer	cancer	NOUN
admet-322	183	34	research	research	NOUN
admet-322	183	35	center	center	NOUN
admet-322	183	36	,	,	PUNCT
admet-322	183	37	heidelberg	heidelberg	PROPN
admet-322	183	38	,	,	PUNCT
admet-322	183	39	germany	germany	PROPN
admet-322	183	40	.	.	PUNCT
admet-322	184	1	references	reference	NOUN
admet-322	184	2	[	[	X
admet-322	184	3	1	1	NUM
admet-322	184	4	]	]	X
admet-322	184	5	n.p	n.p	PROPN
admet-322	184	6	.	.	PROPN
admet-322	184	7	van	van	PROPN
admet-322	184	8	erp	erp	PROPN
admet-322	184	9	,	,	PUNCT
admet-322	184	10	h.	h.	PROPN
admet-322	184	11	gelderblom	gelderblom	PROPN
admet-322	184	12	,	,	PUNCT
admet-322	184	13	h.j	h.j	PROPN
admet-322	184	14	.	.	PROPN
admet-322	184	15	guchelaar	guchelaar	NOUN
admet-322	184	16	,	,	PUNCT
admet-322	184	17	cancer	cancer	NOUN
admet-322	184	18	treatment	treatment	NOUN
admet-322	184	19	reviews	review	NOUN
admet-322	184	20	35	35	NUM
admet-322	184	21	(	(	PUNCT
admet-322	184	22	2009	2009	NUM
admet-322	184	23	)	)	PUNCT
admet-322	184	24	692	692	NUM
admet-322	184	25	-	-	SYM
admet-322	184	26	706	706	NUM
admet-322	184	27	.	.	PUNCT
admet-322	185	1	[	[	X
admet-322	185	2	2	2	X
admet-322	185	3	]	]	PUNCT
admet-322	185	4	j.	j.	PROPN
admet-322	185	5	zhang	zhang	PROPN
admet-322	185	6	,	,	PUNCT
admet-322	185	7	p.l	p.l	PROPN
admet-322	185	8	.	.	PROPN
admet-322	185	9	yang	yang	PROPN
admet-322	185	10	,	,	PUNCT
admet-322	185	11	n.s	n.s	PROPN
admet-322	185	12	.	.	PROPN
admet-322	185	13	gray	gray	PROPN
admet-322	185	14	,	,	PUNCT
admet-322	185	15	nature	nature	NOUN
admet-322	185	16	reviews	review	NOUN
admet-322	185	17	.	.	PUNCT
admet-322	186	1	cancer	cancer	NOUN
admet-322	186	2	9	9	NUM
admet-322	186	3	(	(	PUNCT
admet-322	186	4	2009	2009	NUM
admet-322	186	5	)	)	PUNCT
admet-322	186	6	28	28	NUM
admet-322	186	7	-	-	SYM
admet-322	186	8	39	39	NUM
admet-322	186	9	.	.	PUNCT
admet-322	187	1	[	[	X
admet-322	187	2	3	3	NUM
admet-322	187	3	]	]	PUNCT
admet-322	187	4	a.	a.	PROPN
admet-322	187	5	arora	arora	PROPN
admet-322	187	6	,	,	PUNCT
admet-322	187	7	e.m	e.m	PROPN
admet-322	187	8	.	.	PROPN
admet-322	187	9	scholar	scholar	NOUN
admet-322	187	10	,	,	PUNCT
admet-322	187	11	the	the	DET
admet-322	187	12	journal	journal	NOUN
admet-322	187	13	of	of	ADP
admet-322	187	14	pharmacology	pharmacology	NOUN
admet-322	187	15	and	and	CCONJ
admet-322	187	16	experimental	experimental	ADJ
admet-322	187	17	therapeutics	therapeutic	NOUN
admet-322	187	18	315	315	NUM
admet-322	187	19	(	(	PUNCT
admet-322	187	20	2005	2005	NUM
admet-322	187	21	)	)	PUNCT
admet-322	187	22	971979	971979	NUM
admet-322	187	23	.	.	PUNCT
admet-322	188	1	r.n	r.n	PROPN
admet-322	188	2	.	.	PROPN
admet-322	188	3	hardwick	hardwick	PROPN
admet-322	188	4	et	et	PROPN
admet-322	188	5	al	al	PROPN
admet-322	188	6	.	.	PROPN
admet-322	188	7	admet	admet	PROPN
admet-322	188	8	&	&	CCONJ
admet-322	188	9	dmpk	dmpk	PROPN
admet-322	188	10	4(4	4(4	NUM
admet-322	188	11	)	)	PUNCT
admet-322	188	12	(	(	PUNCT
admet-322	188	13	2016	2016	NUM
admet-322	188	14	)	)	PUNCT
admet-322	188	15	302	302	NUM
admet-322	188	16	-	-	SYM
admet-322	188	17	313	313	NUM
admet-322	188	18	312	312	NUM
admet-322	188	19	[	[	PUNCT
admet-322	188	20	4	4	NUM
admet-322	188	21	]	]	PUNCT
admet-322	188	22	s.	s.	PROPN
admet-322	188	23	niijima	niijima	PROPN
admet-322	188	24	,	,	PUNCT
admet-322	188	25	a.	a.	PROPN
admet-322	188	26	shiraishi	shiraishi	PROPN
admet-322	188	27	,	,	PUNCT
admet-322	188	28	y.	y.	PROPN
admet-322	188	29	okuno	okuno	PROPN
admet-322	188	30	,	,	PUNCT
admet-322	188	31	journal	journal	NOUN
admet-322	188	32	of	of	ADP
admet-322	188	33	chemical	chemical	ADJ
admet-322	188	34	information	information	NOUN
admet-322	188	35	and	and	CCONJ
admet-322	188	36	modeling	model	VERB
admet-322	188	37	52	52	NUM
admet-322	188	38	(	(	PUNCT
admet-322	188	39	2012	2012	NUM
admet-322	188	40	)	)	PUNCT
admet-322	188	41	901	901	NUM
admet-322	188	42	-	-	SYM
admet-322	188	43	912	912	NUM
admet-322	188	44	.	.	PUNCT
admet-322	189	1	[	[	X
admet-322	189	2	5	5	X
admet-322	189	3	]	]	PUNCT
admet-322	189	4	j.	j.	PROPN
admet-322	189	5	andrae	andrae	PROPN
admet-322	189	6	,	,	PUNCT
admet-322	189	7	r.	r.	PROPN
admet-322	189	8	gallini	gallini	PROPN
admet-322	189	9	,	,	PUNCT
admet-322	189	10	c.	c.	PROPN
admet-322	189	11	betsholtz	betsholtz	PROPN
admet-322	189	12	,	,	PUNCT
admet-322	189	13	genes	gene	NOUN
admet-322	189	14	&	&	CCONJ
admet-322	189	15	development	development	PROPN
admet-322	189	16	22	22	NUM
admet-322	189	17	(	(	PUNCT
admet-322	189	18	2008	2008	NUM
admet-322	189	19	)	)	PUNCT
admet-322	189	20	1276	1276	NUM
admet-322	189	21	-	-	SYM
admet-322	189	22	1312	1312	NUM
admet-322	189	23	.	.	PUNCT
admet-322	190	1	[	[	X
admet-322	190	2	6	6	NUM
admet-322	190	3	]	]	X
admet-322	190	4	r.a	r.a	PROPN
admet-322	190	5	.	.	PROPN
admet-322	190	6	bradshaw	bradshaw	PROPN
admet-322	190	7	,	,	PUNCT
admet-322	190	8	r.j	r.j	PROPN
admet-322	190	9	.	.	PROPN
admet-322	190	10	chalkley	chalkley	PROPN
admet-322	190	11	,	,	PUNCT
admet-322	190	12	j.	j.	PROPN
admet-322	190	13	biarc	biarc	PROPN
admet-322	190	14	,	,	PUNCT
admet-322	190	15	a.l	a.l	PROPN
admet-322	190	16	.	.	PROPN
admet-322	190	17	burlingame	burlingame	PROPN
admet-322	190	18	,	,	PUNCT
admet-322	190	19	advances	advance	VERB
admet-322	190	20	in	in	ADP
admet-322	190	21	biological	biological	ADJ
admet-322	190	22	regulation	regulation	NOUN
admet-322	190	23	53	53	NUM
admet-322	190	24	(	(	PUNCT
admet-322	190	25	2013	2013	NUM
admet-322	190	26	)	)	PUNCT
admet-322	190	27	8796	8796	NUM
admet-322	190	28	.	.	PUNCT
admet-322	191	1	[	[	X
admet-322	191	2	7	7	X
admet-322	191	3	]	]	X
admet-322	191	4	m.	m.	NOUN
admet-322	191	5	kollareddy	kollareddy	PROPN
admet-322	191	6	,	,	PUNCT
admet-322	191	7	p.	p.	NOUN
admet-322	191	8	dzubak	dzubak	NOUN
admet-322	191	9	,	,	PUNCT
admet-322	191	10	d.	d.	PROPN
admet-322	191	11	zheleva	zheleva	PROPN
admet-322	191	12	,	,	PUNCT
admet-322	191	13	m.	m.	NOUN
admet-322	191	14	hajduch	hajduch	PROPN
admet-322	191	15	,	,	PUNCT
admet-322	191	16	biomedical	biomedical	ADJ
admet-322	191	17	papers	paper	NOUN
admet-322	191	18	of	of	ADP
admet-322	191	19	the	the	DET
admet-322	191	20	medical	medical	ADJ
admet-322	191	21	faculty	faculty	NOUN
admet-322	191	22	of	of	ADP
admet-322	191	23	the	the	DET
admet-322	191	24	university	university	NOUN
admet-322	191	25	palacky	palacky	NOUN
admet-322	191	26	,	,	PUNCT
admet-322	191	27	olomouc	olomouc	PROPN
admet-322	191	28	,	,	PUNCT
admet-322	191	29	czechoslovakia	czechoslovakia	PROPN
admet-322	191	30	152	152	NUM
admet-322	191	31	(	(	PUNCT
admet-322	191	32	2008	2008	NUM
admet-322	191	33	)	)	PUNCT
admet-322	191	34	27	27	NUM
admet-322	191	35	-	-	SYM
admet-322	191	36	33	33	NUM
admet-322	191	37	.	.	PUNCT
admet-322	192	1	[	[	X
admet-322	192	2	8	8	NUM
admet-322	192	3	]	]	X
admet-322	192	4	m.r	m.r	PROPN
admet-322	192	5	.	.	PROPN
admet-322	192	6	green	green	PROPN
admet-322	192	7	,	,	PUNCT
admet-322	192	8	j.e	j.e	PROPN
admet-322	192	9	.	.	PROPN
admet-322	192	10	woolery	woolery	PROPN
admet-322	192	11	,	,	PUNCT
admet-322	192	12	d.	d.	PROPN
admet-322	192	13	mahadevan	mahadevan	PROPN
admet-322	192	14	,	,	PUNCT
admet-322	192	15	expert	expert	ADJ
admet-322	192	16	opinion	opinion	NOUN
admet-322	192	17	on	on	ADP
admet-322	192	18	drug	drug	NOUN
admet-322	192	19	discovery	discovery	NOUN
admet-322	192	20	6	6	NUM
admet-322	192	21	(	(	PUNCT
admet-322	192	22	2011	2011	NUM
admet-322	192	23	)	)	PUNCT
admet-322	192	24	291	291	NUM
admet-322	192	25	-	-	SYM
admet-322	192	26	307	307	NUM
admet-322	192	27	.	.	PUNCT
admet-322	193	1	[	[	X
admet-322	193	2	9	9	NUM
admet-322	193	3	]	]	X
admet-322	193	4	j.t	j.t	PROPN
admet-322	193	5	.	.	PROPN
admet-322	193	6	hartmann	hartmann	PROPN
admet-322	193	7	,	,	PUNCT
admet-322	193	8	m.	m.	PROPN
admet-322	193	9	haap	haap	PROPN
admet-322	193	10	,	,	PUNCT
admet-322	193	11	h.g	h.g	PROPN
admet-322	193	12	.	.	PROPN
admet-322	193	13	kopp	kopp	PROPN
admet-322	193	14	,	,	PUNCT
admet-322	193	15	h.p	h.p	PROPN
admet-322	193	16	.	.	PROPN
admet-322	193	17	lipp	lipp	PROPN
admet-322	193	18	,	,	PUNCT
admet-322	193	19	current	current	ADJ
admet-322	193	20	drug	drug	NOUN
admet-322	193	21	metabolism	metabolism	NOUN
admet-322	193	22	10	10	NUM
admet-322	193	23	(	(	PUNCT
admet-322	193	24	2009	2009	NUM
admet-322	193	25	)	)	PUNCT
admet-322	193	26	470	470	NUM
admet-322	193	27	-	-	SYM
admet-322	193	28	481	481	NUM
admet-322	193	29	.	.	PUNCT
admet-322	194	1	[	[	X
admet-322	194	2	10	10	NUM
admet-322	194	3	]	]	X
admet-322	194	4	a.	a.	NOUN
admet-322	194	5	azzariti	azzariti	PROPN
admet-322	194	6	,	,	PUNCT
admet-322	194	7	l.	l.	PROPN
admet-322	194	8	porcelli	porcelli	PROPN
admet-322	194	9	,	,	PUNCT
admet-322	194	10	g.m	g.m	PROPN
admet-322	194	11	.	.	PUNCT
admet-322	194	12	simone	simone	PROPN
admet-322	194	13	,	,	PUNCT
admet-322	194	14	a.e	a.e	PROPN
admet-322	194	15	.	.	PROPN
admet-322	194	16	quatrale	quatrale	PROPN
admet-322	194	17	,	,	PUNCT
admet-322	194	18	n.a	n.a	PROPN
admet-322	194	19	.	.	PROPN
admet-322	194	20	colabufo	colabufo	PROPN
admet-322	194	21	,	,	PUNCT
admet-322	194	22	f.	f.	PROPN
admet-322	194	23	berardi	berardi	PROPN
admet-322	194	24	,	,	PUNCT
admet-322	194	25	r.	r.	PROPN
admet-322	194	26	perrone	perrone	PROPN
admet-322	194	27	,	,	PUNCT
admet-322	194	28	m.	m.	NOUN
admet-322	194	29	zucchetti	zucchetti	PROPN
admet-322	194	30	,	,	PUNCT
admet-322	194	31	m.	m.	NOUN
admet-322	194	32	d'incalci	d'incalci	PROPN
admet-322	194	33	,	,	PUNCT
admet-322	194	34	j.m	j.m	PROPN
admet-322	194	35	.	.	PROPN
admet-322	194	36	xu	xu	PROPN
admet-322	194	37	,	,	PUNCT
admet-322	194	38	a.	a.	NOUN
admet-322	194	39	paradiso	paradiso	PROPN
admet-322	194	40	,	,	PUNCT
admet-322	194	41	cancer	cancer	NOUN
admet-322	194	42	chemotherapy	chemotherapy	NOUN
admet-322	194	43	and	and	CCONJ
admet-322	194	44	pharmacology	pharmacology	NOUN
admet-322	194	45	65	65	NUM
admet-322	194	46	(	(	PUNCT
admet-322	194	47	2010	2010	NUM
admet-322	194	48	)	)	PUNCT
admet-322	194	49	335	335	NUM
admet-322	194	50	-	-	SYM
admet-322	194	51	346	346	NUM
admet-322	194	52	.	.	PUNCT
admet-322	195	1	[	[	X
admet-322	195	2	11	11	NUM
admet-322	195	3	]	]	PUNCT
admet-322	195	4	a.	a.	NOUN
admet-322	195	5	brozik	brozik	NOUN
admet-322	195	6	,	,	PUNCT
admet-322	195	7	c.	c.	PROPN
admet-322	195	8	hegedus	hegedus	PROPN
admet-322	195	9	,	,	PUNCT
admet-322	195	10	z.	z.	PROPN
admet-322	195	11	erdei	erdei	PROPN
admet-322	195	12	,	,	PUNCT
admet-322	195	13	t.	t.	NOUN
admet-322	195	14	hegedus	hegedus	NOUN
admet-322	195	15	,	,	PUNCT
admet-322	195	16	c.	c.	PROPN
admet-322	195	17	ozvegy	ozvegy	PROPN
admet-322	195	18	-	-	PUNCT
admet-322	195	19	laczka	laczka	PROPN
admet-322	195	20	,	,	PUNCT
admet-322	195	21	g.	g.	PROPN
admet-322	195	22	szakacs	szakacs	PROPN
admet-322	195	23	,	,	PUNCT
admet-322	195	24	b.	b.	PROPN
admet-322	195	25	sarkadi	sarkadi	PROPN
admet-322	195	26	,	,	PUNCT
admet-322	195	27	expert	expert	ADJ
admet-322	195	28	opinion	opinion	NOUN
admet-322	195	29	on	on	ADP
admet-322	195	30	drug	drug	NOUN
admet-322	195	31	metabolism	metabolism	NOUN
admet-322	195	32	&	&	CCONJ
admet-322	195	33	toxicology	toxicology	NOUN
admet-322	195	34	7	7	NUM
admet-322	195	35	(	(	PUNCT
admet-322	195	36	2011	2011	NUM
admet-322	195	37	)	)	PUNCT
admet-322	195	38	623	623	NUM
admet-322	195	39	-	-	SYM
admet-322	195	40	642	642	NUM
admet-322	195	41	.	.	PUNCT
admet-322	196	1	[	[	X
admet-322	196	2	12	12	NUM
admet-322	196	3	]	]	X
admet-322	196	4	c.	c.	PROPN
admet-322	196	5	ozvegy	ozvegy	PROPN
admet-322	196	6	-	-	PUNCT
admet-322	196	7	laczka	laczka	PROPN
admet-322	196	8	,	,	PUNCT
admet-322	196	9	j.	j.	PROPN
admet-322	196	10	cserepes	cserepes	PROPN
admet-322	196	11	,	,	PUNCT
admet-322	196	12	n.b	n.b	PROPN
admet-322	196	13	.	.	PROPN
admet-322	196	14	elkind	elkind	PROPN
admet-322	196	15	,	,	PUNCT
admet-322	196	16	b.	b.	PROPN
admet-322	196	17	sarkadi	sarkadi	PROPN
admet-322	196	18	,	,	PUNCT
admet-322	196	19	drug	drug	NOUN
admet-322	196	20	resistance	resistance	NOUN
admet-322	196	21	updates	update	VERB
admet-322	196	22	:	:	PUNCT
admet-322	196	23	reviews	review	NOUN
admet-322	196	24	and	and	CCONJ
admet-322	196	25	commentaries	commentary	NOUN
admet-322	196	26	in	in	ADP
admet-322	196	27	antimicrobial	antimicrobial	ADJ
admet-322	196	28	and	and	CCONJ
admet-322	196	29	anticancer	anticancer	NOUN
admet-322	196	30	chemotherapy	chemotherapy	NOUN
admet-322	196	31	8	8	NUM
admet-322	196	32	(	(	PUNCT
admet-322	196	33	2005	2005	NUM
admet-322	196	34	)	)	PUNCT
admet-322	196	35	15	15	NUM
admet-322	196	36	-	-	SYM
admet-322	196	37	26	26	NUM
admet-322	196	38	.	.	PUNCT
admet-322	197	1	[	[	X
admet-322	197	2	13	13	NUM
admet-322	197	3	]	]	PUNCT
admet-322	197	4	m.	m.	NOUN
admet-322	197	5	galetti	galetti	PROPN
admet-322	197	6	,	,	PUNCT
admet-322	197	7	p.g	p.g	PROPN
admet-322	197	8	.	.	PROPN
admet-322	197	9	petronini	petronini	PROPN
admet-322	197	10	,	,	PUNCT
admet-322	197	11	c.	c.	PROPN
admet-322	197	12	fumarola	fumarola	PROPN
admet-322	197	13	,	,	PUNCT
admet-322	197	14	d.	d.	PROPN
admet-322	197	15	cretella	cretella	PROPN
admet-322	197	16	,	,	PUNCT
admet-322	197	17	s.	s.	PROPN
admet-322	197	18	la	la	PROPN
admet-322	197	19	monica	monica	PROPN
admet-322	197	20	,	,	PUNCT
admet-322	197	21	m.	m.	NOUN
admet-322	197	22	bonelli	bonelli	PROPN
admet-322	197	23	,	,	PUNCT
admet-322	197	24	a.	a.	NOUN
admet-322	197	25	cavazzoni	cavazzoni	PROPN
admet-322	197	26	,	,	PUNCT
admet-322	197	27	f.	f.	PROPN
admet-322	197	28	saccani	saccani	PROPN
admet-322	197	29	,	,	PUNCT
admet-322	197	30	c.	c.	PROPN
admet-322	197	31	caffarra	caffarra	PROPN
admet-322	197	32	,	,	PUNCT
admet-322	197	33	r.	r.	PROPN
admet-322	197	34	andreoli	andreoli	PROPN
admet-322	197	35	,	,	PUNCT
admet-322	197	36	a.	a.	PROPN
admet-322	197	37	mutti	mutti	PROPN
admet-322	197	38	,	,	PUNCT
admet-322	197	39	m.	m.	NOUN
admet-322	197	40	tiseo	tiseo	PROPN
admet-322	197	41	,	,	PUNCT
admet-322	197	42	a.	a.	NOUN
admet-322	197	43	ardizzoni	ardizzoni	NOUN
admet-322	197	44	,	,	PUNCT
admet-322	197	45	r.r	r.r	PROPN
admet-322	197	46	.	.	PROPN
admet-322	197	47	alfieri	alfieri	PROPN
admet-322	197	48	,	,	PUNCT
admet-322	197	49	plos	plos	PROPN
admet-322	197	50	one	one	NUM
admet-322	197	51	10	10	NUM
admet-322	197	52	(	(	PUNCT
admet-322	197	53	2015	2015	NUM
admet-322	197	54	)	)	PUNCT
admet-322	197	55	e0141795	e0141795	NUM
admet-322	197	56	.	.	PUNCT
admet-322	198	1	[	[	X
admet-322	198	2	14	14	NUM
admet-322	198	3	]	]	X
admet-322	198	4	e.l	e.l	PROPN
admet-322	198	5	.	.	PROPN
admet-322	198	6	reyner	reyner	PROPN
admet-322	198	7	,	,	PUNCT
admet-322	198	8	s.	s.	PROPN
admet-322	198	9	sevidal	sevidal	PROPN
admet-322	198	10	,	,	PUNCT
admet-322	198	11	m.a	m.a	PROPN
admet-322	198	12	.	.	PROPN
admet-322	198	13	west	west	PROPN
admet-322	198	14	,	,	PUNCT
admet-322	198	15	a.	a.	NOUN
admet-322	198	16	clouser	clouser	NOUN
admet-322	198	17	-	-	PUNCT
admet-322	198	18	roche	roche	NOUN
admet-322	198	19	,	,	PUNCT
admet-322	198	20	s.	s.	PROPN
admet-322	198	21	freiwald	freiwald	PROPN
admet-322	198	22	,	,	PUNCT
admet-322	198	23	k.	k.	PROPN
admet-322	198	24	fenner	fenner	PROPN
admet-322	198	25	,	,	PUNCT
admet-322	198	26	m.	m.	PROPN
admet-322	198	27	ullah	ullah	PROPN
admet-322	198	28	,	,	PUNCT
admet-322	198	29	c.a	c.a	PROPN
admet-322	198	30	.	.	PROPN
admet-322	198	31	lee	lee	PROPN
admet-322	198	32	,	,	PUNCT
admet-322	198	33	b.j	b.j	PROPN
admet-322	198	34	.	.	PROPN
admet-322	198	35	smith	smith	PROPN
admet-322	198	36	,	,	PUNCT
admet-322	198	37	drug	drug	NOUN
admet-322	198	38	metabolism	metabolism	NOUN
admet-322	198	39	and	and	CCONJ
admet-322	198	40	disposition	disposition	NOUN
admet-322	198	41	:	:	PUNCT
admet-322	198	42	the	the	DET
admet-322	198	43	biological	biological	ADJ
admet-322	198	44	fate	fate	NOUN
admet-322	198	45	of	of	ADP
admet-322	198	46	chemicals	chemical	NOUN
admet-322	198	47	41	41	NUM
admet-322	198	48	(	(	PUNCT
admet-322	198	49	2013	2013	NUM
admet-322	198	50	)	)	PUNCT
admet-322	198	51	1575	1575	NUM
admet-322	198	52	-	-	SYM
admet-322	198	53	1583	1583	NUM
admet-322	198	54	.	.	PUNCT
admet-322	199	1	[	[	X
admet-322	199	2	15	15	NUM
admet-322	199	3	]	]	X
admet-322	199	4	x.k	x.k	PROPN
admet-322	199	5	.	.	PROPN
admet-322	199	6	wang	wang	PROPN
admet-322	199	7	,	,	PUNCT
admet-322	199	8	l.w	l.w	PROPN
admet-322	199	9	.	.	PROPN
admet-322	199	10	fu	fu	PROPN
admet-322	199	11	,	,	PUNCT
admet-322	199	12	current	current	ADJ
admet-322	199	13	drug	drug	NOUN
admet-322	199	14	metabolism	metabolism	NOUN
admet-322	199	15	11	11	NUM
admet-322	199	16	(	(	PUNCT
admet-322	199	17	2010	2010	NUM
admet-322	199	18	)	)	PUNCT
admet-322	199	19	618	618	NUM
admet-322	199	20	-	-	SYM
admet-322	199	21	628	628	NUM
admet-322	199	22	.	.	PUNCT
admet-322	200	1	[	[	X
admet-322	200	2	16	16	NUM
admet-322	200	3	]	]	X
admet-322	200	4	s.	s.	PROPN
admet-322	200	5	shukla	shukla	PROPN
admet-322	200	6	,	,	PUNCT
admet-322	200	7	r.w	r.w	PROPN
admet-322	200	8	.	.	PROPN
admet-322	200	9	robey	robey	PROPN
admet-322	200	10	,	,	PUNCT
admet-322	200	11	s.e	s.e	PROPN
admet-322	200	12	.	.	PROPN
admet-322	200	13	bates	bates	PROPN
admet-322	200	14	,	,	PUNCT
admet-322	200	15	s.v	s.v	PROPN
admet-322	200	16	.	.	PROPN
admet-322	200	17	ambudkar	ambudkar	PROPN
admet-322	200	18	,	,	PUNCT
admet-322	200	19	drug	drug	NOUN
admet-322	200	20	metabolism	metabolism	NOUN
admet-322	200	21	and	and	CCONJ
admet-322	200	22	disposition	disposition	NOUN
admet-322	200	23	:	:	PUNCT
admet-322	200	24	the	the	DET
admet-322	200	25	biological	biological	ADJ
admet-322	200	26	fate	fate	NOUN
admet-322	200	27	of	of	ADP
admet-322	200	28	chemicals	chemical	NOUN
admet-322	200	29	37	37	NUM
admet-322	200	30	(	(	PUNCT
admet-322	200	31	2009	2009	NUM
admet-322	200	32	)	)	PUNCT
admet-322	200	33	359	359	NUM
admet-322	200	34	-	-	SYM
admet-322	200	35	365	365	NUM
admet-322	200	36	.	.	PUNCT
admet-322	201	1	[	[	X
admet-322	201	2	17	17	NUM
admet-322	201	3	]	]	X
admet-322	201	4	y.	y.	PROPN
admet-322	201	5	wei	wei	PROPN
admet-322	201	6	,	,	PUNCT
admet-322	201	7	y.	y.	PROPN
admet-322	201	8	ma	ma	PROPN
admet-322	201	9	,	,	PUNCT
admet-322	201	10	q.	q.	PROPN
admet-322	201	11	zhao	zhao	PROPN
admet-322	201	12	,	,	PUNCT
admet-322	201	13	z.	z.	PROPN
admet-322	201	14	ren	ren	PROPN
admet-322	201	15	,	,	PUNCT
admet-322	201	16	y.	y.	PROPN
admet-322	201	17	li	li	PROPN
admet-322	201	18	,	,	PUNCT
admet-322	201	19	t.	t.	PROPN
admet-322	201	20	hou	hou	PROPN
admet-322	201	21	,	,	PUNCT
admet-322	201	22	h.	h.	PROPN
admet-322	201	23	peng	peng	PROPN
admet-322	201	24	,	,	PUNCT
admet-322	201	25	molecular	molecular	ADJ
admet-322	201	26	cancer	cancer	NOUN
admet-322	201	27	therapeutics	therapeutic	NOUN
admet-322	201	28	11	11	NUM
admet-322	201	29	(	(	PUNCT
admet-322	201	30	2012	2012	NUM
admet-322	201	31	)	)	PUNCT
admet-322	201	32	16931702	16931702	NUM
admet-322	201	33	.	.	PUNCT
admet-322	202	1	[	[	X
admet-322	202	2	18	18	NUM
admet-322	202	3	]	]	X
admet-322	202	4	c.	c.	NOUN
admet-322	202	5	hegedus	hegedus	PROPN
admet-322	202	6	,	,	PUNCT
admet-322	202	7	k.	k.	PROPN
admet-322	202	8	truta	truta	NOUN
admet-322	202	9	-	-	PUNCT
admet-322	202	10	feles	fele	NOUN
admet-322	202	11	,	,	PUNCT
admet-322	202	12	g.	g.	PROPN
admet-322	202	13	antalffy	antalffy	PROPN
admet-322	202	14	,	,	PUNCT
admet-322	202	15	g.	g.	PROPN
admet-322	202	16	varady	varady	PROPN
admet-322	202	17	,	,	PUNCT
admet-322	202	18	k.	k.	PROPN
admet-322	202	19	nemet	nemet	PROPN
admet-322	202	20	,	,	PUNCT
admet-322	202	21	c.	c.	PROPN
admet-322	202	22	ozvegy	ozvegy	PROPN
admet-322	202	23	-	-	PUNCT
admet-322	202	24	laczka	laczka	PROPN
admet-322	202	25	,	,	PUNCT
admet-322	202	26	g.	g.	PROPN
admet-322	202	27	keri	keri	PROPN
admet-322	202	28	,	,	PUNCT
admet-322	202	29	l.	l.	PROPN
admet-322	202	30	orfi	orfi	PROPN
admet-322	202	31	,	,	PUNCT
admet-322	202	32	g.	g.	PROPN
admet-322	202	33	szakacs	szakacs	PROPN
admet-322	202	34	,	,	PUNCT
admet-322	202	35	j.	j.	PROPN
admet-322	202	36	settleman	settleman	PROPN
admet-322	202	37	,	,	PUNCT
admet-322	202	38	a.	a.	NOUN
admet-322	202	39	varadi	varadi	NOUN
admet-322	202	40	,	,	PUNCT
admet-322	202	41	b.	b.	PROPN
admet-322	202	42	sarkadi	sarkadi	PROPN
admet-322	202	43	,	,	PUNCT
admet-322	202	44	biochemical	biochemical	ADJ
admet-322	202	45	pharmacology	pharmacology	NOUN
admet-322	202	46	84	84	NUM
admet-322	202	47	(	(	PUNCT
admet-322	202	48	2012	2012	NUM
admet-322	202	49	)	)	PUNCT
admet-322	202	50	260	260	NUM
admet-322	202	51	-	-	SYM
admet-322	202	52	267	267	NUM
admet-322	202	53	.	.	PUNCT
admet-322	203	1	[	[	X
admet-322	203	2	19	19	NUM
admet-322	203	3	]	]	X
admet-322	203	4	n.d	n.d	PROPN
admet-322	203	5	.	.	PROPN
admet-322	203	6	pfeifer	pfeifer	PROPN
admet-322	203	7	,	,	PUNCT
admet-322	203	8	r.n	r.n	PROPN
admet-322	203	9	.	.	PROPN
admet-322	203	10	hardwick	hardwick	PROPN
admet-322	203	11	,	,	PUNCT
admet-322	203	12	k.l	k.l	PROPN
admet-322	203	13	.	.	PROPN
admet-322	203	14	brouwer	brouwer	PROPN
admet-322	203	15	,	,	PUNCT
admet-322	203	16	annual	annual	ADJ
admet-322	203	17	review	review	NOUN
admet-322	203	18	of	of	ADP
admet-322	203	19	pharmacology	pharmacology	NOUN
admet-322	203	20	and	and	CCONJ
admet-322	203	21	toxicology	toxicology	NOUN
admet-322	203	22	54	54	NUM
admet-322	203	23	(	(	PUNCT
admet-322	203	24	2014	2014	NUM
admet-322	203	25	)	)	PUNCT
admet-322	203	26	509	509	NUM
admet-322	203	27	-	-	SYM
admet-322	203	28	535	535	NUM
admet-322	203	29	.	.	PUNCT
admet-322	204	1	[	[	X
admet-322	204	2	20	20	NUM
admet-322	204	3	]	]	SYM
admet-322	204	4	c.d	c.d	PROPN
admet-322	204	5	.	.	PROPN
admet-322	204	6	klaassen	klaassen	PROPN
admet-322	204	7	,	,	PUNCT
admet-322	204	8	l.m	l.m	PROPN
admet-322	204	9	.	.	PROPN
admet-322	204	10	aleksunes	aleksunes	PROPN
admet-322	204	11	,	,	PUNCT
admet-322	204	12	pharmacological	pharmacological	ADJ
admet-322	204	13	reviews	review	NOUN
admet-322	204	14	62	62	NUM
admet-322	204	15	(	(	PUNCT
admet-322	204	16	2010	2010	NUM
admet-322	204	17	)	)	PUNCT
admet-322	204	18	1	1	NUM
admet-322	204	19	-	-	SYM
admet-322	204	20	96	96	NUM
admet-322	204	21	.	.	PUNCT
admet-322	205	1	[	[	X
admet-322	205	2	21	21	NUM
admet-322	205	3	]	]	PUNCT
admet-322	205	4	k.	k.	PROPN
admet-322	205	5	kock	kock	PROPN
admet-322	205	6	,	,	PUNCT
admet-322	205	7	k.l	k.l	PROPN
admet-322	205	8	.	.	PROPN
admet-322	205	9	brouwer	brouwer	PROPN
admet-322	205	10	,	,	PUNCT
admet-322	205	11	clinical	clinical	ADJ
admet-322	205	12	pharmacology	pharmacology	NOUN
admet-322	205	13	and	and	CCONJ
admet-322	205	14	therapeutics	therapeutic	NOUN
admet-322	205	15	92	92	NUM
admet-322	205	16	(	(	PUNCT
admet-322	205	17	2012	2012	NUM
admet-322	205	18	)	)	PUNCT
admet-322	205	19	599	599	NUM
admet-322	205	20	-	-	PUNCT
admet-322	205	21	612	612	NUM
admet-322	205	22	.	.	PUNCT
admet-322	206	1	[	[	X
admet-322	206	2	22	22	NUM
admet-322	206	3	]	]	X
admet-322	206	4	f.j	f.j	PROPN
admet-322	206	5	.	.	PROPN
admet-322	206	6	sharom	sharom	PROPN
admet-322	206	7	,	,	PUNCT
admet-322	206	8	pharmacogenomics	pharmacogenomic	NOUN
admet-322	206	9	9	9	NUM
admet-322	206	10	(	(	PUNCT
admet-322	206	11	2008	2008	NUM
admet-322	206	12	)	)	PUNCT
admet-322	206	13	105	105	NUM
admet-322	206	14	-	-	SYM
admet-322	206	15	127	127	NUM
admet-322	206	16	.	.	PUNCT
admet-322	207	1	[	[	X
admet-322	207	2	23	23	NUM
admet-322	207	3	]	]	X
admet-322	207	4	y.	y.	PROPN
admet-322	207	5	an	an	PROPN
admet-322	207	6	,	,	PUNCT
admet-322	207	7	w.m	w.m	PROPN
admet-322	207	8	.	.	PROPN
admet-322	207	9	ongkeko	ongkeko	PROPN
admet-322	207	10	,	,	PUNCT
admet-322	207	11	expert	expert	ADJ
admet-322	207	12	opinion	opinion	NOUN
admet-322	207	13	on	on	ADP
admet-322	207	14	drug	drug	NOUN
admet-322	207	15	metabolism	metabolism	NOUN
admet-322	207	16	&	&	CCONJ
admet-322	207	17	toxicology	toxicology	NOUN
admet-322	207	18	5	5	NUM
admet-322	207	19	(	(	PUNCT
admet-322	207	20	2009	2009	NUM
admet-322	207	21	)	)	PUNCT
admet-322	207	22	1529	1529	NUM
admet-322	207	23	-	-	SYM
admet-322	207	24	1542	1542	NUM
admet-322	207	25	.	.	PUNCT
admet-322	208	1	[	[	X
admet-322	208	2	24	24	NUM
admet-322	208	3	]	]	PUNCT
admet-322	208	4	m.	m.	NOUN
admet-322	208	5	dohse	dohse	PROPN
admet-322	208	6	,	,	PUNCT
admet-322	208	7	c.	c.	PROPN
admet-322	208	8	scharenberg	scharenberg	PROPN
admet-322	208	9	,	,	PUNCT
admet-322	208	10	s.	s.	PROPN
admet-322	208	11	shukla	shukla	PROPN
admet-322	208	12	,	,	PUNCT
admet-322	208	13	r.w	r.w	PROPN
admet-322	208	14	.	.	PROPN
admet-322	208	15	robey	robey	PROPN
admet-322	208	16	,	,	PUNCT
admet-322	208	17	t.	t.	PROPN
admet-322	208	18	volkmann	volkmann	PROPN
admet-322	208	19	,	,	PUNCT
admet-322	208	20	j.f	j.f	PROPN
admet-322	208	21	.	.	PROPN
admet-322	208	22	deeken	deeken	PROPN
admet-322	208	23	,	,	PUNCT
admet-322	208	24	c.	c.	PROPN
admet-322	208	25	brendel	brendel	PROPN
admet-322	208	26	,	,	PUNCT
admet-322	208	27	s.v	s.v	PROPN
admet-322	208	28	.	.	PROPN
admet-322	208	29	ambudkar	ambudkar	PROPN
admet-322	208	30	,	,	PUNCT
admet-322	208	31	a.	a.	PROPN
admet-322	208	32	neubauer	neubauer	PROPN
admet-322	208	33	,	,	PUNCT
admet-322	208	34	s.e	s.e	PROPN
admet-322	208	35	.	.	PROPN
admet-322	208	36	bates	bates	PROPN
admet-322	208	37	,	,	PUNCT
admet-322	208	38	drug	drug	NOUN
admet-322	208	39	metabolism	metabolism	NOUN
admet-322	208	40	and	and	CCONJ
admet-322	208	41	disposition	disposition	NOUN
admet-322	208	42	:	:	PUNCT
admet-322	208	43	the	the	DET
admet-322	208	44	biological	biological	ADJ
admet-322	208	45	fate	fate	NOUN
admet-322	208	46	of	of	ADP
admet-322	208	47	chemicals	chemical	NOUN
admet-322	208	48	38	38	NUM
admet-322	208	49	(	(	PUNCT
admet-322	208	50	2010	2010	NUM
admet-322	208	51	)	)	PUNCT
admet-322	208	52	1371	1371	NUM
admet-322	208	53	-	-	SYM
admet-322	208	54	1380	1380	NUM
admet-322	208	55	.	.	PUNCT
admet-322	209	1	[	[	X
admet-322	209	2	25	25	NUM
admet-322	209	3	]	]	X
admet-322	209	4	a.	a.	NOUN
admet-322	209	5	argiris	argiris	PROPN
admet-322	209	6	,	,	PUNCT
admet-322	209	7	m.	m.	PROPN
admet-322	209	8	ghebremichael	ghebremichael	PROPN
admet-322	209	9	,	,	PUNCT
admet-322	209	10	j.	j.	PROPN
admet-322	209	11	gilbert	gilbert	PROPN
admet-322	209	12	,	,	PUNCT
admet-322	209	13	j.w	j.w	PROPN
admet-322	209	14	.	.	PROPN
admet-322	209	15	lee	lee	PROPN
admet-322	209	16	,	,	PUNCT
admet-322	209	17	k.	k.	PROPN
admet-322	209	18	sachidanandam	sachidanandam	PROPN
admet-322	209	19	,	,	PUNCT
admet-322	209	20	j.m	j.m	PROPN
admet-322	209	21	.	.	PROPN
admet-322	209	22	kolesar	kolesar	PROPN
admet-322	209	23	,	,	PUNCT
admet-322	209	24	b.	b.	PROPN
admet-322	209	25	burtness	burtness	PROPN
admet-322	209	26	,	,	PUNCT
admet-322	209	27	a.a	a.a	PROPN
admet-322	209	28	.	.	PROPN
admet-322	209	29	forastiere	forastiere	PROPN
admet-322	209	30	,	,	PUNCT
admet-322	209	31	journal	journal	NOUN
admet-322	209	32	of	of	ADP
admet-322	209	33	clinical	clinical	ADJ
admet-322	209	34	oncology	oncology	NOUN
admet-322	209	35	:	:	PUNCT
admet-322	209	36	official	official	ADJ
admet-322	209	37	journal	journal	NOUN
admet-322	209	38	of	of	ADP
admet-322	209	39	the	the	DET
admet-322	209	40	american	american	ADJ
admet-322	209	41	society	society	NOUN
admet-322	209	42	of	of	ADP
admet-322	209	43	clinical	clinical	ADJ
admet-322	209	44	oncology	oncology	NOUN
admet-322	209	45	31	31	NUM
admet-322	209	46	(	(	PUNCT
admet-322	209	47	2013	2013	NUM
admet-322	209	48	)	)	PUNCT
admet-322	209	49	1405	1405	NUM
admet-322	209	50	-	-	SYM
admet-322	209	51	1414	1414	NUM
admet-322	209	52	.	.	PUNCT
admet-322	210	1	[	[	X
admet-322	210	2	26	26	NUM
admet-322	210	3	]	]	X
admet-322	210	4	l.g	l.g	PROPN
admet-322	210	5	.	.	PROPN
admet-322	210	6	paz	paz	PROPN
admet-322	210	7	-	-	PUNCT
admet-322	210	8	ares	are	NOUN
admet-322	210	9	,	,	PUNCT
admet-322	210	10	b.	b.	PROPN
admet-322	210	11	biesma	biesma	PROPN
admet-322	210	12	,	,	PUNCT
admet-322	210	13	d.	d.	PROPN
admet-322	210	14	heigener	heigener	PROPN
admet-322	210	15	,	,	PUNCT
admet-322	210	16	j.	j.	PROPN
admet-322	210	17	von	von	PROPN
admet-322	210	18	pawel	pawel	PROPN
admet-322	210	19	,	,	PUNCT
admet-322	210	20	t.	t.	PROPN
admet-322	210	21	eisen	eisen	PROPN
admet-322	210	22	,	,	PUNCT
admet-322	210	23	j.	j.	PROPN
admet-322	210	24	bennouna	bennouna	PROPN
admet-322	210	25	,	,	PUNCT
admet-322	210	26	l.	l.	PROPN
admet-322	210	27	zhang	zhang	PROPN
admet-322	210	28	,	,	PUNCT
admet-322	210	29	m.	m.	PROPN
admet-322	210	30	liao	liao	PROPN
admet-322	210	31	,	,	PUNCT
admet-322	210	32	y.	y.	PROPN
admet-322	210	33	sun	sun	PROPN
admet-322	210	34	,	,	PUNCT
admet-322	210	35	s.	s.	PROPN
admet-322	210	36	gans	gans	PROPN
admet-322	210	37	,	,	PUNCT
admet-322	210	38	k.	k.	PROPN
admet-322	210	39	syrigos	syrigos	PROPN
admet-322	210	40	,	,	PUNCT
admet-322	210	41	e.	e.	PROPN
admet-322	210	42	le	le	PROPN
admet-322	210	43	marie	marie	PROPN
admet-322	210	44	,	,	PUNCT
admet-322	210	45	m.	m.	PROPN
admet-322	210	46	gottfried	gottfried	PROPN
admet-322	210	47	,	,	PUNCT
admet-322	210	48	j.	j.	PROPN
admet-322	210	49	vansteenkiste	vansteenkiste	PROPN
admet-322	210	50	,	,	PUNCT
admet-322	210	51	v.	v.	PROPN
admet-322	210	52	alberola	alberola	PROPN
admet-322	210	53	,	,	PUNCT
admet-322	210	54	u.p	u.p	PROPN
admet-322	210	55	.	.	PROPN
admet-322	210	56	strauss	strauss	PROPN
admet-322	210	57	,	,	PUNCT
admet-322	210	58	e.	e.	PROPN
admet-322	210	59	montegriffo	montegriffo	PROPN
admet-322	210	60	,	,	PUNCT
admet-322	210	61	t.j	t.j	PROPN
admet-322	210	62	.	.	PROPN
admet-322	210	63	ong	ong	PROPN
admet-322	210	64	,	,	PUNCT
admet-322	210	65	a.	a.	PROPN
admet-322	210	66	santoro	santoro	PROPN
admet-322	210	67	,	,	PUNCT
admet-322	210	68	n.r.e.u.s.i.s	n.r.e.u.s.i.s	PUNCT
admet-322	210	69	.	.	PUNCT
admet-322	210	70	group	group	NOUN
admet-322	210	71	,	,	PUNCT
admet-322	210	72	journal	journal	NOUN
admet-322	210	73	of	of	ADP
admet-322	210	74	clinical	clinical	ADJ
admet-322	210	75	oncology	oncology	NOUN
admet-322	210	76	:	:	PUNCT
admet-322	210	77	official	official	ADJ
admet-322	210	78	journal	journal	NOUN
admet-322	210	79	of	of	ADP
admet-322	210	80	the	the	DET
admet-322	210	81	american	american	ADJ
admet-322	210	82	society	society	NOUN
admet-322	210	83	of	of	ADP
admet-322	210	84	clinical	clinical	ADJ
admet-322	210	85	oncology	oncology	NOUN
admet-322	210	86	30	30	NUM
admet-322	210	87	(	(	PUNCT
admet-322	210	88	2012	2012	NUM
admet-322	210	89	)	)	PUNCT
admet-322	210	90	3084	3084	NUM
admet-322	210	91	-	-	SYM
admet-322	210	92	3092	3092	NUM
admet-322	210	93	.	.	PUNCT
admet-322	211	1	[	[	X
admet-322	211	2	27	27	NUM
admet-322	211	3	]	]	X
admet-322	211	4	t.k	t.k	PROPN
admet-322	211	5	.	.	PROPN
admet-322	211	6	choueiri	choueiri	PROPN
admet-322	211	7	,	,	PUNCT
admet-322	211	8	r.w	r.w	PROPN
admet-322	211	9	.	.	PROPN
admet-322	211	10	ross	ross	PROPN
admet-322	211	11	,	,	PUNCT
admet-322	211	12	s.	s.	PROPN
admet-322	211	13	jacobus	jacobus	PROPN
admet-322	211	14	,	,	PUNCT
admet-322	211	15	u.	u.	PROPN
admet-322	211	16	vaishampayan	vaishampayan	PROPN
admet-322	211	17	,	,	PUNCT
admet-322	211	18	e.y	e.y	PROPN
admet-322	211	19	.	.	PROPN
admet-322	211	20	yu	yu	PROPN
admet-322	211	21	,	,	PUNCT
admet-322	211	22	d.i	d.i	PROPN
admet-322	211	23	.	.	PROPN
admet-322	211	24	quinn	quinn	PROPN
admet-322	211	25	,	,	PUNCT
admet-322	211	26	n.m	n.m	PROPN
admet-322	211	27	.	.	PROPN
admet-322	211	28	hahn	hahn	PROPN
admet-322	211	29	,	,	PUNCT
admet-322	211	30	t.e	t.e	PROPN
admet-322	211	31	.	.	PROPN
admet-322	211	32	hutson	hutson	PROPN
admet-322	211	33	,	,	PUNCT
admet-322	211	34	g.	g.	PROPN
admet-322	211	35	sonpavde	sonpavde	PROPN
admet-322	211	36	,	,	PUNCT
admet-322	211	37	s.c	s.c	PROPN
admet-322	211	38	.	.	PROPN
admet-322	211	39	morrissey	morrissey	PROPN
admet-322	211	40	,	,	PUNCT
admet-322	211	41	g.c	g.c	PROPN
admet-322	211	42	.	.	PROPN
admet-322	211	43	buckle	buckle	PROPN
admet-322	211	44	,	,	PUNCT
admet-322	212	1	w.y	w.y	PROPN
admet-322	212	2	.	.	PUNCT
admet-322	212	3	kim	kim	PROPN
admet-322	212	4	,	,	PUNCT
admet-322	212	5	d.p	d.p	PROPN
admet-322	212	6	.	.	PROPN
admet-322	213	1	petrylak	petrylak	PROPN
admet-322	213	2	,	,	PUNCT
admet-322	213	3	c.w	c.w	PROPN
admet-322	213	4	.	.	PROPN
admet-322	213	5	ryan	ryan	PROPN
admet-322	213	6	,	,	PUNCT
admet-322	213	7	m.a	m.a	PROPN
admet-322	213	8	.	.	PROPN
admet-322	213	9	eisenberger	eisenberger	PROPN
admet-322	213	10	,	,	PUNCT
admet-322	213	11	a.	a.	NOUN
admet-322	213	12	mortazavi	mortazavi	PROPN
admet-322	213	13	,	,	PUNCT
admet-322	213	14	g.j	g.j	PROPN
admet-322	213	15	.	.	PROPN
admet-322	213	16	bubley	bubley	PROPN
admet-322	213	17	,	,	PUNCT
admet-322	213	18	m.e	m.e	PROPN
admet-322	213	19	.	.	PROPN
admet-322	213	20	taplin	taplin	PROPN
admet-322	213	21	,	,	PUNCT
admet-322	213	22	j.e	j.e	PROPN
admet-322	213	23	.	.	PROPN
admet-322	213	24	rosenberg	rosenberg	PROPN
admet-322	213	25	,	,	PUNCT
admet-322	213	26	p.w	p.w	PROPN
admet-322	213	27	.	.	PROPN
admet-322	213	28	kantoff	kantoff	PROPN
admet-322	213	29	,	,	PUNCT
admet-322	213	30	journal	journal	NOUN
admet-322	213	31	of	of	ADP
admet-322	213	32	clinical	clinical	ADJ
admet-322	213	33	oncology	oncology	NOUN
admet-322	213	34	:	:	PUNCT
admet-322	213	35	official	official	ADJ
admet-322	213	36	journal	journal	NOUN
admet-322	213	37	of	of	ADP
admet-322	213	38	the	the	DET
admet-322	213	39	american	american	ADJ
admet-322	213	40	society	society	NOUN
admet-322	213	41	of	of	ADP
admet-322	213	42	clinical	clinical	ADJ
admet-322	213	43	oncology	oncology	NOUN
admet-322	213	44	30	30	NUM
admet-322	213	45	(	(	PUNCT
admet-322	213	46	2012	2012	NUM
admet-322	213	47	)	)	PUNCT
admet-322	213	48	507	507	NUM
admet-322	213	49	-	-	SYM
admet-322	213	50	512	512	NUM
admet-322	213	51	.	.	PUNCT
admet-322	214	1	[	[	X
admet-322	214	2	28	28	NUM
admet-322	214	3	]	]	X
admet-322	214	4	k.t	k.t	PROPN
admet-322	214	5	.	.	PROPN
admet-322	214	6	flaherty	flaherty	PROPN
admet-322	214	7	,	,	PUNCT
admet-322	214	8	s.j	s.j	PROPN
admet-322	214	9	.	.	PROPN
admet-322	214	10	lee	lee	PROPN
admet-322	214	11	,	,	PUNCT
admet-322	214	12	f.	f.	PROPN
admet-322	214	13	zhao	zhao	PROPN
admet-322	214	14	,	,	PUNCT
admet-322	214	15	l.m	l.m	PROPN
admet-322	214	16	.	.	PROPN
admet-322	214	17	schuchter	schuchter	PROPN
admet-322	214	18	,	,	PUNCT
admet-322	214	19	l.	l.	PROPN
admet-322	214	20	flaherty	flaherty	PROPN
admet-322	214	21	,	,	PUNCT
admet-322	214	22	r.	r.	PROPN
admet-322	214	23	kefford	kefford	PROPN
admet-322	214	24	,	,	PUNCT
admet-322	214	25	m.b	m.b	PROPN
admet-322	214	26	.	.	PROPN
admet-322	214	27	atkins	atkins	PROPN
admet-322	214	28	,	,	PUNCT
admet-322	214	29	p.	p.	NOUN
admet-322	214	30	leming	leming	PROPN
admet-322	214	31	,	,	PUNCT
admet-322	214	32	j.m	j.m	PROPN
admet-322	214	33	.	.	PROPN
admet-322	214	34	kirkwood	kirkwood	PROPN
admet-322	214	35	,	,	PUNCT
admet-322	214	36	journal	journal	NOUN
admet-322	214	37	of	of	ADP
admet-322	214	38	clinical	clinical	ADJ
admet-322	214	39	oncology	oncology	NOUN
admet-322	214	40	:	:	PUNCT
admet-322	214	41	official	official	ADJ
admet-322	214	42	journal	journal	NOUN
admet-322	214	43	of	of	ADP
admet-322	214	44	the	the	DET
admet-322	214	45	american	american	ADJ
admet-322	214	46	society	society	NOUN
admet-322	214	47	of	of	ADP
admet-322	214	48	clinical	clinical	ADJ
admet-322	214	49	oncology	oncology	NOUN
admet-322	214	50	31	31	NUM
admet-322	214	51	(	(	PUNCT
admet-322	214	52	2013	2013	NUM
admet-322	214	53	)	)	PUNCT
admet-322	214	54	373	373	NUM
admet-322	214	55	-	-	SYM
admet-322	214	56	379	379	NUM
admet-322	214	57	.	.	PUNCT
admet-322	215	1	admet	admet	PROPN
admet-322	215	2	&	&	CCONJ
admet-322	215	3	dmpk	dmpk	PROPN
admet-322	215	4	4(4	4(4	NUM
admet-322	215	5	)	)	PUNCT
admet-322	215	6	(	(	PUNCT
admet-322	215	7	2016	2016	NUM
admet-322	215	8	)	)	PUNCT
admet-322	215	9	302	302	NUM
admet-322	215	10	-	-	SYM
admet-322	215	11	313	313	NUM
admet-322	215	12	tkis	tki	NOUN
admet-322	215	13	and	and	CCONJ
admet-322	215	14	akis	akis	PROPN
admet-322	215	15	diminish	diminish	VERB
admet-322	215	16	transport	transport	NOUN
admet-322	215	17	of	of	ADP
admet-322	215	18	function	function	NOUN
admet-322	215	19	of	of	ADP
admet-322	215	20	mrp4	mrp4	NOUN
admet-322	215	21	and	and	CCONJ
admet-322	215	22	bcrp	bcrp	PROPN
admet-322	215	23	doi	doi	PROPN
admet-322	215	24	:	:	PUNCT
admet-322	215	25	10.5599	10.5599	NUM
admet-322	215	26	/	/	SYM
admet-322	215	27	admet.4.4.322	admet.4.4.322	PROPN
admet-322	215	28	313	313	NUM
admet-322	215	29	[	[	SYM
admet-322	215	30	29	29	NUM
admet-322	215	31	]	]	PUNCT
admet-322	215	32	k.	k.	PROPN
admet-322	215	33	kock	kock	PROPN
admet-322	215	34	,	,	PUNCT
admet-322	215	35	b.c	b.c	PROPN
admet-322	215	36	.	.	PROPN
admet-322	215	37	ferslew	ferslew	PROPN
admet-322	215	38	,	,	PUNCT
admet-322	215	39	i.	i.	PROPN
admet-322	215	40	netterberg	netterberg	PROPN
admet-322	215	41	,	,	PUNCT
admet-322	215	42	k.	k.	PROPN
admet-322	215	43	yang	yang	PROPN
admet-322	215	44	,	,	PUNCT
admet-322	216	1	t.j	t.j	PROPN
admet-322	216	2	.	.	PROPN
admet-322	216	3	urban	urban	PROPN
admet-322	216	4	,	,	PUNCT
admet-322	216	5	p.w	p.w	PROPN
admet-322	216	6	.	.	PROPN
admet-322	216	7	swaan	swaan	PROPN
admet-322	216	8	,	,	PUNCT
admet-322	216	9	p.w	p.w	PROPN
admet-322	216	10	.	.	PROPN
admet-322	216	11	stewart	stewart	PROPN
admet-322	216	12	,	,	PUNCT
admet-322	216	13	k.l	k.l	PROPN
admet-322	216	14	.	.	PROPN
admet-322	216	15	brouwer	brouwer	PROPN
admet-322	216	16	,	,	PUNCT
admet-322	216	17	drug	drug	NOUN
admet-322	216	18	metabolism	metabolism	NOUN
admet-322	216	19	and	and	CCONJ
admet-322	216	20	disposition	disposition	NOUN
admet-322	216	21	:	:	PUNCT
admet-322	216	22	the	the	DET
admet-322	216	23	biological	biological	ADJ
admet-322	216	24	fate	fate	NOUN
admet-322	216	25	of	of	ADP
admet-322	216	26	chemicals	chemical	NOUN
admet-322	216	27	42	42	NUM
admet-322	216	28	(	(	PUNCT
admet-322	216	29	2014	2014	NUM
admet-322	216	30	)	)	PUNCT
admet-322	216	31	665	665	NUM
admet-322	216	32	-	-	SYM
admet-322	216	33	674	674	NUM
admet-322	216	34	.	.	PUNCT
admet-322	217	1	[	[	X
admet-322	217	2	30	30	NUM
admet-322	217	3	]	]	X
admet-322	217	4	m.a	m.a	PROPN
admet-322	217	5	.	.	PROPN
admet-322	217	6	welch	welch	PROPN
admet-322	217	7	,	,	PUNCT
admet-322	217	8	k.	k.	PROPN
admet-322	217	9	kock	kock	PROPN
admet-322	217	10	,	,	PUNCT
admet-322	217	11	t.j	t.j	PROPN
admet-322	217	12	.	.	PROPN
admet-322	217	13	urban	urban	PROPN
admet-322	217	14	,	,	PUNCT
admet-322	217	15	k.l	k.l	PROPN
admet-322	217	16	.	.	PROPN
admet-322	217	17	brouwer	brouwer	PROPN
admet-322	217	18	,	,	PUNCT
admet-322	217	19	p.w	p.w	PROPN
admet-322	217	20	.	.	PROPN
admet-322	217	21	swaan	swaan	PROPN
admet-322	217	22	,	,	PUNCT
admet-322	217	23	drug	drug	NOUN
admet-322	217	24	metabolism	metabolism	NOUN
admet-322	217	25	and	and	CCONJ
admet-322	217	26	disposition	disposition	NOUN
admet-322	217	27	:	:	PUNCT
admet-322	217	28	the	the	DET
admet-322	217	29	biological	biological	ADJ
admet-322	217	30	fate	fate	NOUN
admet-322	217	31	of	of	ADP
admet-322	217	32	chemicals	chemical	NOUN
admet-322	217	33	43	43	NUM
admet-322	217	34	(	(	PUNCT
admet-322	217	35	2015	2015	NUM
admet-322	217	36	)	)	PUNCT
admet-322	217	37	725	725	NUM
admet-322	217	38	-	-	SYM
admet-322	217	39	734	734	NUM
admet-322	217	40	.	.	PUNCT
admet-322	218	1	[	[	X
admet-322	218	2	31	31	NUM
admet-322	218	3	]	]	PUNCT
admet-322	218	4	m.	m.	NOUN
admet-322	218	5	grube	grube	PROPN
admet-322	218	6	,	,	PUNCT
admet-322	218	7	s.	s.	PROPN
admet-322	218	8	reuther	reuther	PROPN
admet-322	218	9	,	,	PUNCT
admet-322	218	10	h.	h.	PROPN
admet-322	218	11	meyer	meyer	PROPN
admet-322	218	12	zu	zu	PROPN
admet-322	218	13	schwabedissen	schwabedissen	PROPN
admet-322	218	14	,	,	PUNCT
admet-322	218	15	k.	k.	PROPN
admet-322	218	16	kock	kock	PROPN
admet-322	218	17	,	,	PUNCT
admet-322	218	18	k.	k.	PROPN
admet-322	218	19	draber	draber	PROPN
admet-322	218	20	,	,	PUNCT
admet-322	218	21	c.a	c.a	PROPN
admet-322	218	22	.	.	PROPN
admet-322	218	23	ritter	ritter	PROPN
admet-322	218	24	,	,	PUNCT
admet-322	218	25	c.	c.	PROPN
admet-322	218	26	fusch	fusch	PROPN
admet-322	218	27	,	,	PUNCT
admet-322	218	28	g.	g.	PROPN
admet-322	218	29	jedlitschky	jedlitschky	PROPN
admet-322	218	30	,	,	PUNCT
admet-322	218	31	h.k	h.k	PROPN
admet-322	218	32	.	.	PROPN
admet-322	218	33	kroemer	kroemer	PROPN
admet-322	218	34	,	,	PUNCT
admet-322	218	35	drug	drug	NOUN
admet-322	218	36	metabolism	metabolism	NOUN
admet-322	218	37	and	and	CCONJ
admet-322	218	38	disposition	disposition	NOUN
admet-322	218	39	:	:	PUNCT
admet-322	218	40	the	the	DET
admet-322	218	41	biological	biological	ADJ
admet-322	218	42	fate	fate	NOUN
admet-322	218	43	of	of	ADP
admet-322	218	44	chemicals	chemical	NOUN
admet-322	218	45	35	35	NUM
admet-322	218	46	(	(	PUNCT
admet-322	218	47	2007	2007	NUM
admet-322	218	48	)	)	PUNCT
admet-322	218	49	30	30	NUM
admet-322	218	50	-	-	SYM
admet-322	218	51	35	35	NUM
admet-322	218	52	.	.	PUNCT
admet-322	219	1	[	[	X
admet-322	219	2	32	32	NUM
admet-322	219	3	]	]	PUNCT
admet-322	219	4	k.	k.	PROPN
admet-322	219	5	kock	kock	PROPN
admet-322	219	6	,	,	PUNCT
admet-322	219	7	a.	a.	PROPN
admet-322	219	8	koenen	koenen	PROPN
admet-322	219	9	,	,	PUNCT
admet-322	219	10	b.	b.	PROPN
admet-322	219	11	giese	giese	PROPN
admet-322	219	12	,	,	PUNCT
admet-322	219	13	m.	m.	PROPN
admet-322	219	14	fraunholz	fraunholz	PROPN
admet-322	219	15	,	,	PUNCT
admet-322	219	16	k.	k.	PROPN
admet-322	219	17	may	may	AUX
admet-322	219	18	,	,	PUNCT
admet-322	219	19	w.	w.	PROPN
admet-322	219	20	siegmund	siegmund	PROPN
admet-322	219	21	,	,	PUNCT
admet-322	219	22	e.	e.	PROPN
admet-322	219	23	hammer	hammer	PROPN
admet-322	219	24	,	,	PUNCT
admet-322	219	25	u.	u.	PROPN
admet-322	219	26	volker	volker	PROPN
admet-322	219	27	,	,	PUNCT
admet-322	219	28	g.	g.	PROPN
admet-322	219	29	jedlitschky	jedlitschky	PROPN
admet-322	219	30	,	,	PUNCT
admet-322	219	31	h.k	h.k	PROPN
admet-322	219	32	.	.	PROPN
admet-322	219	33	kroemer	kroemer	PROPN
admet-322	219	34	,	,	PUNCT
admet-322	219	35	m.	m.	NOUN
admet-322	219	36	grube	grube	PROPN
admet-322	219	37	,	,	PUNCT
admet-322	219	38	the	the	DET
admet-322	219	39	journal	journal	NOUN
admet-322	219	40	of	of	ADP
admet-322	219	41	biological	biological	ADJ
admet-322	219	42	chemistry	chemistry	NOUN
admet-322	219	43	285	285	NUM
admet-322	219	44	(	(	PUNCT
admet-322	219	45	2010	2010	NUM
admet-322	219	46	)	)	PUNCT
admet-322	219	47	11336	11336	NUM
admet-322	219	48	-	-	SYM
admet-322	219	49	11347	11347	NUM
admet-322	219	50	.	.	PUNCT
admet-322	220	1	[	[	X
admet-322	220	2	33	33	NUM
admet-322	220	3	]	]	X
admet-322	220	4	g.	g.	PROPN
admet-322	220	5	ghibellini	ghibellini	PROPN
admet-322	220	6	,	,	PUNCT
admet-322	220	7	e.m	e.m	PROPN
admet-322	220	8	.	.	PROPN
admet-322	220	9	leslie	leslie	PROPN
admet-322	220	10	,	,	PUNCT
admet-322	220	11	g.m	g.m	PROPN
admet-322	220	12	.	.	PROPN
admet-322	220	13	pollack	pollack	PROPN
admet-322	220	14	,	,	PUNCT
admet-322	220	15	k.l	k.l	PROPN
admet-322	220	16	.	.	PROPN
admet-322	220	17	brouwer	brouwer	PROPN
admet-322	220	18	,	,	PUNCT
admet-322	220	19	pharmaceutical	pharmaceutical	NOUN
admet-322	220	20	research	research	NOUN
admet-322	220	21	25	25	NUM
admet-322	220	22	(	(	PUNCT
admet-322	220	23	2008	2008	NUM
admet-322	220	24	)	)	PUNCT
admet-322	220	25	1851	1851	NUM
admet-322	220	26	-	-	SYM
admet-322	220	27	1860	1860	NUM
admet-322	220	28	.	.	PUNCT
admet-322	221	1	[	[	X
admet-322	221	2	34	34	NUM
admet-322	221	3	]	]	SYM
admet-322	221	4	b.c	b.c	PROPN
admet-322	221	5	.	.	PROPN
admet-322	221	6	ferslew	ferslew	PROPN
admet-322	221	7	,	,	PUNCT
admet-322	221	8	k.	k.	PROPN
admet-322	221	9	kock	kock	PROPN
admet-322	221	10	,	,	PUNCT
admet-322	221	11	a.s	a.s	PROPN
admet-322	221	12	.	.	PROPN
admet-322	221	13	bridges	bridge	NOUN
admet-322	221	14	,	,	PUNCT
admet-322	221	15	k.l	k.l	PROPN
admet-322	221	16	.	.	PROPN
admet-322	221	17	brouwer	brouwer	PROPN
admet-322	221	18	,	,	PUNCT
admet-322	221	19	drug	drug	NOUN
admet-322	221	20	metabolism	metabolism	NOUN
admet-322	221	21	and	and	CCONJ
admet-322	221	22	disposition	disposition	NOUN
admet-322	221	23	:	:	PUNCT
admet-322	221	24	the	the	DET
admet-322	221	25	biological	biological	ADJ
admet-322	221	26	fate	fate	NOUN
admet-322	221	27	of	of	ADP
admet-322	221	28	chemicals	chemical	NOUN
admet-322	221	29	42	42	NUM
admet-322	221	30	(	(	PUNCT
admet-322	221	31	2014	2014	NUM
admet-322	221	32	)	)	PUNCT
admet-322	221	33	1567	1567	NUM
admet-322	221	34	-	-	SYM
admet-322	221	35	1574	1574	NUM
admet-322	221	36	.	.	PUNCT
admet-322	222	1	[	[	X
admet-322	222	2	35	35	NUM
admet-322	222	3	]	]	X
admet-322	222	4	r.e	r.e	PROPN
admet-322	222	5	.	.	PROPN
admet-322	222	6	morgan	morgan	PROPN
admet-322	222	7	,	,	PUNCT
admet-322	222	8	c.j	c.j	PROPN
admet-322	222	9	.	.	PROPN
admet-322	222	10	van	van	PROPN
admet-322	222	11	staden	staden	PROPN
admet-322	222	12	,	,	PUNCT
admet-322	222	13	y.	y.	PROPN
admet-322	222	14	chen	chen	PROPN
admet-322	222	15	,	,	PUNCT
admet-322	222	16	n.	n.	PROPN
admet-322	222	17	kalyanaraman	kalyanaraman	PROPN
admet-322	222	18	,	,	PUNCT
admet-322	222	19	j.	j.	PROPN
admet-322	222	20	kalanzi	kalanzi	PROPN
admet-322	222	21	,	,	PUNCT
admet-322	222	22	r.t	r.t	PROPN
admet-322	222	23	.	.	PROPN
admet-322	222	24	dunn	dunn	PROPN
admet-322	222	25	,	,	PUNCT
admet-322	222	26	2nd	2nd	PROPN
admet-322	222	27	,	,	PUNCT
admet-322	222	28	c.a	c.a	PROPN
admet-322	222	29	.	.	PROPN
admet-322	222	30	afshari	afshari	PROPN
admet-322	222	31	,	,	PUNCT
admet-322	222	32	h.k	h.k	PROPN
admet-322	222	33	.	.	PROPN
admet-322	222	34	hamadeh	hamadeh	PROPN
admet-322	222	35	,	,	PUNCT
admet-322	222	36	toxicological	toxicological	ADJ
admet-322	222	37	sciences	science	NOUN
admet-322	222	38	:	:	PUNCT
admet-322	222	39	an	an	DET
admet-322	222	40	official	official	ADJ
admet-322	222	41	journal	journal	NOUN
admet-322	222	42	of	of	ADP
admet-322	222	43	the	the	DET
admet-322	222	44	society	society	NOUN
admet-322	222	45	of	of	ADP
admet-322	222	46	toxicology	toxicology	NOUN
admet-322	222	47	(	(	PUNCT
admet-322	222	48	2013	2013	NUM
admet-322	222	49	)	)	PUNCT
admet-322	222	50	.	.	PUNCT
admet-322	223	1	[	[	X
admet-322	223	2	36	36	NUM
admet-322	223	3	]	]	X
admet-322	223	4	c.j	c.j	PROPN
admet-322	223	5	.	.	PROPN
admet-322	223	6	van	van	PROPN
admet-322	223	7	staden	staden	PROPN
admet-322	223	8	,	,	PUNCT
admet-322	223	9	r.e	r.e	PROPN
admet-322	223	10	.	.	PROPN
admet-322	223	11	morgan	morgan	PROPN
admet-322	223	12	,	,	PUNCT
admet-322	223	13	b.	b.	PROPN
admet-322	223	14	ramachandran	ramachandran	PROPN
admet-322	223	15	,	,	PUNCT
admet-322	223	16	y.	y.	PROPN
admet-322	223	17	chen	chen	PROPN
admet-322	223	18	,	,	PUNCT
admet-322	223	19	p.h	p.h	PROPN
admet-322	223	20	.	.	PROPN
admet-322	223	21	lee	lee	PROPN
admet-322	223	22	,	,	PUNCT
admet-322	223	23	h.k	h.k	PROPN
admet-322	223	24	.	.	PROPN
admet-322	223	25	hamadeh	hamadeh	PROPN
admet-322	223	26	,	,	PUNCT
admet-322	223	27	current	current	ADJ
admet-322	223	28	protocols	protocol	NOUN
admet-322	223	29	in	in	ADP
admet-322	223	30	toxicology	toxicology	NOUN
admet-322	223	31	/	/	SYM
admet-322	223	32	editorial	editorial	NOUN
admet-322	223	33	board	board	NOUN
admet-322	223	34	,	,	PUNCT
admet-322	223	35	mahin	mahin	PROPN
admet-322	223	36	d.	d.	PROPN
admet-322	223	37	maines	maines	PROPN
admet-322	223	38	chapter	chapter	PROPN
admet-322	223	39	23	23	NUM
admet-322	223	40	(	(	PUNCT
admet-322	223	41	2012	2012	NUM
admet-322	223	42	)	)	PUNCT
admet-322	223	43	unit	unit	NOUN
admet-322	223	44	23	23	NUM
admet-322	223	45	25	25	NUM
admet-322	223	46	.	.	PUNCT
admet-322	224	1	[	[	X
admet-322	224	2	37	37	NUM
admet-322	224	3	]	]	X
admet-322	224	4	j.e	j.e	PROPN
admet-322	224	5	.	.	PROPN
admet-322	224	6	karlsson	karlsson	PROPN
admet-322	224	7	,	,	PUNCT
admet-322	224	8	c.	c.	PROPN
admet-322	224	9	heddle	heddle	NOUN
admet-322	224	10	,	,	PUNCT
admet-322	224	11	a.	a.	NOUN
admet-322	224	12	rozkov	rozkov	PROPN
admet-322	224	13	,	,	PUNCT
admet-322	224	14	j.	j.	PROPN
admet-322	224	15	rotticci	rotticci	PROPN
admet-322	224	16	-	-	PUNCT
admet-322	224	17	mulder	mulder	PROPN
admet-322	224	18	,	,	PUNCT
admet-322	224	19	o.	o.	PROPN
admet-322	224	20	tuvesson	tuvesson	PROPN
admet-322	224	21	,	,	PUNCT
admet-322	224	22	c.	c.	PROPN
admet-322	224	23	hilgendorf	hilgendorf	PROPN
admet-322	224	24	,	,	PUNCT
admet-322	224	25	t.b	t.b	PROPN
admet-322	224	26	.	.	PROPN
admet-322	224	27	andersson	andersson	PROPN
admet-322	224	28	,	,	PUNCT
admet-322	224	29	drug	drug	NOUN
admet-322	224	30	metabolism	metabolism	NOUN
admet-322	224	31	and	and	CCONJ
admet-322	224	32	disposition	disposition	NOUN
admet-322	224	33	:	:	PUNCT
admet-322	224	34	the	the	DET
admet-322	224	35	biological	biological	ADJ
admet-322	224	36	fate	fate	NOUN
admet-322	224	37	of	of	ADP
admet-322	224	38	chemicals	chemical	NOUN
admet-322	224	39	38	38	NUM
admet-322	224	40	(	(	PUNCT
admet-322	224	41	2010	2010	NUM
admet-322	224	42	)	)	PUNCT
admet-322	224	43	705	705	NUM
admet-322	224	44	-	-	SYM
admet-322	224	45	714	714	NUM
admet-322	224	46	.	.	PUNCT
admet-322	225	1	[	[	X
admet-322	225	2	38	38	NUM
admet-322	225	3	]	]	X
admet-322	225	4	m.j	m.j	PROPN
admet-322	225	5	.	.	PROPN
admet-322	225	6	zamek	zamek	PROPN
admet-322	225	7	-	-	PUNCT
admet-322	225	8	gliszczynski	gliszczynski	PROPN
admet-322	225	9	,	,	PUNCT
admet-322	225	10	c.a	c.a	PROPN
admet-322	225	11	.	.	PROPN
admet-322	225	12	lee	lee	PROPN
admet-322	225	13	,	,	PUNCT
admet-322	225	14	a.	a.	NOUN
admet-322	225	15	poirier	poirier	PROPN
admet-322	225	16	,	,	PUNCT
admet-322	225	17	j.	j.	PROPN
admet-322	225	18	bentz	bentz	PROPN
admet-322	225	19	,	,	PUNCT
admet-322	225	20	x.	x.	PROPN
admet-322	225	21	chu	chu	PROPN
admet-322	225	22	,	,	PUNCT
admet-322	225	23	h.	h.	PROPN
admet-322	225	24	ellens	ellens	PROPN
admet-322	225	25	,	,	PUNCT
admet-322	225	26	t.	t.	PROPN
admet-322	225	27	ishikawa	ishikawa	PROPN
admet-322	225	28	,	,	PUNCT
admet-322	225	29	m.	m.	NOUN
admet-322	225	30	jamei	jamei	PROPN
admet-322	225	31	,	,	PUNCT
admet-322	225	32	j.c	j.c	PROPN
admet-322	225	33	.	.	PROPN
admet-322	225	34	kalvass	kalvass	PROPN
admet-322	225	35	,	,	PUNCT
admet-322	225	36	s.	s.	PROPN
admet-322	225	37	nagar	nagar	PROPN
admet-322	225	38	,	,	PUNCT
admet-322	225	39	k.s	k.s	PROPN
admet-322	225	40	.	.	PROPN
admet-322	225	41	pang	pang	PROPN
admet-322	225	42	,	,	PUNCT
admet-322	225	43	k.	k.	PROPN
admet-322	225	44	korzekwa	korzekwa	PROPN
admet-322	225	45	,	,	PUNCT
admet-322	225	46	p.w	p.w	PROPN
admet-322	225	47	.	.	PROPN
admet-322	225	48	swaan	swaan	PROPN
admet-322	225	49	,	,	PUNCT
admet-322	225	50	m.e	m.e	PROPN
admet-322	225	51	.	.	PROPN
admet-322	225	52	taub	taub	PROPN
admet-322	225	53	,	,	PUNCT
admet-322	225	54	p.	p.	PROPN
admet-322	225	55	zhao	zhao	PROPN
admet-322	225	56	,	,	PUNCT
admet-322	225	57	a.	a.	NOUN
admet-322	225	58	galetin	galetin	PROPN
admet-322	225	59	,	,	PUNCT
admet-322	225	60	c.	c.	PROPN
admet-322	225	61	international	international	ADJ
admet-322	225	62	transporter	transporter	NOUN
admet-322	225	63	,	,	PUNCT
admet-322	225	64	clinical	clinical	ADJ
admet-322	225	65	pharmacology	pharmacology	NOUN
admet-322	225	66	and	and	CCONJ
admet-322	225	67	therapeutics	therapeutic	NOUN
admet-322	225	68	94	94	NUM
admet-322	225	69	(	(	PUNCT
admet-322	225	70	2013	2013	NUM
admet-322	225	71	)	)	PUNCT
admet-322	225	72	64	64	NUM
admet-322	225	73	-	-	SYM
admet-322	225	74	79	79	NUM
admet-322	225	75	.	.	PUNCT
admet-322	226	1	[	[	X
admet-322	226	2	39	39	NUM
admet-322	226	3	]	]	X
admet-322	226	4	n.d	n.d	PROPN
admet-322	226	5	.	.	PROPN
admet-322	226	6	pfeifer	pfeifer	PROPN
admet-322	226	7	,	,	PUNCT
admet-322	226	8	k.b	k.b	PROPN
admet-322	226	9	.	.	PROPN
admet-322	226	10	harris	harris	PROPN
admet-322	226	11	,	,	PUNCT
admet-322	226	12	g.z	g.z	PROPN
admet-322	226	13	.	.	PROPN
admet-322	226	14	yan	yan	PROPN
admet-322	226	15	,	,	PUNCT
admet-322	226	16	k.l	k.l	PROPN
admet-322	226	17	.	.	PROPN
admet-322	226	18	brouwer	brouwer	PROPN
admet-322	226	19	,	,	PUNCT
admet-322	226	20	drug	drug	NOUN
admet-322	226	21	metabolism	metabolism	NOUN
admet-322	226	22	and	and	CCONJ
admet-322	226	23	disposition	disposition	NOUN
admet-322	226	24	:	:	PUNCT
admet-322	226	25	the	the	DET
admet-322	226	26	biological	biological	ADJ
admet-322	226	27	fate	fate	NOUN
admet-322	226	28	of	of	ADP
admet-322	226	29	chemicals	chemical	NOUN
admet-322	226	30	(	(	PUNCT
admet-322	226	31	2013	2013	NUM
admet-322	226	32	)	)	PUNCT
admet-322	226	33	.	.	PUNCT
admet-322	227	1	©	©	PROPN
admet-322	227	2	2016	2016	NUM
admet-322	227	3	by	by	ADP
admet-322	227	4	the	the	DET
admet-322	227	5	authors	author	NOUN
admet-322	227	6	;	;	PUNCT
admet-322	227	7	licensee	licensee	PROPN
admet-322	227	8	iapc	iapc	PROPN
admet-322	227	9	,	,	PUNCT
admet-322	227	10	zagreb	zagreb	PROPN
admet-322	227	11	,	,	PUNCT
admet-322	227	12	croatia	croatia	PROPN
admet-322	227	13	.	.	PUNCT
admet-322	228	1	this	this	DET
admet-322	228	2	article	article	NOUN
admet-322	228	3	is	be	AUX
admet-322	228	4	an	an	DET
admet-322	228	5	open	open	ADJ
admet-322	228	6	-	-	PUNCT
admet-322	228	7	access	access	NOUN
admet-322	228	8	article	article	NOUN
admet-322	228	9	distributed	distribute	VERB
admet-322	228	10	under	under	ADP
admet-322	228	11	the	the	DET
admet-322	228	12	terms	term	NOUN
admet-322	228	13	and	and	CCONJ
admet-322	228	14	conditions	condition	NOUN
admet-322	228	15	of	of	ADP
admet-322	228	16	the	the	DET
admet-322	228	17	creative	creative	ADJ
admet-322	228	18	commons	common	NOUN
admet-322	228	19	attribution	attribution	NOUN
admet-322	228	20	license	license	NOUN
admet-322	228	21	(	(	PUNCT
admet-322	228	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-322	228	23	)	)	PUNCT
admet-322	228	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN